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Abstract 
Germ cell tumour (GCT) is the collective term for several subtypes of 
tumour. GCTs most commonly occur in the testis or ovary around puberty, but 
they also occur at several non-gonadal locations in the human body. These so-
ĐĂůůĞĚ  “ĞǆƚƌĂ-ŐŽŶĂĚĂů ? 'dƐ ŚĂǀĞ ƚŚĞ ƐĂŵĞ ŚŝƐƚŽůŽŐǇ ĂŶĚ ƉƌŽƚĞŝŶ ŵĂƌŬĞƌƐ ĂƐ
those that arise at gonadal locations. This observation prompted several 
hypotheses to explain where these tumours come from. Extragonadal locations 
include the base of the spine (sacrococcygeal region), the abdomen 
(retroperitoneum), the chest cavity (mediastinum), and the brain (intracranial). 
The origin of central nervous system (CNS) GCTs is the main focus of this thesis.  
The most widely accepted hypothesis for extragonadal GCTs was originally 
proposed by Gunnar Teilum in 1965. Teilum proposed that all GCTs that arise in 
ƚŚĞ ŚƵŵĂŶ ďŽĚǇ ŚĂǀĞ Ă ĐŽŵŵŽŶ ĐĞůů ŽĨ ŽƌŝŐŝŶ ? dĞŝůƵŵ ?ƐĞǆƉĞƌŝŵĞŶƚƐ ƐŚŽǁĞĚ
that a germ cell progenitor could give rise to a GCT. This was one piece of 
evidence that led him to suggest that since GCTs in the testis and ovary arise 
from a germ cell progenitor, perhaps GCTs in other locations also arise from 
these progenitors. For extra-gonadal GCTs, these progenitors are thought to 
mismigrate and become trapped at several locations around the body. The 
regions where GCTs occur are suggested to be those regions where these 
progenitors have become trapped, such as the brain. However, research into 
pluripotency has revealed a mechanism of generating a GCT from an endogenous 
population of cells isolated from the brain, neural stem cells, using the 
upregulation of only a single gene, Oct4.  
In this thesis I test the hypothesis that CNS GCTs may arise from a neural 
progenitor, and not just from a germ-cell progenitor. I will use several strategies 
to test this hypothesis with different methodologies. Published literature is first 
used to review and re-analyse the case for a neural cell of origin for CNS GCTs. 
This hypothesis is then experimentally tested in subsequent chapters, 
culminating in a unifying hypothesis for how CNS GCTs may arise.  
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Chapter 1: Introduction 
1.1. Germ cell tumours  
Germ cell tumours (GCTs) are a diverse group of tumours that can occur at 
multiple sites around the body. Regardless of where GCTs arise, they are all 
thought, by most, to originate from germ-cell progenitors, which have a specific 
migratory pattern (Figure 1.1 A). 
GCTs include polyembryomas, yolk sac tumours (endodermal sinus 
tumours), seminomas/dysgerminoma/germinoma (together known as 
 ‘ŐĞƌŵŝŶŽŵĂƚŽƵƐ ? ), teratomas, embryonal carcinomas, and choriocarcinomas. 
GCTs mainly occur in the gonads (testis and ovary) but can form at extragonadal 
locations. Outside of the gonads, GCTs generally occur in the midline of the body, 
in the mediastinum (chest cavity), the retroperitoneum (abdomen), the 
sacrococcygeal symphysis region (base of the spine), or in the brain (Figure 1.1 
B).   
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Figure 1.1. The germ-cell progenitor hypothesis. (A) Schematic of the migration of 
primordial germ cells. PGCs originate in the yolk sac at approximately 3-4 weeks after 
conception in humans. These PGCs migrate from the endodermal epithelium  to dorsal 
mesentery of the hindgut then towards the genital ridges. Taken from [1] (B) Germ cell 
tumours have been documented to mainly occur in the midline of the body highlighted 
in green.  
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Terminology can be confusing, with each tumour type being referred to by 
the same name regardless of the location except for germinomatous (or 
seminomatous) tumours. In the brain, these are referred to as germinomas; in 
the testis, these are seminomas; and in the ovary, they are called 
dysgerminomas [2] (Figure 1.2 A). In the brain, GCTs mainly occur in the pineal 
and suprasellar regions (near the hypothalamus), but have been found in the 4
th
 
ventricle and thalamus regions (Figure 1.2 B). Embryologically, all these sites can 
be classed as being in the ventral midline [3]. As an added complication, GCTs 
have often been found with mixed subtypes; for example, a germinoma mixed 
with a teratoma. 
Teratomas also have contentious terminology. These can be benign 
tumours, often called mature teratomas, or teratomas with an embryonal 
component, also called immature teratomas or teratocarcinomas [4]. Teratomas 
are graded on the percentage of embryonal or neuroepithelium component [5]. 
This begins with grade 0, a mature teratoma; grade 1 contains <10% immature 
component; and grade 3 contains >50%. The immature component has been 
used as a marker for potential metastasis, but it is only considered metastatic 
when it has spread. Since GCTs can vary widely before becoming metastatic, it is 
often better to grade a tumour based on protein markers and other prognostic 
factors to determine the probable outcome, rather than whether it has 
metastasised. For the purposes of simplicity in this thesis these will all be 
referred to as teratomas.  
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.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. GCT categorisation, locations, and incidence (A) A table of the subcategories 
of GCT; either germinomatous or non-germinomatous. Note that germinomatous 
tumours are histologically identical regardless of location but the terminology varies if it 
is in the brain, ovary, or testis. (B) Sagittal view of a brain with the most common 
locations for GCTs; the pineal region, the suprasellar/hypothalamic region, the thalamus, 
and the fourth ventricle. (C) Incidence rate in million person years compared to age in 
years in the CNS for male/female, and germinomas/non-germinomas. The dotted lines 
signify germinoma, and black lines signify non-germinoma [taken from Arora, 2012] 
 
 
 
 
 
 
 
 
 
 
 
 
 
WŝŶĞĂůŐůĂŶĚ 
,ǇƉŽƚŚĂůĂŵŝĐ ? ƐƵƉƌĂƐĞůůĂƌ
ƌĞŐŝŽŶ 
&ŽƵƌƚŚǀĞŶƚƌŝĐůĞ 
dŚĂůĂŵƵƐ 
 ? ) 
 ? ) 
 ? ) 
5 
 
1.2. Clinical review of CNS GCTs 
 
This section briefly outlines the major clinical features of CNS GCTs; 
including, geographical variation, locations of GCTs, and age of incidence. This 
section will begin with a brief introduction to GCTs. 
GCTs are classed as a single group of tumours but each GCT subtype (see 
Figure 1.2 A and Figure 1.3) varies significantly in its clinical behaviour. 
Teratomas are generally benign, and germinomatous tumours are malignant but 
highly curable; in contrast, yolk sac tumours and choriocarcinomas are often 
malignant and less responsive to standard therapies [6]. Despite being benign, 
teratoma has a far worse prognosis in all locations when diagnosed prenatally. 
Excluding those which arise intracranially, the survival rates for pre- and 
perinatal teratomas range from 23% to 100% depending upon the location [7]. 
However, intracranial teratomas, the second most common location for 
teratoma in neonates, are almost invariably fatal when diagnosed at birth [8, 9]. 
This poor prognosis is largely due to their size and growth at the expense of 
normal brain tissue. Also, as discussed in Chapter 3, surgical removal of a 
relatively benign form of GCT can be followed by the recurrence of a higher-
grade tumour of the same or a different malignant subtype at the same site.  
Extragonadal GCTs are most common in children and young people. In 
particular, intracranial tumours are the most common form of extragonadal GCT 
in young males [10]. Unlike neonatal teratomas, most GCTs (such as 
germinomas) are regarded as highly curable. However, because of the young age 
of the patients, the side-effects of chemotherapy and radiotherapy are 
particularly problematic. In addition to effects on the hormonal development of 
those young people, treatment at such an early age leads to a particularly high 
rate of late sequelae - primarily cardiovascular disease and secondary 
malignancies - increasing the probability of these occurring by approximately 
twofold [11, 12].  
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Figure 1.3. Germ cell tumour classifications. A hierarchy of how the World Health 
Organisation classifies germ cell tumours [Kleihues, 1993][13] Germinomas and non-
germinomas are segregated, but all can contribute to a mixed tumour. 
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Late sequelae are mainly caused by the non-specific methods of action used 
to treat CNS GCTs. A better understanding of the biology of these tumours might 
lead to alternative treatments that are equally or more effective but carry less 
severe side effects.  
CNS GCT varies both in incidences between different countries, and in their 
locations in the CNS. These features, along with the age that these tumours arise, 
are important in understanding the aetiology of CNS GCTs. Therefore, these will 
be the next topic for discussion. 
 
Geographical variation in occurrence  
CNS GCTs are rare compared to other GCT locations, but incidence varies 
geographically. In the Far East, the incidence is 2-3% of all primary intracranial 
neoplasms and 8-16% of paediatric cases, compared with 0.3-0.6% and 3-4% 
respectively in the West [14-16].  This percentage equates to an approximate 
incidence of 1 child per 1 million [17]. The differences found between the East 
and the West vary widely between studies  W in fact, some reports dispute that 
there is a difference at all [18]. 
 
Location of GCTs and age distribution for occurrence 
Each of the subtypes of GCT in specific anatomical locations has a distinctive 
age distribution. Since GCTs can arise at several locations in the body, the 
statistics below are separated into GCTs in general, and then those that arise in 
the brain. 
Epidemiological studies have revealed that when all ages are included, over 
90% of GCTs are testicular. These testicular GCTs most frequently occur in young 
men. Although much less common, ovarian tumours span a similar, but slightly 
younger age range [19]. In comparison, sacrococcygeal tumours are 
predominantly perinatal; CNS GCTs occur predominantly before the age of 3; and 
mediastinal GCTs occur between the ages of 15-40. GCTs in neonates are one of 
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the most common tumours of this age, and approximately 95% of these tumours 
are teratomas. 
In the brain, each histological subtype has a particular age distribution, with 
germinomas arising in patients between 7 and 30 years of age. In contrast, the 
peak age of occurrence for non-germinomas is from birth to 20 years, after 
which their occurrence remains low but approximately constant into old age 
(Figure 1.2 C). Teratomas are particularly unusual as they are most frequently 
diagnosed at birth. Indeed, a very notable feature is that GCTs account for only 
~3% of brain tumours in children or adults, few of which are teratomas, but over 
50% of brain tumours diagnosed pre- and peri-natally are teratomas [7]. The 
male to female incidence of CNS GCTs is approximately 3:1, with the majority in 
the pineal region in males, and an excess of suprasellar tumours in females. This 
has been disputed when CNS GCTs have been stratified by location: pineal region 
tumours appear to show gender differences but non-pineal CNS GCTs do not 
[20]. 
One of the largest studies examined Japanese and American registries and 
found that 40% of CNS GCTs were located in the pineal region, with the 
remaining 60% in non-pineal regions of the brain. The overwhelming majority of 
CNS GCTs, 82%, were diagnosed as germinomas [18]. 
The true incidence of prenatal CNS GCTs is difficult to determine.  Between 
20-30% of all pregnancies are spontaneously aborted before term [21]; since 
teratomas can be well-formed by the end of the first trimester, it is plausible that 
CNS GCTs could cause miscarriage. Autopsies on these aborted foetuses are only 
carried out if there is a specific reason to do so, so the studies required to 
determine if teratomas might have been present and even caused the 
miscarriage are rarely performed.  
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1.3. The germ-cell progenitor hypothesis for CNS GCTs 
GCTs have been introduced from a clinical perspective, but how do these 
tumours arise? This thesis proposes a hypothesis that contradicts the currently 
accepted model to explain the aetiology of GCTs. In order to understand how 
these two hypotheses differ, both are explained in the next two sections. The 
currently accepted hypothesis of how GCTs develop will be described by 
introducing the history of GCTs, the mechanism that has been proposed to 
explain their origin, and the observations that have been used as evidence to 
support the argument.  
 
History of GCTs 
All GCTs are proposed to derive from the progenitors of the male and female 
germ line. For exƚƌĂŐŽŶĂĚĂů'dƐ ?dĞŝůƵŵ ?Ɛ ‘ŐĞƌŵ-cell hypothesis ? proposes that 
germ-cell progenitors mismigrate during early embryogenesis, become trapped 
ŝŶŵŝĚůŝŶĞůŽĐĂƚŝŽŶƐĂƚǀĂƌŝŽƵƐƉŽŝŶƚƐĂůŽŶŐƚŚĞďŽĚǇ ?ƐĂŶƚĞƌŽƉŽƐƚĞƌŝŽƌĂǆŝƐ ?ĂŶĚ
emerge as tumours when local events allow or promote reactivation of their 
proliferation (Teilum [22] referenced by Oosterhuis [2]) (Figure 1.1 A). In short, 
the normal process of germ-cell migration is disrupted. 
This hypothesis therefore arose because GCTs that form in the brain and 
ŽƚŚĞƌ ƐŝƚĞƐ ĂůŽŶŐ ƚŚĞ ďŽĚǇ ?Ɛ ŵŝĚůŝŶĞ ƐŚĂƌĞ ƐĞǀĞƌĂů ĨĞĂƚƵƌĞƐ ŝŶ ĐŽŵŵŽŶ ǁŝƚŚ
gonadal GCTs, such as chromosomal alterations and marker secretion. 
Investigations into specific gene expression, DNA-methylation, and mutations 
(such as activating mutations of the KIT oncogene [23]) of these tumours were 
later uƐĞĚƚŽƐƵƉƉŽƌƚdĞŝůƵŵ ?ƐŵŽĚĞů ?These arguments in favour of the germ cell 
hypothesis were recently reviewed by Oosterhuis et al. (2007) [2], and will each 
be discussed in this section. While markers and histology are undeniably similar 
regardless of location, I propose that the mismigration of germ-cells is not the 
only possible explanation for extragonadal GCT formation. In section 1.4 I will 
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outline the arguments to suggest that an alternative model for GCT formation at 
extragonadal locations is more likely.  
Before explaining the currently accepted hypothesis for extragonadal GCT 
formation, it is important to mention an alternative hypothesis. This alternative 
ƚŽ ďŽƚŚ dĞŝůƵŵ Žƌ ŽƵƌ ŚǇƉŽƚŚĞƐĞƐ  ŝƐ ƚŚĞ  “ĞŵďƌǇŽŶŝĐ ĐĞůů ƚŚĞŽƌǇ ?[24]. This 
hypothesis suggests that these tumours may arise from embryonic stem-cell 
(ESC) progenitors in the brain. However, this hypothesis also relies on 
misplacement of these progenitors. Since this is neither the consensus, nor 
relevant to my proposed hypothesis, it will not be discussed further.  
 
The currently accepted hypothesis for the origins of GCTs 
In 1965, Teilum proposed that germ-cell tumours that arose outside of the 
gonads had a germ-cell progenitor as the cell of origin. Since then, clinicians have 
accepted the assumption that all GCTs originated from a germ-cell progenitor, 
regardless of location [25]. The arguments to support this hypothesis are 
outlined below. 
Primordial or progenitor germ-cells (PGCs), or their derivatives, have been 
proposed to be the cells of origin for all GCTs. PGCs originate outside of the 
embryo in the extraembryonic mesoderm of the yolk sac around 7 days post 
coitum (dpc) in mice or 3-4 weeks after conception in humans [26, 27]. During 
development, PGCs migrate from the dorsal mesentery of the hindgut towards 
the gonads [20] (Figure 1.1 A). The normal migration of PGCs is in the  ‘midline ? 
plane of the embryo.  
It has been proposed that extragonadal GCTs arise from mismigration of 
PGCs along the midline of the embryo instead of towards the gonadal ridge. 
GCTs have been well documented to arise in midline locations of the brain, such 
as the pineal region. The formation of tumours in a specific pattern, such as in 
the midline, has not been found for any other type of tumour; indeed, the 
closest known observation is a metastasis, but primary CNS GCTs are not 
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classified as metastases. Before exploring the proposed mechanism for 
mismigration of PGCs that leads to the development of extragonadal GCTs, it is 
important to understand the aetiology of gonadal GCTs. 
Chaganti et al. (2000) have suggested that since GCTs often contain 
ĐŚƌŽŵŽƐŽŵĂů ĂďĞƌƌĂƚŝŽŶƐ ? ƚŚĞ ĐĞůů ŽĨ ŽƌŝŐŝŶ  “ŵĂǇ ďĞ ŽŶĞ ǁŝƚŚ ƌĞƉůŝĐĂƚĞĚ
chromosomes that expresses wild-type p53, harbours DNA breaks, and may be 
ƉƌŽŶĞƚŽĂƉŽƉƚŽƐŝƐ ?[28]. This cell has been proposed as the zygotene-pachtyene 
spermatocyte (figure 1.4 A; approximately 9 days) because of the recombination 
checkpoint it operates [29]. Aberrations in this mechanism would hypothetically 
allow an increased 12p, expression of cyclin D2, and p53 expression. All of these 
features are found in at least some gonadal and non-gonadal GCTs.  
ŚĂŐĂŶƚŝ ?Ɛexplanation is relevant to gonadal GCTs but occurs after PGCs 
have migrated. Since extragonadal locations do not provide the correct 
environment to form spermatogonia, it seems unlikely that PGCs could migrate 
and form spermatogonia, acquire mutations or chromosomal aberrations, and 
then form a GCT. Equally, it seems unlikely that developed zygotene-pachtyene 
spermatocytes could leave the gonads and migrate to the brain.  
In contrast, Schneider et al. (2006) [30] proposed that CNS GCTs arise from 
mismigration of germ-cell progenitors. According to this theory, these PGCs 
become trapped in distinct extragonadal locations before forming a tumour by 
proliferating and differentiating in an aberrant environment. It is important to 
compare the undifferentiated forms of germ cell progenitors with 
undifferentiated GCTs in order to understand their relationship. 
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Figure 1.4. Germ-cell model schematics. (A) A schematic showing the hierarchy of 
development from spermatogonia to spermatogenesis. Spermatogonia are found in the 
developed testis so this process occurs after puberty [Schwartz, 1999]. (B) A diagram 
showing the comparison between normal development from PGCs to an embryo, and a 
proposed mechanism for tumour formation. Spermatogonia or spermatocytes acquire 
mutations such as 12p gain and form CIS, which can lead to any type of GCT depending 
on additional mutations [Chaganti, 2000]. 
  
(A) 
(B) 
 
13 
 
Primordial germ cells (PGCs), or gonocytes, are cells that are normally 
responsible for gametogenesis. PGCs have the potential to form intratubular 
germ cell neoplasia unclassified (IGCNU), also known as carcinoma in situ (CIS). 
PGCs are accepted to be the progenitors of testicular GCTs, and are an 
undifferentiated progenitor cell type. Skakkebaek et al. (1998) suggested that 
germinoma/seminoma is a proliferative form of CIS, and that non-
germinomatous GCTs developed from CIS cells that have acquired additional 
stem cell properties (Figure 1.4 A). Non-germinomatous tumours are seen early 
in human development and germinomatous tumours more frequently occur later 
in development. Skakkebaek et al. (1998) proposes this relationship between 
various subtypes and age as evidence that CIS is an intermediate form of 
progenitor. Teratomas often occur at birth, and germinomatous and non-
germinomatous GCTs can be found during teenage years; however, 
germinomatous tumours are the most common GCT subtype found in older 
patients.  
In summary, Skakkebaek et al. (1998) suggests that 
germinoma/seminoma is simply a PGC/CIS/ITGCNU that has proliferated, in 
comparison to non-germinomatous GCTs, which have acquired stem-like 
properties [31]. The origins of GCTs in the gonads have been widely accepted 
and will be uncontested in this thesis. However, how do these PGCs arrive at 
extragonadal sites? The currently accepted mechanism  W the dysregulation of 
PGC pathway tracking  W is the next topic of discussion. 
 
The currently accepted mechanism for the mismigration of germ-cell 
progenitors 
PGC migration is controlled by the protein KIT and its ligand, STEEL. Local 
tissue releases STEEL and this determines the route for PGCs to travel (the 
migration route of PGCs is illustrated in red in Figure 1.1A.). When STEEL is 
absent, PGCs undergo apoptosis [32, 33]. One mechanism that might circumvent 
the need for STEEL to activate KIT receptor would be a mutation in the KIT gene 
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that abrogates </d ?Ɛ need for a ligand. Indeed, these mutations are found in 
many germinomas, which may support the germ-cell hypothesis. However, some 
germinomas, and most non-germinoma GCT subtypes lack KIT mutations, which 
argues against this hypothesis.  
The occurrence of sacrococcygeal GCTs has been used to strengthen the 
argument that extragonadal GCTs arise from PGCs that have mismigrated. PGCs 
arise close to the coccyx, and teratomas occur in a similar region around birth 
[34-36]. Since PGCs originate close to the tissue that forms the coccyx, non-
migrating PGCs may give rise to these tumours in this location. Since proponents 
of a PGC origin for GCTs suggest coccygeal GCTs arise from PGCs that have not 
migrated, they also propose that PGCs also initiate GCTs in other non-gonadal 
locations [37]. This evidence is contentious, and Chapter 1.4 explains why GCTs 
are found in this region. 
This section examined the mechanism that is currently accepted for PGC 
migration from the hindgut to various locations in the body, and how they 
eventually form GCTs. The next sections will examine the evidence that has been 
used to support this hypothesis. 
 
GCTs exhibit similar histology and markers regardless of location 
GCTs that have arisen in non-gonadal locations have very similar histology to 
those in the gonads. This includes the secretion of alpha-fetoprotein (AFP) in yolk 
sac tumours and human chorionic gonadotropin (HCG) for choriocarcinomas. The 
tumour cells also have similar morphology; for example, germinomas and 
seminomas both display undifferentiated germinal epithelium regardless of the 
location. Equally, germinomatous tumours in all locations express high levels of 
the protein KIT [25]. 
The incidence of the different GCT subtypes varies in different ages and 
locations (Figure 1.2 C). Schneider et al. (2006) [30] suggested stratifying GCTs by 
age rather than by tumour site or histology. They based their hypothesis on a 
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genetic analysis of isochromosome 12p and other gains. Specifically, the tumours 
that were analysed had the same histology/morphology regardless of age but 
had different molecular biology i.e. chromosomal aberrations [37]. These 
differences in chromosome copy number are discussed later. First, a different 
type of marker that supports a primordial germ cell origin will be discussed. 
 
Experiments in transgenic mice confirm that germ cells can mismigrate to 
extragonadal locations  
Gonadal GCT formation and mismigration of PGCs have been studied in 
several mouse models. Cook et al. (2011) [38] developed a population of mice 
that could consistently form teratomas in the gonads. These mice had mutations 
in Dnd1 and Bax genes, which control PGC migration and survival. These 
mutations prevented PGCs from downregulating pluripotent genes such as 
Nanog and Oct4. In summary, pluripotent abilities of PGCs were maintained in 
these mice and these progenitors formed teratomas in the gonads. However, no 
GCTs formed outside of the gonads. 
To test if PGCs or germ cells could, in principle, survive in non-gonadal 
locations, Runyan et al. (2008) [39] utilised Bax-null mice crossed with GFP-OCT4 
mice. Briefly, BAX controls apoptosis of PGCs, so PGCs that migrate outside of 
the normal route to the gonads would now survive. In GFP-OCT4 mice, GFP 
expression was found where OCT4 was expressed. OCT4 was used as a marker 
for PGCs, therefore, GFP expression was used to visualise the migration of PGCs. 
This study found that PGCs do migrate near the coccyx, where teratomas have 
been known to arise, suggesting that PGCs that did not undergo apoptosis could 
perhaps form sacrococcygeal teratomas. Since PGCs appeared to be able to form 
one type of extragonadal GCT, this was extended as a potential mechanism to 
form all extragonadal GCTs. Criticisms of this study and mechanism are discussed 
later in Chapter 1.4. 
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Gonadal and extragonadal tumours exhibit loss of imprinting 
Lack of imprinting in extragonadal GCTs suggests that GCTs arise from germ-
cell progenitors. To understand this, it is first important to discuss the process of 
DNA silencing through methylation, and imprinting. 
DNA methylation is a process whereby methyl groups are attached to a DNA 
base; specifically, a cytosine group. These methyl groups have been hypothesised 
to block the transcriptional machinery from binding to DNA; therefore, DNA 
methylation is a process to silence transcription. The sites to which methyl 
groups attach are known as  ‘CpG sites ? because methyl groups are only attached 
to a cytosine (C) base when it is  ? ?to a guanine (G) base [40].  DNA methylation is 
complex and not fully understood. Hypermethylation of a region of DNA in the 
promoter region will often silence a gene, but it is unknown what level of 
methylation in a region will allow transcription: is 40% methylation of the CpG 
sites in a gene promoter enough to silence transcription? The current consensus 
is that the regulation of each gene by methylation is different and some CpGs are 
more important than other. Later, DNA methylation and its role in silencing the 
gene that transcribed the transcription factor OCT4 will be discussed (Chapter 
1.4). For now, the importance of methylation in silencing genes will be used to 
describe imprinting. 
Imprinting occurs during embryogenesis, and results in the exclusive 
expression of either the maternal allele or the paternal allele. For this parental-
specific expression to occur, the allele that is not transcribed is silenced by 
methylation. An example of an imprinted gene is IGF2, which is expressed from 
the non-imprinted paternal allele. In comparison, H19 is expressed exclusively 
from the non-imprinted maternal allele (reviewed by [41]).  
Imprinting can occur in many cell types of the body, and many loci in the 
genome. High resolution analysis of embryonic and adult mouse brains revealed 
that over 1300 loci are influenced by parent-of-origin effects [42]. Different 
regions and ages of the brain were regulated by either maternal or paternal 
influences. Specifically, maternal alleles were activated during embryogenesis, 
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while paternal alleles were silenced. This process reverses during later brain 
development, with paternal alleles becoming activated, and maternal alleles 
being silenced. Indeed, sex-specific differences in genes apparently control 
hypothalamic region function, i.e. imprinted genes were more commonly shown 
in females [43]. In summary, imprinting is a complex process that influences a 
wide range of genes and in a variety of tissues. However, erasure of imprinting is 
thought to normally occur exclusively in germ cells. 
Imprinted genes in primary gonocytes have their methylation marks and 
histone modifications erased at 10.5-12.5 dpc in mice. Imprinting is then re-
established between 10-25 dpc in developing oocytes and 14.5-18.5 dpc for 
spermatogonia (Figure 1.5)[44]. Therefore, the cell of origin of GCTs has been 
suggested to be a germ-cell progenitor because of the similarity in imprinting 
status between GCTs and PGCs that have had their imprinting erased; 
furthermore, extragonadal GCTs also lack imprinting. 
 The erasing of imprinting enables the selective methylation of genes 
depending on the gender of the gametes. This erasure of imprinting, or lack of 
imprinting, is a phenomenon that is only thought to occur in germ cell 
progenitors, at specific times. Since GCTs often exhibit lack of imprinting, this has 
been used as evidence of GCT aetiology.  
GCTs that arise in the testis or ovary have been examined for imprinted 
genes and several studies found a significant lack of imprinting [45]. This pattern 
of imprinting is also seen in GCTs that arise in the brain. The commonality 
between lack of imprinting in both gonadal and non-gonadal GCT supports their 
analogous cell of origin. SNRPN is one gene that has been examined for the lack 
of imprinting. The imprinting pattern for SNRPN has not been seen in other 
cancers and does not appear to have a role in oncogenesis [37]. Therefore 
SNRPN was proposed as a good marker for imprinting since it should only inform 
about the cell of origin, rather than a protein that could cause cancer.   
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Figure 1.5. Schematics of models relating to the germ-cell theory. (A) CIS and gonocytes 
are presumed to be similar entities. CIS has been proposed to either proliferate to form 
germinoma, or undergo acquisition of stem-like properties to form the other subtypes of 
GCT. Adapted from [Skakkebaek, 1998][31] (B) The erasure and re-establishment of 
imprinting in mice. Methylation is erased between 10.5-12.5 dpc, before being re-
established for normal spermatogonia or oocyte function [Jelinic, 2007][44]. 
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When IGF2 is maternally imprinted, H19 is paternally imprinted and vice 
versa. However, analysis of both gonadal and non-gonadal GCTs revealed 
monoallelic expression of IGF2 but biallelic H19 expression, indicating a lack of 
imprinting of the maternal alleles. This erasure of methylation occurs during the 
development of female gametes, suggesting that this methylation pattern is a 
signature of where the cell of origin came from i.e. a PGC [37]. There also 
appears to be a difference in the IGF2 and H19 imprinting pattern in paediatric 
patients compared to adults, which has prompted the suggestion that the PGC 
was at a different stage of maturation in younger patients than in older ones.  
 
Gain of isochrome 12p is a marker for GCTs in all locations 
Chromosomal gain studies examining gonadal GCTs revealed an increase of 
chromosome 12p copy number [46]. Other studies found other gains such as 1q, 
3p, and 20q, or deletions such as 1p, 6q, and 18q, but these will not be discussed 
in detail [47]. Instead, in this section I will discuss 12p or i(12p) because these 
have been suggested markers of germ-cell progenitor as the cell of origin for all 
GCTs  [5]. To allow an understanding of this argument, I will describe the 
progression of GCTs in the gonads and the link of i(12p) to invasiveness, before 
exploring the relevance of i(12p) or 12p gain in the CNS. 
Nearly all gonadal GCTs have one or more copies of isochrome 12p (i(12p)), 
or a partial gain of 12p at one of several locations in the genome [28]. This gain 
has been suggested to be an aberration which occurred early in the oncogenesis 
pathway and has been retained. Indeed, the frequency of 12p or i(12p) gain 
suggests that it is required for GCT formation or progression in the gonads.  
Carcinoma in situ (CIS), or intratubular germ cell neoplasm unclassified 
(ITGCNU), is the equivalent to gonocytes (Figure 1.5 A). As previously mentioned, 
ITGCNU is histologically similar to germinoma, and germinoma may be an 
undifferentiated form of CIS. For gonadal GCTs, the cell of origin has been 
proposed to be either CIS/ITGCNU or the differentiated cell type spermatocytes 
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[48]. Chiganti et al. (2000) suggested that i(12p) is gained by aberrant 
recombination of a spermatocyte during meiosis [28](Figure 1.5 B). In order to 
understand the origins of CNS GCTs, it is important to first understand how 
gonadal GCTs are believed to form with respect to i(12p).  
The gain of i(12p) has been associated with ITGCNUs that were invasive, but 
non-invasive ITGCNU do not appear to exhibit i(12p) gain. Diagnoses of non-
invasive ITGCNU are rare but have been documented. This indicates that the 
acquisition of i(12p) can be an event occurring after the germ cells reach the 
gonads [49]. Equally, embryonal carcinoma-like cells have only been detected 
after the invasive stage i.e. when they have acquired i(12p) gain. Embryonal 
carcinoma cells are very similar to embryonic stem cells, and are thought to be a 
CIS cell that has acquired other stem-like or invasive properties. The consensus is 
that i(12p) is a marker for invasiveness, not necessarily GCT initiation [48]. This is 
important because if these aberrations can occur in GCTs which have been 
formed after successful germ-cell progenitor migration, i(12p) gain cannot be 
used as a marker or an event that is exclusively acquired during PGC migration. 
Most CNS GCTs also exhibit chromosomal aberrations, which can include the 
i(12p) or partial 12p gain, suggesting that extragonadal GCTs arise from the same 
progenitor as gonadal GCTs [30]. It has been suggested that the gain occurs 
between the gonadocyte and the spermatocyte stage when germ cell 
progenitors are proposed to undergo mismigration and travel with this 
aberration to the brain. In summary, the gain of i(12p) or parts of 12p have been 
found in all gonadal GCTs and the majority of CNS GCTs, which has been used to 
suggest that gain of 12p is a marker for a GCT cell of origin. 
Gain of 12p in CNS GCTs have been examined in several studies [50]. These 
studies suggested that since 12p was not ubiquitous in all CNS GCTs, 12p did not 
have an integral role in their initiation or maintenance.  
Indeed, GCTs arising before puberty may be genetically distinct from those 
that arise later, allowing them to be stratified by age rather than location [37]. 
Extragonadal GCTs that arise in children between prenatal and infant stages lack 
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gain of 12p, instead having a range of different chromosomal aberrations 
including 1q gain or 1p loss [47]. Isochrome 12p gain is much more common in 
adolescent boys, approximately 80%; in the brain, however, there are examples 
for each of the subtypes of GCT that either possess or do not possess the 12p 
gain [51-55].  
Proponents of the currently accepted hypothesis for extragonadal GCTs have 
argued that the 12p gain is found in both gonadal and extragonadal locations, 
and therefore they have a common cell of origin. Schneider et al. (2006) 
[30]believe that the 12p gain is likely to occur during the early stages of 
migration of primordial germ cells and this either forms gonadal GCTs or 
extragonadal tumours.  
Studies examining other types of brain tumours, such as medulloblastomas, 
have revealed that two histologically-identical tumours can have a different cell 
of origin and mechanism of formation [56]. Identifying the cell of origin for 
extragonadal GCTs is clearly complicated; it seems counter-intuitive that 12p has 
been suggested as a marker for germ cell tumour formation as an early event 
because this gain is not required to form a GCT. A gain that is found in two 
histologically similar tumours is not necessarily indicative of their common cell of 
origin, but it may be informative about the mechanism of forming that tumour. 
In summary, 12p gain may be an aberration that can initiate an event that leads 
to the formation of a GCT, but the cell of origin is not necessarily of PGC origin. 
This section has examined the data and 12p, or i(12p), is not necessarily 
gained in all CNS GCTs. Chromosomal gains are discussed in Chapter 1.4 as a 
possible mechanism for formation or invasiveness, but they do not appear to be 
strong evidence of a PGC lineage. 
 
1.4. Hypothesis for the aetiology of CNS GCTs 
In this section I will argue against the currently accepted hypothesis for the 
origins of extragonadal GCTs, specifically in the CNS. First, the arguments that 
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have been used in section 1.3 will be contended using relevant literature, and 
then the arguments in favour of an alternative mechanism will be discussed, i.e. 
the activation of OCT4 in neural progenitors. 
 
Evidence against germ-cell progenitors as the cell of origin for CNS GCTs 
The main arguments against the currently accepted hypothesis have been 
reviewed before [24], so this section will update the evidence against a germ-cell 
as the cell of origin for extragonadal GCTs.  
SNRPN has been implicated as a reliable marker for lack of imprinting, a 
phenomenon that has been suggested to only occur in germ cells. However, Lee 
et al. (2010) [57] provided evidence that SNRPN exhibits variable methylation in 
neural stem cells in the brains of mice and humans. Therefore, germ-cells are not 
the only cells that lack methylation or imprinting.  
It appears plausible that a brain tumour arises from a population of cells 
endogenous to the brain, rather than from mismigration of cells that originate 
outside of the embryo. Therefore, our hypothesis suggests that lack of imprinting 
is intrinsic to cancer formation and progression. Further, Jelinic et al. (2007) [44] 
showed that loss of imprinting has been documented in a range of other cancers. 
More importantly, lack of imprinting has been determined in gliomas, a type of 
brain tumour that originates from neural progenitors [58]. Here, Uyeno et al. 
(1996) proved that it is possible for a cancer that lacks imprinting to develop 
from a population of cells endogenous to the brain. Therefore, a CNS GCT would 
not be unique in exhibiting a lack of imprinting, and lack of imprinting is more 
likely to be a mechanism to form a cancer instead of being a marker for germ-cell 
progenitor mismigration.  
The other arguments to support a germ-cell progenitor as the cell of origin 
for CNS GCTs include i(12p) gain and experiments to disrupt germ-cell migration 
that form GCTs. Gain of copy number has already been discussed - briefly, it 
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appeared to be a marker for invasiveness and progression, rather than an early 
event in germ-cell migration.  
The evidence for PGC mismigration by Runyan et al. (2008) [39] presented in 
Chapter 1.3 requires further discussion. ZƵŶǇĂŶ ?Ɛ ƐƚƵĚǇ ƐƵŐŐĞƐƚĞĚ ƚŚĂƚ W'Ɛ
could migrate near the sacrum or coccyx when BAX had been mutated. The 
authors suggested that this observation was evidence that PGCs may form 
sacrococcygeal GCTs, and therefore extragonadal GCTs. However, there are 
several arguments against extrapolating extragonadal GCTs to include CNS GCTs. 
Firstly, no PGCs migrated to the brain, or even near the brain. Second, no GCT 
formation was observed in the brain. Even though there was a much higher 
number of PGCs that migrated to extragonadal locations, due to apoptotic 
disruption, PGCs still did not form tumours. Indeed, in a normal embryo, it is 
likely that the number of mismigrated PGC would be far fewer without the 
additional mutations used in the BAX model. Therefore, if a higher number of 
PGCs could not form a GCT, it is unlikely that this is a mechanism for initiating 
GCTs in the sacrococcygeal region.  
Proponents for the PGCs hypothesis would argue that perhaps additional 
mutations are required to form GCTs, such as mismigratory mutations. However, 
if an apoptotic mechanism is required in order to promote PGC survival it may be 
unlikely that another mutation to dysregulate migration would also occur in a 
human patient. Tumours in children often have very few mutations since they do 
not have a long time in order to acquire multiple somatic mutations. Therefore, 
it seems unlikely that a mutation in apoptosis and mismigration would both 
occur in a single cell that migrates to the brain.  
We will propose an alternative mechanism for sacrococcygeal teratoma 
formation at the end of this chapter. Since the arguments for germ-cell 
progenitors forming CNS GCTs have been reviewed, our alternative hypothesis 
for CNS GCTs will be the next topic for discussion.  
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Evidence for pluripotency as a mechanism for CNS GCT formation 
In recent years, many studies have used the ability of cells to generate a 
ƚĞƌĂƚŽŵĂ ?ŽŶĞƐƵďƚǇƉĞŽĨ'd ?ĂƐĂŶĂƐƐĂǇŽĨƚŚĂƚĐĞůů ?ƐĂďŝůŝƚǇƚŽƉƌŽĚƵce all cell 
types of the body i.e. pluripotency [4]. These studies have provided new support 
for the hypothesis that teratomas could be derived from cell types in the body 
other than germ-cell progenitors. Furthermore, there is good evidence that the 
other GCT subtypes ĂƌĞ  ‘ůŝŶĞĂŐĞ ƌĞůĂƚĞĚ ? ƚŽ ƚĞƌĂƚŽŵĂƐ ? dŚĞƌĞĨŽƌĞ ? ŝĨ ƚĞƌĂƚŽŵĂƐ
could arise from non-germ cell lineages the same could be true of the other 
subtypes. The evidence for both propositions will be analysed: that teratomas 
could readily arise from somatic cells with no relationship to the germ-cell 
lineage; and that other GCTs are directly related to teratomas and could 
therefore have the same non-germ cell origins. These considerations suggest 
that all CNS GCTs are likely to be caused by transformation of endogenous brain 
cell progenitors. One reason that they share features in common with gonadal 
germ-cell-derived GCTs may be that they share the same molecular defects, and 
in turn these cause shared biological features.  In order to dispute the arguments 
in favour of a germ-cell progenitor as the cell of origin for extragonadal GCTs, it is 
necessary to understand what makes a cell pluripotent.  
One of the most important genes is Oct4 (also known as Pou5f1) and this 
encodes the transcription factor OCT4, so this will be discussed at length. This 
section will first examine the gene structure for Oct4 before detailing the 
mechanisms that regulate OCT4, and the processes that OCT4 regulates. The 
final topic of this section will describe the role of OCT4 in pluripotency and 
explain the relevance to this thesis, i.e. as a potential mechanism for neural 
progenitors to form GCTs. 
 
Oct4 gene structure and Oct4 isoforms 
Oct4, also known as Oct3, OTF3, or OTF4, is an octamer-binding transcription 
factor that is crucial for development and pluripotency. OCT4 is transcribed from 
the Pou5f1 (POU domain, class 5, transcription factor 1) gene on chromosome 17 
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in mice or chromosome 6 in humans. POU (or Pit/Oct/Unc) domain-containing 
proteins have the ability to bind DNA. For consistency, this thesis will use Oct4 as 
the gene name synonymous to Pou5f1. Oct4 can generate 3 different transcripts 
known as OCT4A, OCT4B, and OCT4B1 (Figure 1.6 A). These transcripts can form 
4 isoforms; OCT4A, OCT4B-190, OCT4B-265, and OCT4B-164, due to alternative 
stop and start codons or alternative splicing. Only OCT4A is known to be 
important in embryonic stem cell self-renewal and pluripotency. Although the 
functions of other isoforms are not fully characterised, it is known that they 
cannot sustain ESC self-renewal and are not thought to have similar functions to 
OCT4A [59, 60]. OCT4 in this thesis refers to the pluripotency-related protein 
translated from the OCT4A transcript. 
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Figure 1.6. OCT4 transcripts and interaction pathways. (A) Diagram of the Oct4 ŐĞŶĞ ?Ɛ
alternative splicing and isoforms for Oct4. Each exon is labelled E1-E4 with exon 2 
divided into E2a-E2d. Alternative splicing produces three mRNA transcripts of Oct4A, 
Oct4B, and Oct4B1. These transcripts produce a total of 4 isoforms but only Oct4A 
protein is found to be important in pluripotency. Diagram from [Wang, 2010][59] (B) A 
summary of the important interactions that Oct4 is regulated by (in blue) or interacts 
with (in red). Oct4 is part of a vast regulatory network.  
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Oct4 contains two POU domains: an amino-terminal specific POU domain 
(POUs), and a carboxyl-terminal homeodomain (POUh) [61]. Both of these 
domains use a helix-loop-helix conformation to bind DNA for OCT4s various 
functions - the most noteworthy of which is its role as a transcription factor.  
The Oct4 gene is conserved across diverse species from mammals such as 
Homo sapiens (humans), Pan troglodytes (chimpanzee), and Mus musculus 
(house mouse), to Danio rerio (zebrafish) suggesting its importance across 
evolution. The importance of OCT4 is reinforced by the extensive network of 
proteins that OCT4 interacts with.  
 
Mechanisms that regulate OCT4  
OCT4 itself is regulated by several mechanisms (Figure 1.6 B). The first is 
related to a protein called UBC9, which is an E2 Ubiquitin conjugating enzyme for 
SUMO modification. UBC9 is thought to stabilise OCT4 as one mechanism to 
regulate the levels of protein in the cell [62]. This is significant because OCT4 
regulates stem cell renewal and pluripotency in a concentration-dependent 
manner.  
OCT4 expression is a complex process that is controlled by a multitude of 
factors that interact with the promoter, and the distal- and proximal- enhancers. 
Retinoic acid has been shown to dissociate the factors involved in all three of 
these areas, which leads to a decrease in OCT4 mRNA levels [63]. However, when 
the complexes that interact with only one of these regulatory elements 
(promoter, distal, or proximal enhancer) are removed, there is little effect on 
OCT4 mRNA levels. This suggests a complex regulatory pathway for the 
regulation of Oct4 expression. One mechanism to regulate whether these 
proteins can bind to either the promoter, proximal, or distal enhancers is DNA 
methylation. DNA methylation is arguably the most important mechanism to 
regulate Oct4 expression. 
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The Oct4 gene has multiple regions of dense CpG sites called islands. When a 
high percentage of the CpG sites in islands become methylated the transcription 
of Oct4 is silenced [64]. 5-Aza-2-Deoxycytidine (5-Aza) is a drug that has been 
experimentally shown to globally demethylate the genome, which includes the 
promoter region of Oct4 to allow Oct4 expression. 5-Aza inhibits methylation by 
binding DNA methyltransferases (DNMTs) covalently to the DNA and disrupting 
interactions between DNMTs and transcriptional repressors. This leads to 
inhibition of methylation and dissociation of histone deacetylases (HDACs), 
which can in turn remodel the chromatin in order for genes to be expressed [65].  
Oct4 transcription is silenced by methylation of the distal enhancer, proximal 
enhancer, and promoter region of Oct4. The mechanism by which Oct4 is 
transcriptionally silenced by methylation is outlined by Deb-Rinker et al. (2005) 
[66]. This process of methylation and maintenance is one that may have a role in 
tumour formation. If DNA methylation is not properly established the result may 
be aberrant gene expression. In fact, aberrant DNA methylation is a hallmark of 
many cancers [40]. Indeed, cancer is not the only disease with underlying DNA 
methylation dysfunction, highlighting the importance of this silencing 
mechanism [67]. 
Aberrant DNA methylation has been documented as a cause for several 
developmental diseases. Spina bifida is one such disease, which is caused by lack 
of methyl groups or metabolites [67, 68]. The fact that methylation has been 
known to cause both developmental diseases and cancer is important for this 
thesis. Dysregulation of methylation has been established as a mechanism for 
forming tumours, therefore it may be relevant for GCTs in the CNS.  
Demethylation is associated with activation of a gene, and therefore this 
may be one mechanism of activating Oct4. Undifferentiated ESCs have 
predominately unmethylated promoter- and enhancer-regions, which supports 
this theory. Demethylation appears to be a prerequisite to expression but there 
are other factors that are required. For example, the promoter region of Oct4 
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can be acetylated at lysine 9 and 14 to allow the gene to be transcriptionally 
active [69]. This modification is one of several that are not fully understood. 
Oct4 expression requires a complex network of proteins. LRH-1 (liver 
receptor homolog-1), also known as NR5A2, binds to the proximal enhancer and 
promoter regions to activate and maintain Oct4 expression; however the 
mechanism for this activation is unknown.  
GCNF expression is thought to inversely correlate with Oct4 expression due 
to a complex network of interactions [70]. GCNF differentially recruits 
methylated CpG binding domain (MPD) factors to the Oct4 promoter for DNA 
methylation and silencing. Knockout of GCNF caused the Oct4 promoter to be 
less methylated and allowed expression of Oct4; however, the level of 
expression was lower than normal, suggesting redundancy in the regulation of 
Oct4 expression.  
Embryonic stem cells (ESCs) highlight the balance between Oct4 expression 
and silencing. Once the promoter or other regulatory elements in Oct4 are 
methylated, transcription is normally permanently silenced. The most obvious 
question is how ESCs maintain Oct4 expression after it has been activated. In 
ESCs where Oct4 is active, the promoter, distal, and proximal enhancers are 
complexed by DNA binding proteins and transcription factors, which prevent 
methylation. The complexes that bind DNA allow continuous expression of Oct4 
until differentiation signals remove these factors. During differentiation these 
factors are removed and transiently replaced by repressors that are thought to 
ensure long term silencing of the gene. Soon after these repressors bind, 
sequential DNA methylation occurs, which silences Oct4 [66]. Silencing of Oct4 in 
mice occurs by E8.5 and correlates strongly with increased expression of GCNF 
[71]. However, some studies have shown that neural stem cells still express Oct4 
as late as E13.5 [64]. Notably, expression of Oct4 in NSCs at E13.5 was much 
lower than ESCs. 
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Processes regulated by OCT4 
OCT4 interacts with a wide range of proteins (as reviewed by Pardo et al 
(2010) [72], summarised in Figure 1.6 B), which control several processes 
including recombination and chromatin remodelling. OCT4 interacts with the 
topoisomerase TOP2A, and helicases XRCC 5 and XRCC 6, which are all associated 
with recombination. OCT4 is also known to have a role in chromatin remodelling 
by binding to NANOG [73] and interacts with the chromatin remodelling proteins 
NFRKB (Nuclear factor related to kappa-B-binding protein), ACTL6A (Actin-like 
protein 6A), and INO80. OCT4 binds to subunits at the ISWI Chromatin 
Remodelling Complex such as SMARCA5 indicating OCT ? ?Ɛ ĚŝǀĞƌƐĞ ƌŽůĞs in 
chromatin remodelling. While the mechanism for OCT ? ?ƐƌĞŐƵůĂƚŝŽŶŽĨĐŚƌŽŵĂƚŝŶ
remodelling through such factors is unclear, dysregulation of OCT4 may have 
disruptive effects on chromatin structure. 
Pardo et al.(2010) [72] showed OCT4 interaction with several enzymes 
including OGT (O-linked N-acetylglucosamine transferase). OGT links O-linked N-
acetylglucosamine to OCT4 to regulate apoptosis and epiboly movements. OCT4 
in ESCs has been shown to be modified by O-GlcNAc by Webster et al [74]; 
however, the exact effect of this modification is not known. 
OCT4 is also known to bind to several key pluripotency factors including 
KLF4, SOX2, and NANOG [72]. Clearly, OCT4 is regulated in a complex manner 
with several redundant mechanisms. This implies that OCT4 is an important 
transcription factor, and evolution has selected for mechanisms that tightly 
control Oct4 expression. The role of OCT4 in pluripotency and as a master 
regulator is the most relevant process to this thesis and therefore will be 
examined more closely. 
 
OCT4 function in pluripotency 
 OCT4 is a transcription factor that has been well-documented for its role 
in pluripotency and stemness: stemness is a feature that separates a stem cell 
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from a somatic cell. Pluripotency will be discussed first, and the role of OCT4 will 
be highlighted after. 
 A pluripotent cell is one that can self-renew, and has the capability to 
differentiate into all of the cell lineages in the embryo and adult. ESCs from the 
inner cell mass of an embryo are a good example of a pluripotent cell type. Four 
key genes are required for the induction of a pluripotent cell from a somatic cell: 
KLF4, SOX2, OCT4, and MYC [75]. Regulation of the levels of OCT4 is a tightly 
controlled balance because downregulation of OCT4 causes differentiation into 
mesoderm and endoderm, but overexpression causes differentiation into 
ectoderm. In this respect, OCT4 is different from many other transcription 
factors because OCT4 level needs to be carefully maintained in order to either 
activate or repress transcription. Sterneckert et al. (2012) [76] have suggested 
that OCT4 does not simply activate pluripotency; rather, they suggest that OCT4 
ŝƐ Ă  “ŐĂƚĞŬĞĞƉĞƌ ŝŶƚŽ ĂŶĚ ŽƵƚ ŽĨ ƚŚĞ ƌĞƉƌŽŐƌĂŵŵŝŶŐ ĞǆƉƌĞƐƐǁĂǇ ƚŚĂƚ ĐĂŶ ďĞ
ĚŝƌĞĐƚĞĚ ďǇ ĂůƚĞƌŝŶŐ ƚŚĞ ĞǆƉĞƌŝŵĞŶƚĂů ĐŽŶĚŝƚŝŽŶƐ ? ? WůƵƌŝƉŽƚĞŶĐǇ ĂƉƉĞĂƌs to rely 
on several factors, and crucially OCT4 is required for reprogramming. 
 OCT4 has been suggested as a gatekeeper/master regulator, and 
transdifferentiation has been used as evidence for this. Activation of OCT4 in the 
presence of signals such as fibroblast growth factor (Fgf) and epidermal growth 
factor (Egf) have been used to induce somatic cells directly into neural 
progenitors instead of pluripotent ones [77]. In summary, OCT4 is integral to 
initiating pluripotency and stemness.  
In addition to initiation of pluripotency, OCT4 is also important in self-
renewal. OCT4 cooperates with two transcription factors: SOX2 and NANOG. 
Both SOX2 and NANOG are integral to self-renewal; however, it is important to 
note that NANOG is not necessary for induction of pluripotency. NANOG, OCT4, 
and SOX2 can activate or repress expression of each other. Aside from 
modulating the expression of these genes, OCT4 and NANOG can bind to MYC-N, 
which is known to promote self-renewal and proliferation [78]. Within the 
genome, OCT4 and NANOG were shown to have 1083 or 3006 DNA binding sites 
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respectively [78]. This suggests that these pluripotency regulators interact with a 
wide range of sites, and maintain pluripotency through a complex network. It is 
likely that there are several feedback mechanisms to regulate pluripotency 
instead of a binary system to activate and maintain pluripotency; for example, 
the regulation of NANOG, OCT ? ? ĂŶĚ^Ky ?ŵŽĚƵůĂƚŝŶŐĞĂĐŚŽƚŚĞƌ ?ƐĞǆƉƌĞƐƐŝŽŶ
levels [79].  
 The OCT4-SOX2-NANOG regulatory network is clearly crucial for the 
maintenance of pluripotency in stem cells. Each of these proteins can maintain 
its own expression by combining into complexes with other pluripotent factors; 
for example, OCT4 and SOX2 can form a heterodimer, which feedback to 
maintain their own expression [80]. Equally, OCT4 can repress its own 
expression, presumably to regulate the fine balance between over- and under-
expression [79]. This illustrates the intricate regulation of each of these genes. 
The complexity of this process provides several mechanisms that may be a cause 
for dysregulation. This thesis tests the hypothesis that dysregulation of one of 
these mechanisms may lead to the aberrant expression of genes such as OCT4.  
 In summary, OCT4 is a master regulator of both induction of pluripotency 
and self-renewal. While it is integral to these processes, several other pathways 
modulate the behaviour of the pluripotency of the cell, such as SOX2, NANOG, 
MYC, and KLF4. This complex and vast network is finely balanced and may be a 
weakness that allows tumour formation through activation of OCT4.  
 
Neural stem cells can be readily activated to form teratomas by activation of 
the pluripotency gene Oct4 
Teratomas are very unusual because they include cell types derived from all 
of the three germ layers that make up the developing embryo. As such, they can 
contain many of the differentiated cell types of the body, such as skin, bone, 
muscle and hair, but in a disorganized form. Despite their size, and sometimes 
very rapid growth, teratomas rarely metastasise and so are considered benign.  
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Since teratomas contain all three germ layers, the ability of a cell to form a 
ƚĞƌĂƚŽŵĂ ŝƐƵƐĞĚĂƐĂŶĂƐƐĂǇŽĨ ƚŚĂƚĐĞůů ?ƐƉůƵƌŝƉŽƚĞŶĐǇ ? /ŶƉĂƌƚŝĐƵůĂƌ ? ƚĞratoma 
formation has recently been used to determine if specific treatments can cause a 
cell to acquire such pluripotency, a key goal of studies to generate stem cells 
from somatic cells in regenerative medicine. 
In 2006, Takahashi et al. [75] found that the overexpression of just four 
genes was sufficient to trigger a process in somatic cells, such as fibroblasts, that 
led some of them to become pluripotent. This technique parallels other methods 
of forming pluripotent cells such as somatic cell nuclear transfer, and cell fusion 
(Figure 1.7). Pluripotent cells produced by overexpression of these four genes 
(also known as  ‘induction ?) were then able to form teratomas when transplanted 
into immune deficient mice [75]. More strikingly, in 2009, Kim et al. found that 
overexpression of a single gene, Oct4, was sufficient to initiate a process in 
neural stem cells (NSCs) that eventually induces pluripotent cells to form [81].  
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Figure 1.7. Three mechanisms known to be able to form a pluripotent cell. Three 
methods for generating pluripotent cells are illustrated. (i) Somatic cell nuclear transfer: 
an enucleated oocyte is injected with a somatic nucleus. In vitro, these cells can be 
cultured to produce embryonic stem (ES) cells. (ii) Transcription factor reprogramming: a 
specific combination of several genes expressed in combination can reprogram a 
somatic cell to form a pluripotent cell. The original four factors are OCT4, KLF4, C-MYC, 
and SOX2; however, each of these can be replaced by a different gene illustrating the 
redundancy in reprogramming [Greenow,2012] [82]. (iii) Cellular fusion: ES cells and 
somatic cells can be fused to form a cell that exhibits pluripotent features. Each one of 
these methods generates a pluripotent cell that can contribute either to a chimeric 
mouse or to a teratoma if transplanted.  
  
 
35 
 
In fact, NSCs may be the only somatic cell type that is so easily encouraged 
to become pluripotent - in other words, to acquire the ability to form a teratoma. 
For many years, Oct4 has been regarded as one of the key genes necessary for 
the pluripotent capability of an embryonic stem cell (ES cell). But what do we 
know of OCT4 in the cells of the developing brain?  
Dividing cells in the early developing brain of foetal mice maintain a low 
level of expression of Oct4, but by this stage of development the cells are clearly 
no longer pluripotent [64]. In fact, these cells express a dramatically reduced 
level of OCT4 compared with the embryonic stem cells that are found much 
earlier in embryonic development. This reduced expression seems to be due to 
methylation of the regulatory region of the gene, which becomes even more 
pronounced as brain development proceeds, such that the Oct4 gene is 
effectively silenced by two thirds of the way through gestation.  However, Oct4 
expression can be readily reactivated by treatment with the demethylating 
agent, 5-azacytidine [83-85]. If the same is true in humans, then disruption to the 
methylation of this gene in just one cell during the early period when this 
methylation is incomplete, and therefore potentially more plastic, could 
recapitulate the pluripotency experiments described above. This could lead to 
inappropriate expression of Oct4 resulting in the formation of a teratoma. The 
activation of OCT4 in neural progenitors provides a plausible mechanism to 
explain why this type of tumour can appear in the brain by the point of birth and 
occur at a much lower frequency later in life.  
 
Expression of pluripotency genes in GCTs 
So is there any evidence that OCT4 is reactivated in human teratomas or 
other GCTs seen in the brains of patients? Recent studies of GCTs, including 
those using global gene expression analyses, have demonstrated substantial 
expression of Oct4 in germinomatous tumours, including those in the brain [86-
88]. Oct4 expression is not, however, a notable feature of teratomas or yolk sac 
tumours. This can be explained by the complex nature of these tumours.  
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In fact it would be surprising if Oct4 did feature highly on the list of genes 
seen in pure teratomas or yolk sac tumours; the majority of cells in such tumours 
are differentiated, and OCT4 is a feature of the proliferating stem cell proposed 
to be responsible for growth of the tumour.  
In summary, Oct4 overexpression in NSCs can trigger teratoma formation, 
and Oct4 expression is a significant feature of cells from several subtypes of GCT. 
Since Oct4 expression correlates closely with the methylation status of its 
promoter and can be activated experimentally by demethylation, loss of 
methylation of the Oct4 gene in NSCs during embryogenesis would be predicted 
to allow these cells to form teratomas. This leads us to hypothesise that Oct4 is 
more readily activated by demethylation in early embryogenesis and that this 
leads to one or more cells to become pluripotent. These cells then form a 
teratoma that can grow to a significant size by birth.  
 
Extragonadal GCT subtypes share a common lineage 
Activation of Oct4 expression in NSCs can lead to the formation of 
teratomas, although this has not been shown in the brain. This is significant and 
Chapter 4 tests the hypothesis that OCT4 can initiate the formation of a CNS GCT. 
But what of the other subtypes of GCT? The most direct line of evidence in 
support of the hypothesis that Oct4 expression can result in the formation of all 
subtypes of CNS GCT is the direct lineage relationship these other subtypes have 
to teratomas. Since there is strong evidence that little needs to go wrong for 
NSCs to form teratomas, this relationship implies that the other CNS GCTs could 
also be NSC-derived. This topic will be discussed in greater depth in Chapter 3. 
 
Mechanisms by which NSCs might be transformed to form GCTs 
We propose that CNS GCTs are likely to originate from neural progenitors 
rather than germ-cell progenitors that have mismigrated. We hypothesise that 
Oct4 expression may be the mechanism by which neural progenitors retain or 
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acquire pluripotent properties leading to the formation of teratomas and 
perhaps other types of GCT. It seems likely that other subtypes of GCT arise 
when additional events also occur in GCT progenitor cells. In addition to 
expressing high levels of OCT4, germinomatous tumours often exhibit mutations 
in the tyrosine kinase receptor oncogene, KIT, regardless of their location [23]. 
These mutations may therefore drive the tumour to develop as this class of GCT. 
Other common molecular events that are highly restricted to specific subtypes of 
GCT remain to be elucidated. 
One striking feature of non-germinomatous tumours is a high level of gene-
specific methylation [89, 90], which could therefore play a role in determining 
the GCT subtype. Hence, disrupted methylation might cause activation of Oct4, 
but silence other genes, thus providing a unifying mechanism for this group of 
tumours. A schematic containing our NSC hypothesis can be found in Figure 1.8. 
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Figure 1.8. The brain-cell theory for intracranial germ cell tumours. (A) Model for the 
aetiology of different histological subtypes of GCT. Activation of OCT4 may lead to 
aberrant cell growth and pluripotency to form something equivalent to CIS. This will go 
on to form an immature embryonal carcinoma and progress to a teratoma. (B) Model 
for the aetiology of neural stem cell-derived intracranial GCT. Neural stem cells acquire 
or maintain Oct4 expression to form a cell with pluripotent features. This cell can form 
any type of germ cell tumour found in the CNS. If these cells are in an environment that 
supports tumour formation, these cells can simply differentiate into teratoma and 
embryonal carcinoma. Yolk sac tumours and choriocarcinomas may require an 
additional event to allow differentiation into this lineage, possibly involving aberrant 
methylation. Since germinomas robustly express KIT that often carries an activating 
mutation, this may be the event that biases the cells towards this type of tumour. 
 (A) 
 (B) 
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Demethylation as a mechanism for GCT formation 
The carcinogenic model of cancer development, which is accepted for adult 
cancers, seems unlikely to explain the earliest tumours seen in children. The 
reason that cancer is generally a disease of old age is the time it takes for 
sequential carcinogenic damage to accumulate in the genome of a single cell. 
Given the early age of occurrence in children, especially teratomas that are 
found at birth ? Ă ĨĂƐƚĞƌ ĂůƚĞƌŶĂƚŝǀĞ ŵĞĐŚĂŶŝƐŵ ŝƐ ŶĞĞĚĞĚ ƚŽ ĞǆƉůĂŝŶ ĐŚŝůĚƌĞŶ ?Ɛ
tumours (Reviewed in [91]). Methylation changes are a prime candidate for a 
single event that could disrupt the expression of many genes, producing cells 
with all of the features necessary to form a cancer.  Indeed, aberrant 
methylation has been shown to occur in a range of other types of paediatric 
brain tumours [92-94]. 
Our model suggests that demethylation of Oct4 either activates or maintains 
its expression inappropriately. If demethylation of Oct4 is a pivotal event in GCT 
aetiology, this could have a direct bearing on therapeutic strategies since levels 
of DNA methylation can be directly affected by drugs such as 5-azacytidine. By 
better understanding the role of methylation in the aetiology of these different 
classes of GCT, evidence-based strategies targeting methylation could be 
developed. In particular, if the molecular machinery that specifically regulates 
Oct4 methylation can be determined, then this could be targeted by a more 
directed therapy instead of using drugs that alter DNA methylation globally.  
The Oct4 gene has been examined for promoter methylation as a 
mechanism for silencing expression. However, little is known about the role of 
OCT4 protein and methylation of other regions of DNA. OCT4 has been shown to 
have a role in demethylating specific regions of DNA, although this mechanism 
has not been elucidated [95]. This may eventually provide a mechanism by which 
OCT4 self regulates its own methylation - by methylating and silencing other 
genes. In short, the gene that encodes Oct4 expression, and OCT4 itself, are both 
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part of a complex regulatory system that involves DNA methylation, and 
disruption of this system may lead to the formation of a GCT. 
 
Diseases associated with GCTs and their relationship to OCT4 
A ƐƚƌŝŬŝŶŐŽďƐĞƌǀĂƚŝŽŶ ŝƐ ƚŚĂƚŽǁŶ ?ƐƐǇŶĚƌŽŵĞ ?ĐĂƵƐĞĚďǇƚŚĞƉƌĞƐĞŶĐĞŽĨ 
an extra chromosome 21) and KlineĨĞůƚĞƌ ?ƐƐǇŶĚƌŽŵĞ ?ĐĂƵƐĞĚďǇƚŚĞƉƌĞƐĞŶĐĞŽĨ
an extra X chromosome) are associated with an increased prevalence of CNS 
GCTs [96-98]. Why these very different disorders result in this particular type of 
brain tumour is not yet known, but it does imply that overexpression of a 
complex set of genes produces a particular bias towards extragonadal GCTs. This 
presumably overrides any deficiency in brain cell proliferation that might exist in 
ƉĞŽƉůĞ ǁŝƚŚ ŽǁŶ ?Ɛ ƐǇŶĚƌŽŵĞ ? 'ŝǀĞŶ ƚŚĂƚ ƚŚĞƐĞ ĚŝƐŽƌĚĞƌƐ ŝŶǀŽůǀĞ ĚŝĨĨĞƌĞŶƚ
chromosomes, it seems possible that any mechanism that causes overexpression 
of a large set of genes might also bias towards extragonadal GCT development. 
Deregulation of epigenetic gene control (such as DNA methylation) represents 
one such potential mechanism and an alternative to a model that relies simply 
on activation of OCT4. 
Similar arguments may apply to the origins of GCTs in other extragonadal 
regions, such as mediastinal and sacrococcygeal tumours. This requires that a 
likely progenitor be identified in these locations.  In the case of the 
sacrococcygeal tumours there is indeed evidence of such a progenitor. In 
Chapter 1.3 the argument in favour of a germ-cell progenitor suggested that 
sacrococcygeal tumours arose from mismigration of germ-cells. This was partially 
due to the proximity of the normal germ-cell progenitor migratory route. 
However, recent studies of mouse embryos, Cambray and Wilson (2007,2002) 
[99, 100] have shown that pluripotent progenitor cells remain present at the 
base of the spine as late as mid-gestation in mice. Given that sacrococcygeal 
tumours are generally seen by birth, when they can already be very large, it is 
plausible that these tumours are initiated at a time during foetal development 
when such pluripotent progenitor cells might still be present.  To date, no similar 
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progenitor has been identified in the mediastinal region, though there have been 
few studies that had the potential to identify such cells. In summary, at least one 
extragonadal location appears to contain a pluripotent GCT-progenitor, which 
weakens the argument that all GCTs arise from mismigrating PGCs. 
 
1.5. Aims of project 
This project aims to test an alternative to the hypothesis that all GCTs arise 
from PGCs that have mismigrated. One of the main aims is to determine if there 
is an alternative cellular origin for intracranial GCTs along with a potential 
mechanism: the activation of Oct4 by demethylation of its promoter region. Our 
model provides a testable hypothesis; that activation of OCT4 in NSCs of the 
developing brain could trigger formation of a GCT, most likely a teratoma.  If this 
proves to be true, it will then provide a starting point to establish the full 
aetiology of these tumours. Published clinical reports support a model in which 
the various histological subtypes of GCT are largely inter-convertible; therefore, 
it should also be possible to use a mouse model to analyse potential mechanisms 
that underlie these transitions, such as KIT mutations in germinomatous 
tumours.  
The topics discussed in this thesis examine several features related to CNS 
GCTs. The first section examines phenomena specific to GCTs, such as the 
frequent occurrence in the midline instead of the lateral regions of the brain. The 
second section examines Oct4 expression as a mechanism for CNS GCT formation 
using in vitro and in vivo techniques. The final section proposes a mechanism to 
form one of the subtypes of CNS GCT: germinomas.  
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Chapter 2: Materials and methods 
Literature review criteria 
There were several criteria for the literature review examining teratomas 
in the intracranial region. The intracranial region was defined as the CNS, 
excluding the spinal cord. There are several types of teratoma near the CNS that 
were not included; for example, epignathus (teratoma of the palate) and 
intraocular teratomas. Equally, cases where teratomas were mixed with other 
subtypes were not included in the results. 
There were no restrictions on the age of the patient, language of the 
publication, or access to publication. For inclusion in the results, there must have 
been a diagnostic scan, (for example MRI or CT), and only cases published after 
1990 were included. 
The main sources of peer-reviewed cases were Pubmed 
(www.ncbi.nlm.nih.gov/pubmed), and Web of Knowledge 
 ?ŚƚƚƉ P ? ?ĂƉƉƐ ?ǁĞďŽĨŬŶŽǁůĞĚŐĞ ?ĐŽŵ ) ? ^ĞĂƌĐŚ ƚĞƌŵƐ ŝŶĐůƵĚĞĚ  ‘ƚĞƌĂƚŽŵĂ ? ?
 ‘ŝŶƚƌĂĐƌĂŶŝĂů ? ? ‘ĐĞŶƚƌĂůŶĞƌǀŽƵƐƐǇƐƚĞŵ ? ? ‘ŐĞƌŵĐĞůůƚƵ ŽƵƌ ? ? ‘ďƌĂŝŶ ? ?ĂŶĚ ‘ŚĞĂĚ ?ŝŶ
various combinations.  
Each of the cases that matched the criteria was assessed for references to 
other papers; for example, if a paper mentioned other cases of CNS teratoma, 
these were also included as long as they matched the criteria. Over 500 papers 
were reviewed, and all those papers that matched the criteria were included in 
the results. 
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Transgenic Mice 
Nestin-rtTA, TetO-Oct4 mice  
 Nestin-rtTA mice (FVB-Tg (Nes-rtTA) 306Rvs/J, The Jackson Laboratory) 
were crossed with TetO-OCT4 mice (B6;129-Gt(ROSA)26Sor
tm1(rtTA*M2)Jae
 
Col1a1
tm2(tetO-Pou5f1)Jae
/J, The Jackson Laboratory). This produced mice that were 
homozygous for the Nestin-rtTA transgene, and homozygous for TetO-OCT4. 
 
Col1a1::TetOP-OCT4 mice 
 All mice were homozygous for the Rosa26-rtRA-nls cassette. Adult male 
mice (B6;129-Gt(ROSA)26Sor
tm1(rtTA*M2)Jae
 Col1a1
tm2(tetO-Pou5f1)Jae
/J, The Jackson 
Laboratory) that were heterozygous for the Col1a1::TetOP-OCT4 cassette were 
crossed with homozygous females to set up a colony of mice. The genotype for 
each mouse in the breeding program was confirmed to be either homozygous, 
heterozygous, or wild-type for the Col1a1::TetOP-OCT4 cassette. 
 
In vivo induction of OCT4 in Col1a1::TetOP-OCT4 mice with doxycycline 
 OCT4 was induced in vivo by administering 100µl of 2.4mg/ml doxycycline 
(Fluka) in sterile water per day by gavage.  
 
Genotyping 
Ear punches from Col1a1::TetOP-OCT4 mice were digested in DirectPCR lysis 
reagent (Tail) (Viagen) and 0.5mg/ml proteinase K (Roche) in a rotating oven at 
55°C for 18 hours. Lysates were then heated to 85°C for 45 minutes.  
PCR reactions (for primers see Table 6.1) were carried out using the 
following reagents: Biomix Red (Bioline) (1x), primers (250nM of each), water, 
and DNA lysate.  
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PCR was used to amplify regions of DNA using a thermo cycler (Techne-
312 or G-Storm-GS1) with the following conditions: 96°C for 2 minutes, 30 cycles 
at 96°C for 30 seconds /59°C for 30 seconds/72°C for 30 seconds, and a final 
extension of 72°C for 2 minutes. The PCR mixture was loaded directly into a 1.2% 
agarose gel and electrophoresed for 25 minutes at 150V. 
 
 
Tissue culture and cell culture assays 
Fibroblast culture 
 Mouse embryonic fibroblasts (MEFs) (American Type Culture Collection  W 
STO cells, CRL-1503) were cultured in medium (DMEM, 10% FBS) and placed in 
0.1% gelatin (Sigma-Aldrich G1393)-coated flasks.  MEFs were passaged when 
80-90% confluent and the medium was changed at least every 3 days.  
 MEFs were prepared for passage by removing medium and washing with 
PBS. Warm 1x trypsin (Invitrogen) was added to the flask and left for 6 minutes 
at 37°C. PBS was added to the cell suspension and centrifuged at 200 G for 5 
minutes. The supernatant was aspirated, leaving the cell pellet. The pellet was 
either plated at a concentration of 5x10
6
 cells per T75 flask, or frozen. When the 
cells required freezing 1x10
7
 cells were suspended in cold freezing medium (20% 
DMSO, 80% FBS) placed directly into a -80°C freezer. 
 To culture MEFs from frozen, one vial was placed directly from -80°C to a 
37°C water bath and left to thaw for approximately 2 minutes. The cells were 
washed with PBS and centrifuged at 200 G for 5 minutes. The supernatant was 
removed and the cell pellet was resuspended in warm culture medium. These 
cells were cultured in a 0.1% gelatin-coated T75 flask. 
 
 
 
Mitotic inactivation of MEFs 
 MEFs were mitotically inactivated using mitomycin C (Sigma Aldrich). 
MEFs were cultured until 70-80% confluent before being treated with 10µg/ml 
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mitomycin C for 24 hours. After treatment, the cells were washed with PBS; 
which was subsequently replaced with culture medium. 
 
Culturing of primary mouse neural stem cells 
Mouse brain tissue of various ages (E11.5, E13.5, P7) was dissected from 
the lateral ventricular region, ventral midline, or mixed brain. The dissected 
tissue was homogenised using a scalpel in 1x PBS and the partially homogenised 
suspension was liquidised further. After allowing the solid clusters of tissue settle 
to the bottom of the tube the PBS was aspirated off (and kept for direct culture) 
and Accutase (Patricell) was added to the remaining pellet. Tubes were 
incubated at 37°C for 20 minutes with periodic agitation. The cell solution was 
pipetted and the tubes were filled with PBS. The supernatant was transferred to 
clean tubes and centrifuged for 5 minutes at 200 G. Accutase was added to the 
remaining solid tissue pellet for a second homogenisation step then PBS was 
added and centrifuged. The supernatant from these two sets of tubes was 
discarded and pellet resuspended in warm neural stem cell medium (NSC 
medium) [Neurobasal medium 1x (Gibco), 1:1 DMEM F-12 1x (Gibco), B27 
(0.1x)(Invitrogen), N2 final (0.1x)(Invitrogen), FGF (20ng/ml)(Invitrogen), and EGF 
(20ng/ml)(Sigma)]. Pen/strep (0.05U/ml penicillin and 50ng/ml streptomycin in 
0.9% NaCl)(Sigma) were added when contamination was a risk. Each cell type 
was plated into a different well in a 6-well plate in neural stem cell medium and 
incubated at 37°C in 5% CO2. 
Neural stem cells were split by first centrifuging the liquid medium 
containing the floating neurospheres. The supernatant was removed and 
accutase was used to resuspend the pellet before being left for 20 minutes at 
37°C. Accutase was diluted with PBS (5x) (phosphate buffered saline) and 
centrifuged at 200 G. The supernatant was aspirated and the cells were 
resuspended in warm medium. This single cell solution was plated at a cell 
density of between 1x10
4
 and 1x10
5
 per well in a 6-well plate. 
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 Neurospheres were prepared for freezing by dissociating with accutase 
(as above). Single cells were frozen using 10% DMSO in DMEM F-12 at a 
minimum cell concentration of 1x10
5
 cells.  
 
Self-renewal assay 
 Cultured neurospheres were rinsed, centrifuged, and dissociated using 
the method previously stated. The single cell suspension was washed with 
DMEM and centrifuged at 200 G for 5 minutes. Pelleted cells were resuspended 
in neural stem cell medium including growth factors. The number of cells was 
calculated using a haemocytometer and trypan blue (Sigma). The volume 
required for 1/3 neural stem cell was calculated and volume was added to one 
well of a 24 well plate. A minimum of 3 wells were plated and a final well which 
contained approximately 1x10
3
 cells functioned as a cell stock. An appropriate 
amount of warm medium was added and then incubated at 37°C in 5% CO2. 
 Single cells were monitored for growth into neurospheres over 3 days. 
Wells that contained neurospheres had the medium carefully removed and 
replaced with accutase, then incubated at 37°C in 5% CO2 for 8 minutes. Single 
cell suspensions were washed with PBS and centrifuged at 200 G for 5 minutes. 
The cell pellet was resuspended in neural stem cell medium and plated into a 
single well of a 24-well plate at a dilution of 1/3 cell per well.  
 This process of plating a single neural stem cell into a well of a 24-well 
plate, culturing, dissociating, washing, centrifuging, and replating constituted a 
single passage. Each original neural stem cell underwent 3 consecutive passages 
to confirm its ability to self-renew.  
 
Differentiation assay 
 Coverslips were coated with 15µg/ml laminin (Sigma) suspended in 
DMEM for 4 hours. Neural stem cells were cultured on laminin-coverslips and 
cultured as a monolayer until 50% confluent. The medium coating the coverslip 
was aspirated and changed to:  Neurobasal medium 1x (Gibco), 1:1 DMEM F-12 
1x (Gibco), pen/strep (0.05U/ml penicillin and 50ng/ml streptomycin in 0.9% 
NaCl)(Sigma), B27 (0.1x)(Invitrogen), N2 final (0.1x)(Invitrogen), and 10µM  
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retinoic acid (Sigma). After 24 hours this medium was replaced with neural stem 
cell medium without growth factors i.e.  Neurobasal medium 1x, 1:1 DMEM F-12 
1x, pen/strep (0.05U/ml penicillin and 50ng/ml streptomycin in 0.9% NaCl), B27 
(0.1x), and N2 final (0.1x). The monolayer of differentiated neural stem cells was 
allowed to grow for 3 days before being prepared for immunofluorescence. 
 
Doxycycline treatment of neural stem cells 
Neural stem cells that required doxycycline for activation of the 
transgene were treated with 1µg/ml of doxycycline (Fluka) added to normal 
neural stem cell medium. Neural stem cells were sustained under doxycycline 
once treatment began and the medium was changed a minimum of once every 3 
days. 
 
Culturing mouse embryonic stem cells 
Mouse embryonic stem cells (E14TG2A) were provided by Val Wilson and 
The Institute for Stem Cell Research, Edinburgh. T75 flasks were coated with 
0.1% gelatin (Sigma) for 1 hour. The gelatin was aspirated and flasks were left to 
dry for 20 minutes. Frozen ES cells were thawed quickly at 37
o
C and added to 
10ml warm embryonic stem cell medium  [GMEM (Sigma), 10% foetal calf serum 
(Gibco), 1x  non-essential amino acids (Invitrogen), 2mmols/L glutamine 
(Invitrogen),  1mmols/L sodium pyruvate (invitrogen), 0.1mols/L 2-
mercaptoethanol (Sigma), 100units/ml Lif (donated by Val Wilson)]. This cell 
solution was centrifuged at 200 G for 5 minutes. The medium was aspirated and 
the cell pellet was resuspended in warm ES medium, before being transferred to 
a gelatin-coated T75 flask. 
ES cells were prepared for passage by removing the medium and rinsing 
twice with PBS. Trypsin was added to the cells and incubated at 37°C for 6 
minutes. Trypsinised cells were transferred into ES medium then centrifuged at 
200 G for 5 minutes. The cell pellet was resuspended in ES medium and the cells 
were counted using a hemocytometer. Dissociated cells were either plated in 
T75 flasks or frozen. Approximately 5x10
6
 cells were plated in ES medium per 
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gelatin-coated T75. If in excess, 1x10
7
 cells were frozen in ES medium with DMSO 
(Sigma) at a final concentration of 10% per vial and stored in a -80 freezer. 
 
Zeocin kill curve 
ES cells were plated at 1x10
5
 ES cells per well in a 0.1% gelatin-coated 6-
well plate. After 24 hours, the medium in each well was aspirated and replaced 
with 3ml of ES medium including Zeocin (Invivogen) at final concentrations of 
0µg/ml, 5µg/ml, 10µg/ml, 20µg/ml, 35µg/ml, and 50µg/ml. Four wells for each 
concentration were tested. Every 2 days one well was counted using a 
hemocytometer whilst the others were passaged with fresh medium and Zeocin.  
 
 
Bacterial plasmid cloning 
ETV1 RNA probe plasmid 
PCR was used to amplify the full-length coding sequence of ETV1 to 
produce a 1kb product (see table 1 for primer list). A pBluescriptII SK+ plasmid 
(Stratagene) was cut using restriction enzymes; Xba1 (NEB) and Xho1 (NEB). This 
cut pBluescriptII SK+ plasmid was ligated to the 1kb ETV1 insert using 400U of T4 
ligase (New England BioLabs, M0202) per 20ul reaction. A molar ratio of insert to 
vector ratio of 3:1 was used. This ligation was incubated at 37°C for 1 hour. 
 
Transformation 
ɲ-select chemically competent cells (Bronze efficiency)(Bioline) were 
thawed slowly on ice. Plasmid DNA [250ng pEGFP (Clontech) or 200ng pORF 
(InvivoGen)] was added separately to competent cells and incubated on ice for 
30minutes. Bacterial cells were heat shocked at 42°C for 40 seconds and then 
placed on ice for 2 minutes. SOC medium was added to the transformation 
reactions, and the mixture was incubated for 1hr at 37°C whilst being shaken.  
Transformation mix was plated onto LB agar containing ampicillin 
(100µg/ml) or kanamycin (100µg/ml), for pORF and pEGFP respectively. Plates 
were incubated overnight at 37°C. Single colonies from transformed bacteria 
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grown on LB plates with appropriate selection were selected and cultured in Mu 
medium overnight shaking at 200 RPM (New Brunswick Scientific C25 Incubated 
Shaker) at 37°C.  
 
Plasmid DNA purification 
5ml of bacterial culture was centrifuged at 16000 G for 1 minute. The 
supernatant was discarded and the pellet was resuspended by vortexing with 
resuspension solution (GenElute Plasmid Miniprep kit, Sigma). Lysis buffer was 
added (GenElute Plasmid Miniprep kit, Sigma), followed by neutralisation buffer 
(GenElute Plasmid Miniprep kit, Sigma), and then the tubes were centrifuged at 
16000 G for 10 minutes. The cleared lysate was mixed with isopropanol and 
centrifuged at 16000 G for 5 minutes. The supernatant was discarded and 70% 
ethanol was added before being centrifuged again at 16000 G for 2 minutes. The 
supernatant was removed and the pellet was air-dried before resuspending the 
DNA pellet in sterile distilled water.   
For larger plasmid concentrations plasmid maxi kit (Qiagen) was used 
following the manufacturers protocol.   
Where clones were confirmed as having the correct insert, 5ml bacterial 
culture was mini-prepped using GenElute HP Plasmid Miniprep Kit (Sigma) 
following the recommended protocol. 
 
Plasmid DNA restriction digest 
 Plasmid DNA (200ng) was digested using 2U/µl of the appropriate 
restriction enzyme (New England Biolabs) and 1x buffer before being incubated  
for 1-2 hours at 37°C (see Table X.2 for enzymes).   
To digest and verify ligation in pJet vector (CloneJET PCR Cloning Kit) 
(Fermentas), DNA (200ng) was digested using BglII (2U/µl) (New England 
Biolabs), and BglII buffer (1x)(New England Biolabs) before leaving for1-2 hours 
at 37°C.  
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Transfection and stable selection of eukaryotic cells 
Transfection of Embryonic stem cells  
ES cells were seeded at 1x10
6
 in each of 3 T75 flasks. Two tubes were 
prepared; 20µl DharmaFECT3 (Thermo Scientific) in 500µl OptiMEM, and 10µg 
DNA (GFP, pORF, or equivalent volume of water) in 500µl OptiMEM. Each pair of 
tubes (GFP, pORF, and control) was mixed and left for 20minutes at room 
temperature. Each solution was added drop wise to a separate T75 and placed in 
a 37°C incubator. Medium was changed the next day to include Zeocin at final 
concentration 10µg/ml. Cells were then cultured using the above mouse 
embryonic stem cell protocol. 
 
Immunostaining 
ES or neural stem cells at a cell concentration of 1x10
4
 were cultured as a 
monolayer on gelatin-coated (0.1%) or laminin-coated (15µg/ml) coverslips 
respectively. Each coverslip was washed twice with PBS then fixed with 0.4% 
paraformaldehyde (PFA) for 15 minutes. The coverslips were rinsed twice with 
PBS for 5 minutes. The PBS was aspirated and replaced with 0.2% Triton X 
(Sigma) in PBS for 15minutes, then washed twice with PBS for 5 minutes each. 
The coverslips were blocked for 1 hour 30 minutes using 3% BSA (Sigma) 
dissolved in 0.1% Triton X/PBS for OCT4 (Santa Cruz)(see Table 6.3). For NANOG 
(Abcam), 10% sheep serum in PBS was used to block coverslips for 2 hours at 
room temperature. The cells were incubated with 5µg/ml primary antibody in 
blocking solution for overnight at 4°C. Each coverslip was washed twice with PBS 
for 5 minutes. This was followed by two PBS washes for 30 minutes each whilst 
slowly shaking. Secondary antibodies (see Table 6.3 for antibodies) were added 
and left at room temperature for 1 hour. Each coverslip was again washed with 
PBS twice for 5 minutes, then twice for 30 minutes. PBS was removed and 
mounted with Dapi solution (Vectashield). 
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Polymerase chain reaction (PCR) 
 PCR reactions were carried out using the following reagents: buffer (1x), 
dNTP (0.8mM), primer (250nM of each), and a high fidelity pfx DNA polymerase 
Platinum Taq (0.1u/µl  W requires 1.5mM MgCl2) (Invitrogen). PCR was used to 
amplify regions of DNA or cDNA using a thermo cycler (Techne-312 or G-Storm-
GS1) with the following conditions: 95°C for 5 minutes, 35-40 cycles of 94°C 1 
minute /58°C 1 minute/72°C 45 seconds, and a final extension of 72°C for 2 
minutes.  
 
PCR purification 
Amplified PCR products were purified using a PCR purification kit (Qiagen) 
ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ƉƌŽƚŽĐŽů ? dŚĞ E ǁĂƐĞůƵƚĞĚ ƵƐŝŶŐ ƐƚĞƌŝůĞ
distilled water. 
 
Sequencing 
  DNA samples were prepared for sequencing using the following reaction: 
100-200ng purified DNA, 0.5µl/5µl reaction of BigDye (Applied Biosystems), 1x 
buffer, 1pmol/µl primer (Fermentas), and if necessary 0.5M Betaine (Sigma). 
Sequencing  conditions were 96°C for 1 minute, 99 cycles of 96°C 20sec/50°C 
20sec/60°C 1min, hold at 4°C. DNA was precipitated using adding 30µM sodium 
acetate, 100ng/µl glycogen, and ethanol. The mixture was incubated at -20°C for 
15 minutes then centrifuged at 16000 G for 15 minutes. The supernatant was 
aspirated and the pellet was washed with 75% ethanol then centrifuged at 16000 
G for 5 minutes. The supernatant was again aspirated and the pellet was left to 
air dry. The pellet was resuspended in sterile distilled water before being sent to 
Geneservice, Nottingham for sequencing. 
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RNA extraction 
 TRI reagent (Sigma) was added to each ES or NSC cell pellet and 
incubated at room temperature for 5 minutes. Chloroform was added and 
incubated at room temperature for 10 minutes then centrifuged at 16000 G for 
15 minutes at 4°C. The aqueous layer removed and mixed with isopropanol then 
left at room temperature for 5 minutes. The mixture was centrifuged at 16000 G 
for 15 minutes at 4°C. Isopropanol was removed and washed with 70% ethanol 
before being centrifuged for 5 minutes at 16000 G. Ethanol was removed and the 
pellet was air dried before resuspending in DEPC water. The RNA was quantified 
using a Nanodrop spectrophotometer (Thermo Scientific). DNase 1 Amp grade 
(New England Biolabs) (0.05U/µl) and reaction buffer (1x) were added to the 
RNA and incubated for 10 minutes. Tubes were heated at 65°C for 10 minutes 
and stored at -80°C if necessary. 
 
 
cDNA synthesis 
 For each reaction, 2µg RNA, 25ng/µl oligoDTs (Fermentas), 25ng/µl 
random primers (Promega), dNTP (10µM), and RNase free water were combined. 
The reactions were heated to 65°C for 5 minutes before being placed on ice for 1 
minute. A final concentration of 1x first strand buffer (Invitrogen), 50mM DTT 
(Invitrogen) and 0.5U/µl Superscript III (Invitrogen) were added to each tube and 
placed in the thermocycler (Techne) for 5 minutes at 25°C, 45minutes at 50°C, 
then 15 minutes at 70°C. cDNA was stored in a -20°C freezer or used directly for 
PCR. Each reverse transcriptase reaction had a separate reaction with exactly the 
same contents except without Superscript III as a control. 
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Luciferase assay 
Twelve wells of a 96-well plate were coated with 0.1% gelatin. ES cells 
were plated at a concentration of 2x10
4 
in 6 of these wells and another 6 with ES-
Luc cells (2 at 1x10
4
, 2 at 2x10
4
, and 2 at 4x10
4
). A luciferase assay was 
performed using a Glomax 96 microplate illuminator (Promega) following the 
manufacturers protocol including cell lysis for 2 minutes with Bright-Glo Reagent. 
 
Wax embedding 
Embryos or brains from various transgenic rtTA-OCT4 mice were 
dissected and placed in 4% PFA for 24 hours at 4°C. The tissue was then serially 
dehydrated by changing the solution to 70% IMS for 24 hours, 80% IMS for 1 
hour, 90% IMS for 1 hour, 95% IMS for 1 hour, and finally 100% EtOH for 1 hour. 
This solution was replaced with xylene for 10-30 minutes until the tissue became 
translucent. The xylene was removed and the tissue was transferred to hot wax 
for 1 hour. This wax was replaced with fresh wax and left for a further hour. The 
wax was replaced for the final time and the mould was left to set at room 
temperature.  
 
 
Tissue transplantations into immune-deficient mice 
Teratoma formation assay 
ES-Luc cells and control ES cells were diluted to a total of 5x10
6 
cells in 
100µl PBS, and 20µl of each injected into the kidney capsule of SCID mice at pre-
clinical oncology (PK ? YƵĞĞŶ ?Ɛ DĞĚŝĐĂů ĞŶƚƌĞ ? EŽƚƚŝŶŐŚĂŵ ) ? dŚĞ ŵŝĐĞ ǁĞƌ
terminated 3 weeks after injection and the tumours were processed. A similar 
anaesthetic procedure was used to the intracranial injections below. 
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ES-Luc cell transplant into mouse brains 
Mice were anesthetised using ketamine/metetomidine, and a small 
incision through the skin was made along the midline of the skull. The mouse 
was secured onto an electronic Stereotaxic frame using a nose clamp. A small 
burr-hole was drilled through the skull using a 0.7mm diameter surgical drill bit.  
The specific location of injection varied depending on whether the site 
was midline or lateral. The bregma is the point where the cranial bone sutures 
meet and can be viewed from the external anterior skull. Therefore, the bregma 
was used as a reference point for midline coordinates (AP -1.6mm, ML 1mm, DV 
5mm), or lateral coordinates (AP -1.6mm, ML 3mm, DV 1mm). 
ES-Luc cells were diluted to either 100,000 or 5,000 cells in 5µl of PBS and 
were loaded into a sterile Hamilton syringe with a 26g needle. The needle was 
slowly inserted through the burr hole to various depths and the cell suspension 
was slowly injected over a period of 1 minute. The needle was left in situ for a 
further minute before being slowly withdrawn over a period of 2 minutes. The 
burr hole was plugged with bone wax and the skin sutured. 
The mice were given analgesia (Rimadyl 4mg/kg) before recovery, with 
further doses administered daily as required. 
 
Luminescence imaging 
Mice were anaesthetised and images were captured using a Xenogen 
biophotonic Spectrum and IVIS100 Imaging Systems. The light was detected in 
several different planes of view, which allowed for the construction of a three-
dimensional image. This work was carried out by the division of pre-clinical 
oncology (PCO) at QMC.  
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Dissection, sectioning, and staining of brains 
In all cases of Schedule 1, mice were terminated by cervical dislocation. 
The brain was dissected and placed into a fixative solution  W 4% PFA.  
Mice brains injected with ES-Luc cells were stored in fixative and 
processed (wax embedded and sectioned) by the Translational Research & 
Biobank in QMC. Haematoxylin and eosin staining was performed on at least one 
section from every processed brain.  
 
In situ hybridisation 
RNA probe synthesis 
 1µg of linearised DNA was added to transcription buffer (1x) (Promega), 
DTT (6mM) (Promega), rATP (6mM) (Promega), rGTP (6mM) (Promega), rCTP 
(6mM) (Promega), rUTP (6mM) (Promega), DIG-UTP (6mM) (Roche), RNasin 
(40U) (Promega), RNA polymerase (20U of either T7, or T3) (Promega). This 
mixture was left for 6 hours at 37°C. The probe solution was cleaned using the 
standard protocol for Illustra MicroSpin G-50 Columns (GE healthcare).  
 
In situ hybridisation 
 N.B. PBST is PBS with 0.1% Tween 20 (Sigma); Hybridisation buffer is 50% 
formamide (Fisher), 5x SSC (pH4.5 with citric acid), 50µg/mL yeast tRNA (Roche), 
1% SDS, and 50µg/mL heparin (Sigma); 20x SSC is 0.3M NaCl and 0.3M sodium 
citrate; 10x TBS is 135mM NaCl and 250mM Tris-HCl; 1x TBST is 10x TBST diluted 
1 in 10 and 0.1% Tween-20; Alkaline phosphatase buffer is 100mM NaCl, 50mM 
MgCl2, 100mM Tris-HCl pH9.5, 1% Tween-20, and 2mM levamisole (Sigma).  
Wax-embedded embryos or brains were sectioned using a sectioning 
block (Anglia Scientific) set to 8µM, and attached to Superfrost Plus charged 
slides (Fisher). Sections were placed in histolene twice for 10 minutes. Histolene 
was replaced with 100% methanol for 1 minute, 75% methanol/25% PBST for 1 
minute, 50% methanol/50% PBST for 1 minute, 25% methanol/75% PBST for 1 
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minute, and 100% PBST for 5 minutes. Proteinase K (10µg/ml) (Roche) at 37°C 
was used to overlay the slides for 15 minutes at room temperature. Slides were 
washed with PBST three times for 3 minutes each, and then immersed in ice-cold 
4% paraformaldehyde in PBS for 20 minutes. Slides were washed three times for 
5 minutes each. Approximately 200ng was added to hybridisation mix pre-
warmed to 70°C. The mixture was overlaid on the slides and covered with Hybri-
Slips (Sigma) then incubated in a sealed container at 70°C for 18 hours. 
Slides were submerged in 50% formamide, 5xSSC, 1% SDS for 30 minutes 
at 65°C, and coverslips were removed. The solution was changed to 50% 
formamide, 2xSSC at 65°C for 30 minutes; this step was then repeated. The slides 
were washed three times for 5 minutes at room temperature. They were then 
placed in TBST with 10% FBS for 30 minutes. The solution was removed, and 
TBST with 1% FBS and 1/5,000 alkaline-phosphatase anti-DIG fragments (Roche) 
were added. The slides in this solution were left at 4°C for 18 hours. 
The slides were washed three times for 20 minutes in TBST, then two 
times for 5 minutes in alkaline phosphatase buffer. The slides were incubated in 
alkaline phosphatase solution with 7.5mg/mL NBT (Roche) and 5mg/mL BCIP 
(Roche). 
 
RNA Whole-mount in situ hybridisation 
 Whole E13.5 mouse embryos were fixed in 4% PFA in PBS for 24 hours. 
Embryos were sliced in half and dehydrated in methanol using a graded 
methanol/PBST series 25%, 50%, 75%, and 100% methanol for 5 minutes each. 
The methanol was replaced with fresh methanol and the sections were stored at 
-20°C.  
 Embryos were rehydrated in a 75%, 50%, 25% methanol/PBST series for 5 
minutes each wash, followed by four 5 minute washes in PBST. PBST was 
replaced with 10µg/ml proteinase K in PBST for 20-60 minutes. The embryos 
were washed three times for 15 minutes in 2mg/ml glycine in PBST, then two 
times for 5 minutes in PBST. The embryos were post-fixed with 4% PFA for 20 
minutes, before being washed 5 times for 5 minutes each in PBST. The samples 
were equilibrated slowly firstly for 10 minutes in 1:1 hybridisation solution/PBST, 
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then 10 minutes in hybridisation solution at 72°C. Incubation at 70°C in fresh 
hybridisation solution was left for 1 hour before being replaced with fresh 
hybridisation solution containing the RNA probe and left at 70°C for 24-72 hours. 
 The hybridisation solution containing the RNA probe can be stored at -
20°C and re-used. The embryos were washed three times in 50% formamide, 
5xSSC, 1% SDS at 65°C for 30 minutes each. This solution was replaced by 50% 
formamide, 2xSSC and again washed three times for 30 minutes each at 65°C. 
The embryos were left in 2% blocking reagent (Roche) in MABT for 60-90 
minutes, before being left overnight at 4°C in 1/5000 anti-DIG AP antibody in 
MAB. 
 Post-antibody washes included eight in MAB for 15 minutes each, and 
three times in alkaline phosphatase buffer for 10 minutes each. The embryos 
were left to develop by adding 3.75mg/mL NBT (Roche) and 2.5mg/mL BCIP 
(Roche) in alkaline phosphatase solution. After 1-72hours of colour development, 
the embryos were washed with PBST and fixed in 4% PFA for 20 minutes before 
being washed again in PBST. 
 
RNA probe binding specificity assay 
 Between 1-5ng of digested or undigested plasmid used to generate an 
RNA probe was baked onto a positively charged nylon membrane (Roche) for 2 
hours at 80°C. Probe was diluted in 300ul of hybridisation buffer and rotated in a 
1.5ml tube with the membrane. The membrane solution was changed to 2xSSC 
for 30 minutes at 65°C, then 0.1xSSC for 30 minutes at 65°C. The membrane was 
washed twice for 3 minutes in TBST at room temperature before being blocked 
with 10% serum in TBST for 30 minutes. The membrane was left at 4°C for 18 
hours in 1 in 10,000 anti-dig fragments in TBST. 
 The membrane was washed in TBST three times for 10 minutes each. This 
was replaced by alkaline phosphatase buffer for 5 minutes before being 
incubated in alkaline phosphatase solution with 7.5mg/mL NBT (Roche) and 
5mg/mL BCIP (Roche). 
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Name of gene Primer 5'>3' Size of product 
   
Clathrin TTT GTG CTT CTG GAG GAA AGA A 567bp 
 GAC AGT GCC ATC ATG AAT CC  
Nestin CGC TGG AAC AGA GAT TGG AAG G 257bp 
 GTC TCA GGG TAT TAG GGC AAG  
Sox2 CCG CGA TTG TTG TGA TTA GT 94bp 
 AGG GCT GGG AGA AAG AAG AG  
Oct4 CTC GAA CCA CAT CCT TCT CT 856bp 
 TAG GTG AGC CGT CTT TCC AC  
Oct4-Nested TGA TTG GCG ATG TGA GTG AT 470bp 
 CAC GAG TGG AAA GCA ACT CA  
Etv1 ATG GAT GGA TTT TAT GAC CAG 1434BP 
 TTA GTA CAC GTA TCC TTC GTT  
Col1a1 (Common) CCC TCC ATG TGT GAC CAA GG  
Col1a1 (WT F) GCA CAG CAT TGC GGA CAT GC 331bp 
Col1a1 (Mut F) GCA GAA GCG CGG CCG TCT GG 551bp 
Rosa26 (Common) AAA GTC GCT CTG AGT TGT TAT  
Rosa26 (WT R) GGA GCG GGA GAA ATG GAT ATG 340bp 
Rosa26 (Mut R GCG AAG AGT TTG TCC TCA ACC 650bp 
Table 2.1. Primer sequences for mouse genes. Oct4-Nested amplifies part of the 
Oct4 coding sequence within the sequence that is amplified by Oct4 primers. All 
three genotyping primers are mixed together for either Col1a1 or Rosa26 
amplification; common amplified either wild-type or mutant DNA. The larger 
amplified product indicates the presence of the transgene, while the smaller one 
lacks the transgene. A combination of a large band and a small band indicates 
heterogeneity. Primers were supplied by Fisher. 
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Name of enzyme Restriction site sequence Company 
      
Apa1  GGGCC|C New England Biolabs 
Xba1 T|CTAGA New England Biolabs 
Xho1 C|TCGAG New England Biolabs 
Not1 GC|GGCCGC New England Biolabs 
BamH1 G|GATCC New England Biolabs 
BglII  A|GATCT New England Biolabs 
Table 2.2. Restriction enzymes used to digest plasmids. The restriction cutting 
site is labelled within the enzyme-specific sequence. 
 
 
 
Antibody 
name 
Raised in Concentration 
Mono- or 
polyclonal 
Company Code 
      
MAP2 Chicken 1 in 250 Poly Abcam ab5392 
GFAP Mouse 1 in 250 Mono Abcam ab4648 
NANOG Rabbit 1 in 100 Poly Abcam ab21603 
OCT4 Mouse 1 in 100 Mono 
Santa 
cruz 
sc5279 
(C-10) 
Anti-mouse 
488 
Chicken 1 in 500 Mono Alexa A-21200 
Anti-rabbit 
488 
Goat 1 in 500 Mono Alexa A-11008 
Anti-Chicken 
FITC IgY 
Goat 1 in 500 Polyclonal Abcam ab46969 
Table 2.3. Primary and secondary antibodies used in immunohistochemistry.  
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Chapter 3: A meta-analysis of the location and 
biology of GCTs in the brain 
 
3.1 Introduction 
GCTs are thought to arise from germ cells that migrate along the midline 
during embryogenesis. Contrary to this, we have proposed that GCTs that have 
arisen in the CNS had a neural or brain-cell progenitor instead of a germ-cell 
progenitor (see Chapter 1).  
The generally accepted aetiology of CNS GCTs states that germ-cell 
progenitors migrate through the sagittal plane of the body, which is based on the 
observation that GCTs have been found at several locations that were considered 
midline. However, this does not necessarily mean that germ-cell progenitors 
were the cells of origin.  
GCTs are a diverse group of tumours with large differences in gene 
expression and morphology. In order to limit the variables while studying this 
phenomenon, it is important to focus on only one of these tumours to begin 
with. Teratomas, one type of GCT, are easily formed using embryonic stem cells, 
which have been extensively studied and well characterised. The aetiology of the 
other GCT types is unknown, so the only known way to form a germinoma, for 
example, would be to use a cell line derived from a human tumour. For this 
reason, teratomas are an ideal candidate to study. 
Teratomas are the most easily studied subtype of GCT because they are 
easily formed by several established methods, including embryonic stem-cell 
(ESC) transplantation. Teratomas do not require any activating mutations such as 
mutation of the oncogene MYC, and are easily identified by histopathology, as 
previously described. To understand GCTs as a group, teratomas can provide an 
initial insight into testing the current consensus of ƚŚĞŝƌ ĂĞƚŝŽůŽŐǇ ŝ ?Ğ ? dĞŝůƵŵ ?Ɛ
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theory of a germ-cell progenitor, compared to the proposed theory of a neural 
cell of origin. 
Teratomas have been diagnosed during the prenatal period. Since they are 
well-formed by birth, we can infer that the cell of origin is also prenatal. In fact, 
since ultrasound has become more advanced, several papers have shown that 
teratomas can form as early as 11 or 13 weeks i.e. at the end of the first 
trimester [101, 102]. As stated in Chapter 1, the cell of origin for teratomas must 
therefore have existed between conception and the first trimester. 
There are several questions to be answered: can teratomas/GCTs form in 
non-midline regions? Is there a growth advantage or disadvantage for the lateral 
regions? Are certain regions adverse to GCT survival? Or are GCTs that arise in 
ĐĞƌƚĂŝŶƌĞŐŝŽŶƐĚĞƚƌŝŵĞŶƚĂůƚŽĂĐŚŝůĚ ?ƐƐƵƌǀŝǀĂů ? 
These questions are each addressed over the next two chapters. This 
chapter discusses the observations of these tumours using a literature review to 
re-evaluate the locations that CNS teratomas can grow in, and why CNS GCTs are 
found mainly in the midline of the brain. The strategy includes a literature search 
for which GCT subtypes arise after resection, and which tumours can be mixed 
with GCT subtypes. The next chapter then uses these observations to test our 
hypothesis in vivo using ES cells to examine the potential for teratomas to form 
outside of the midline.  
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3.2 Results: 
 Teratomas can invade any region of the brain 
The main strategy for this chapter used relevant literature to analyse the 
locations of intracranial teratomas. Several criteria were set before acquiring 
suitable papers, for example, only papers published 1990-2012 were used. 
Clinical cases that had an uncertain diagnosis or cases where teratomas were 
mixed with other subtypes were not included. Epignathus is a type of teratoma 
that develops in the mouth, so in order to simplify the study, epignathus were 
not included.  
The majority of teratomas are known to occur in the perinatal range, and 
most germinomas occur in the teenage years. Since CNS GCTs are relatively rare, 
it is important to acknowledge that there may be a large amount of publication 
bias. Therefore, statistical analysis is not heavily relied on when analysing the 
regions where these tumours occur. 
Data on a total of 96 CNS teratomas were collated from the literature and 
separated into two groups. These two groups were the ventral midline and non-
midline locations (Table 3.1). Teratomas in the ventral midline group represent 
teratomas that occur in locations where GCTs have traditionally been associated 
i.e. the suprasellar region, the pineal region, and the basal ganglia. These data 
show that the majority of the teratomas analysed occurred in the midline (56 out 
of 96), mainly in the suprasellar and pineal regions, but 40 out of 96 occur in non-
midline locations. Since there are only a limited number of CNS teratomas, it was 
inappropriate to test statistical significance of how frequent teratomas occur in 
the midline compared to the lateral hemispheres.  
This study mainly focussed on teratomas that occur in the perinatal range 
and some in the teenage years. In addition, there were several studies that found 
teratomas in adulthood and these could be found in both midline and lateral 
locations [103, 104]. These case reports have clearly shown that teratomas have 
the ability to grow in all regions of the brain.  
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If the brain is separated into four lobes (frontal, parietal, occipital, and 
temporal) teratomas can be found contained in each one of these areas (Figure 
3.1). Indeed, teratomas have even been found to arise in the cerebellum [103-
105]. As expected there is an abundance of teratomas found in the classic 
locations for GCTs in the brain, with particularly frequency of occurrence in the 
pineal region (40 out of 96) and suprasellar (15 out of 96). 
 
Location of tumour (Midline) Age of patient Survival Treatment Reference 
     
Pineal region 9 Yes TR [106] 
Pineal region 9 Yes PR + C [107] 
Pineal region 27 Yes TR [108] 
Pineal region 16 No TR + R + C [14] 
Pineal region 9 Yes TR + R [109] 
Pineal 14 Yes TR + R [110] 
Pineal 6 Yes TR [110] 
Pineal Neo Yes TR [110] 
Pineal Neo No ST [111] 
Pineal Neo No ST [112] 
Pineal 2 Yes TR + R + C [50] 
Pineal 5 Yes PR + R [113] 
Pineal 16 Yes PR + R [113] 
Pineal 12 Yes PR + R [113] 
Pineal 18 Yes PR [113] 
8x pineal 
   
[114] 
17x pineal 
   
[115] 
Suprasellar 12 No  TR [110] 
Suprasellar Neo No ST [116] 
Suprasellar 6 Yes PR [117] 
Sella turcica 
 
No ST [118] 
Suprasellar  Neo No N [119] 
Suprasellar Neo No N [120] 
3x suprasellar 
   
[114] 
6x suprasellar 
   
[115] 
1x Basal ganglia 
   
[114] 
Table 3.1 A  W Locations of CNS teratomas in the ventral midline 
Neo = neonate, only a few days; 2nd T = second trimester; TR = total resection; PR = 
partial resection; NA = none; ST = stillborn or terminated; C  W chemotherapy; R = 
radiotherapy. 
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Location of tumour (Non-midline) Age of patient Survival Treatment Reference 
     
Right frontal lobe 2nd T No ST [102] 
Midline of the posterior fossa 6 Yes TR [121] 
Left supratentorial region Neo No N [122] 
Mid cranial fossa/ right frontal lobe Neo Yes TR [123] 
Left anterior and middle cranial fossa Neo Yes PR [107] 
Right lateral ventricle  Neo No TR [124] 
Cavernous sinus, i.e. Left frontal lobe >1 Yes TR [125] 
Left ventricle >1 Yes  TR [126] 
Left cerebellar hemisphere >1 
 
TR [127] 
Third ventricle 1 Yes TR [128] 
Right lateral ventricle 8 Yes TR [129] 
Bi-Lateral ventricle and third ventricle >1 Yes TR [129] 
Both lateral  and 3rd ventricle 5 Yes TR [130] 
Right frontal lobe 10 Yes TR [130] 
Left cerebral hemisphere Neo No N [131] 
Choroid plexus of lateral ventricle Neo No N [132] 
Left frontal lobe Neo No PR [133] 
Pineal into right lateral ventricle Neo No ST [134] 
Posterior fossa 
   
[134] 
Right temporal area (sylvian) 
   
[134] 
Lateral and 4th ventricle 
   
[134] 
Posterior regions 
   
[134] 
Cavernous sinus. 
   
[134] 
Midline and left lateral hemisphere Neo Yes TR [134] 
Skull base Neo No N [135] 
Left lateral ventricle Neo No N [136] 
Centrally located and third ventricle Neo No N [137] 
Temporal fossa Neo Yes  
 
[138] 
Anterior cranial fossa Neo No ST [139] 
Right lateral ventricle Neo No N [140] 
4th ventricle 
   
[115] 
Right temporal area (sylvian) 
   
[115] 
Posterior fossa 
   
[115] 
Cavernous sinus 
   
[115] 
Table 3.1 B  W Locations of CNS teratomas in non-midline regions 
Neo = neonate, only a few days; 2nd T = second trimester; TR = total resection; PR = 
partial resection; NA = none; ST = stillborn or terminated; C  W chemotherapy; R = 
radiotherapy. 
Table 3.1 A and B. The approximate location of the tumour reported in each paper is 
listed together with the age of the patient, the type of treatment, and whether the 
patient survived while part of each study. Locations are arranged by traditional ventral 
midline structures in the table A, followed by non-midline locations in table B. Sections 
left empty are due to unknown or ambiguous data.  
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Figure 3.1  W Overlapping regions of where teratomas can grow in the central nervous 
system. Three views of an adult human brain (coronal, horizontal, and sagittal) with 
approximate teratoma formation transposed onto them. Importantly, a single reference 
was assumed to be able to form on either hemisphere, so each colour has two circles 
representing possible locations for teratomas. Brain scans modified from 
http://brainmuseum.org: Coronal Level 2240, Horizontal Level 1640, Sagittal Level 0212 
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Evidence for a cell of origin in the lateral regions of the brain 
Patients were often diagnosed after they presented with significant 
symptoms, by which time the CNS teratomas in this study were at least several 
centimetres in diameter. Therefore the exact location of the cell of origin is 
difficult to determine. In some circumstances, radiological images have appeared 
to suggest that the cell of origin may not be midline; for example, Canan et al. 
(2000) published a clinical case of a neonate with a lateral teratoma exclusively 
in the left side of the brain [133]. However, other cases show ambiguity such as 
the case report by Selcuki et al. (1998). Selcuki reported a teratoma in the lateral 
ventricle but when examining the images it is unclear whether the origin was 
midline [129].  
 
CNS GCTs can recur as almost any of the other GCT 
subtypes 
GCTs are classified as a single group of tumours unified by the hypothesis 
that they have the same cell of origin, a germ cell progenitor. But what is the 
relationship between each of these distinct subgroups? Can one be transformed 
into another? 
In order to investigate this, the literature was analysed for the resection of a 
GCT (embryonal carcinoma, teratoma, yolk sac tumour, or germinoma) followed 
by recurrence of a different one of these four subtypes. The search was unbiased 
in the first instance: only papers where the subtype that recurred was different 
to the original tumour after surgical resection were included; the patient could 
be any age; and only a single subtype of tumour could be present before and 
after resection. After this unbiased search, specific combinations of recurrence 
after surgery were examined.   
Embryonal carcinomas were not separated from teratomas since they were 
assumed to be the undifferentiated version of a teratoma. Studies have shown 
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that it is quite common to find a pure, differentiated teratoma mixed with an 
undifferentiated embryonal carcinoma i.e. a teratocarcinoma.  
Table 3.2 is an amalgamation of the included literature showing that it is 
possible for any of the GCT subtypes to recur after resection of one of the other 
GCT subtypes in the brain, illustrated in Figure 3.2. The only tumour that this 
situation was not found was the resection of a yolk-sac tumour recurring as a 
germinoma. Even with a search for this combination there were no cases in the 
literature.  
 
 
 
 
 
 
Figure 3.2 - The relationship between the different subtypes of germ cell tumour. 
When one of the subtypes is resected it is possible for any of the other subtypes to 
recur.  
  
'ĞƌŵŝŶŽŵĂ 
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Original tumour Location 
Recurrent 
tumour 
Location Reference 
     
Teratoma Pineal Germinoma Basal ganglia [143] 
Teratoma  Pineal Germinoma Suprasellar [144] 
Teratoma Pineal Germinoma  Pineal [145] 
Epidermoid 
cyst/teratoma 
Pineal Germinoma Pineal [146] 
Teratoma Sellar Germinoma Third ventricle [147] 
Teratoma Sacrococcygeal Yolk sac tumour Sacrococcygeal [148] 
Germinoma Corpus callosum Teratoma 
Corpus 
callosum 
[149] 
Germinoma 
Suprasellar and 
pineal 
Yolk sac tumour Mediastinum [150] 
Yolk sac tumour 
Diencephalon/ 
suprasellar 
Teratoma Suprasellar [151] 
Table 3.2  W Resection and recurrence of GCTs. Each row shows a report of a germ cell 
tumour recurring as a different subtype of germ cell tumour. The original tumour was 
resected and in some cases treated with chemotherapy before the recurrence of a 
different tumour. Teratomas, yolk sac tumours, embryonal carcinomas, and germinomas 
are all found to recur as each of the subtypes of GCTs. Choriocarcinoma was not 
included in this search, and to-date there are no papers showing the resection of a yolk 
sac tumour recurring as a germinoma.  
 
CNS GCTs can be mixed with other GCT or non-GCT 
subtypes 
CNS GCTs are frequently diagnosed with multiple subtypes of GCT present. 
These mixed GCT subtypes may seem counter-intuitive because the GCT 
subtypes differ greatly in their behaviour and gene expression. The current 
explanation for the presence of different GCT subtypes is that the proposed cell 
of origin for GCTs can give rise to all the different subtypes i.e. a germ-cell 
progenitor. The topic of GCTs mixed with a different type of cancer raises two 
questions: is there a pattern by which GCT subtypes are mixed with other GCT 
subtypes; and are GCT subtypes mixed with non-GCT cancers? 
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The method used to answer these questions was a review of published 
literature on GCT subtypes mixed with either another GCT subtype, or a non-GCT 
cancer. The initial search was initially limited to the brain and testis in order to 
determine which combinations of GCT subtype could be mixed. This was 
extended to include a case of all subtypes present in a tumour in the 
mediastinum and nearly all subtypes present in a single tumour in the ovary - 
these searches were specifically for occurrences of all subtypes of GCT present in 
a single tumour. Here, examples of each GCT subtype being mixed with each of 
the other subtypes of GCT were found (Table 3.3). 
When examining a GCT subtype mixed with a non-GCT cancer, the search 
was not limited to a specific location in the body or the type of cancer the GCT 
subtype was mixed with. Table 3.4 shows that a range of non-GCT types have 
been found mixed with GCTs. A frequent observation was that GCTs contained a 
sarcomatous component. The most relevant observation is a choriocarcinoma 
and yolk sac tumour mixed with an astrocytoma and glioblastoma (Table 3.4). In 
fact, this case study reported that the mixed GCT was partially removed and 
irradiated before astrocytomas and glioblastomas arose. This subject is examined 
in more detail in the discussion. 
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Table 3.3  W Germ cell tumour subtypes mixed with other GCT subtypes. Each row 
constitutes a single tumour and whether it contained teratomas, embryonal carcinoma, 
germinoma/seminoma, yolk sac tumour, or choriocarcinoma. Both teratomas and 
embryonal carcinoma were identified as positive when the histological report indicated 
teratocarcinoma. Choriocarcinoma was not found in the brain but was found in the 
mediastinum. Ovary and mediastinum are included to illustrate the occurrence of mixed 
subtypes at non-testicular and non-brain locations.  
 
 
 
Location Teratoma 
Embryonal 
Carcinoma 
Germinoma/ 
seminoma 
Yolk sac 
tumour 
Chorio-
carcinoma 
Reference 
Mediastinum X X X X X [152] 
Ovary X  X X X [153] 
       
Testis X X 
   
[154] 
Testis X 
 
X 
  
[154] 
Testis X 
  
X 
 
[154] 
Testis X 
   
X [154] 
Testis 
 
X X 
  
[154] 
Testis 
 
X 
 
X 
 
[154] 
Testis 
 
X 
  
X [154] 
Testis 
  
X X 
 
[154] 
Testis 
  
X 
 
X [154] 
Testis 
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Key: T - Teratoma, E - Embryonal carcinoma, G/S - Germinoma/seminoma, Y- Yolk sac 
tumour, C  W Choriocarcinoma 
Table 3.4  W Germ cell tumour subtypes mixed with non-GCTs. Each row highlights a 
paper showing the region and type of germ cell tumour mixed with a non-germ cell 
tumour type. The studies are ordered approximately by location beginning with the 
brain and ending at the sacrum for extra-gonadal GCTs, and gonadal GCTs at the bottom 
of the table.  
Region of GCT 
Primary 
GCT 
Tumour mixed with GCTs Reference 
Brain C + Y astrocytoma or glioblastoma [163] 
Cerebellum T + C + GS hemangioblastoma [164] 
Para-aortic lymph 
node  
Mixed epithelioid trophoblastic tumour  [165] 
Thyroid T Primitive neuroectodermal tumour [166] 
Mediastinum G + T Ganglioneuroma [167] 
Mediastinum T + E neuroblastoma [168] 
Mediastinum T angiosarcoma [169] 
Mediastinum GS angiosarcoma [169] 
Mediastinum Y angiosarcoma [169] 
Mediastinum E angiosarcoma [169] 
Mediastinum C angiosarcoma [169] 
Lung T + Y blastoma [170] 
Retroperitoneal T Papillary renal cell-like carcinoma [171] 
Liver Y + T Sarcoma [172] 
Colon Y + C Adenocarcinoma [173] 
Sacrum T Oligodendroglioma [174] 
Sacrum T Anaplastic ependymoma [175] 
    
Testis T + Y rhabdomyosarcoma [176] 
Testis GS + T + Y angiosarcoma in mediastinum [177] 
Testis E + T + Y sarcoma [178] 
Testis Mixed Neuroblastoma [179] 
Testis T nephroblastoma and rhabdomyosarcoma [180] 
Testis T + E + GS Meningioma [181] 
Ovary T + Y Rhabdomyosarcoma [182] 
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3.3 Discussion 
This chapter examined where GCTs can arise in the CNS, and the types of 
cancer that GCTs can be mixed with. There were two questions that this chapter 
aimed to address: are teratomas confined to the midline of the brain; and what 
is the relationship between the GCT subtypes and either GCT or non-GCT tumour 
subtypes. 
There were several interesting treatment features that need to be discussed 
from the data; for example, why resection and therapy of one subtype of GCT 
could result in the formation of any of the other subtypes of GCT. The lines of 
evidence are used to argue that CNS GCTs originate from a brain-cell progenitor. 
Furthermore, we examine why teratomas seem able to arise anywhere in the 
CNS but are rarely diagnosed in lateral locations. 
 
All GCTs in the CNS can form from a common cell of origin  ? resection and 
recurrence 
There are several questions about the relationship between GCT masses and 
either their cell of origin or other subtypes of GCT. In an attempt to address 
these, the literature was assessed for examples of resection of a CNS GCT 
followed by the recurrence of a different GCT. This strategy examines which 
progenitors are present after the bulk of the tumour has been removed.  
There were several assumptions and alternatives for this strategy; for 
example, the resected tumour and the recurred tumour were both assumed to 
arise from the same progenitor. Alternatively, chemotherapy or radiotherapy 
may have altered the original tumour.  
After the resection of a CNS GCT subtype, any other GCT can recur; for 
example, the resection of a germinoma recurring as a teratoma. This suggests 
that when the tumour mass was removed, a progenitor cell remained and 
formed a different type of GCT. The original tumour was assumed to arise from 
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similar progenitors. This can be assumed because it is unlikely that several 
different progenitor types would be present in the same location at the same 
time. Resection and recurrence of a different subtype suggests that all GCTs have 
a common cell of origin.  
It is important to acknowledge that this has not given us an insight into 
whether the cell of origin is from the brain or from germ cell progenitors. 
Proponents of PGCs forming CNS tumours would have perhaps suggested that 
one or more PGCs mismigrated to a location where they were not eradicated and 
had the potential to grow; for example in the pineal region. This cell may have 
proliferated without differentiating, leaving some PGC progenitors to proliferate 
and differentiate when the tumour is resected. Although this data could not be 
used to distinguish between the germ-cell hypothesis and the brain-cell 
hypothesis, it can be used to understand the relationship between each of the 
subtypes of GCT in the CNS. 
There has been some ambiguity in categorising the different subtypes of 
GCT. Each subtype has significantly different morphology, gene expression, and 
methylation status to the others, which has prompted the subcategories of 
germinomatous/seminomatous and non-germinomatous tumours, with 
teratomas/teratocarcinomas sometimes being classed as a separate entity [183]. 
A teratoma can recur as either a yolk sac tumour or a germinoma, which 
suggests the same progenitors that can form a teratoma can form a germinoma. 
This observation shows that teratomas are a tumour type that is representative 
of all GCT subtypes, since the progenitors that can form a teratoma are also 
capable of forming any other type of GCT. The relationship of teratomas to the 
other subtypes is important to bear in mind because this thesis uses teratoma 
formation as a surrogate assay for the potential to form a GCT.  
There were no occurrences of germinomas arising after the resection of a 
yolk sac tumour. One possible explanation for this is that YSTs have a more 
aggressive chemotherapy and radiotherapy regime, so any progenitors to 
germinomas (which are very chemotherapy- and radiotherapy-sensitive) would 
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be eradicated. The lack of germinomas occurring after yolk sac tumours does not 
diminish the argument that each subtype is linked by their common aetiology 
because all other combinations of resection and recurrence of subtypes have 
been documented; for example, germinoma occurring after a teratoma, or 
teratoma after a yolk sac tumour.  
 
All GCTs in the CNS have a common cell of origin  ? mixed GCTs 
The types of tumour that were mixed in CNS GCTs were analysed in order to 
reinforce the evidence that all GCTs had a common cell of origin. In short, each 
subtype of GCT could be found mixed with each of the other subtypes of GCT. 
This suggests that all subtypes of GCT can arise from a single cell or group of 
progenitors. Whether these subpopulations form a hierarchy in which they 
represent increased differentiation, or whether they can all arise from a single 
population is debatable (Figure 3.3).  
It would seem more likely that each subtype can arise from a common 
progenitor because it is possible to find each subtype with only one other 
subtype; for example, a mixed tumour of teratoma and germinoma does not 
always contain yolk sac tumour. Further, there may be a case for transforming 
one type of GCT into another; however this will be the discussion of another 
chapter. This heterogeneity and clonal evolution occurs in other types of cancers, 
even brain tumours. 
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Figure 3.3 - A summary of two different hypotheses of how germ cell tumour 
progenitors could form a GCT after it has been resected. Either (A) all subtypes of GCT 
can arise from the same progenitor and it is the environment that dictates the subtype 
or (B) there is a hierarchy of formation based on how differentiated the subtype is. 
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Regardless of whether CNS GCTs are derived from PGCs or from brain cells 
these data provide evidence that all CNS GCTs can arise from the same cell of 
origin. The germ-cell hypothesis states that mismigrated cells have become 
trapped in distinct locations. However, patients are rarely diagnosed with GCTs 
in several locations throughout the body. Metachronous germinomas in the 
pineal and suprasellar regions are an exception. However, no patients have been 
documented with several GCTs in different locations at the same time; for 
example, in the gonads, retroperitoneum, sacrococcygeal, mediastinum, and 
brain. If there were patients with GCTs in several of these locations, it would be 
strong evidence of the route that PGCs have migrated and eventually formed 
GCTs. Therefore, proponents of a PGC of origin for extragonadal GCTs must 
concede that if their hypothesis is correct, only a few PGCs capable of forming 
GCTs reach extragonadal locations.  
In summary, if the current germ-cell hypothesis is correct, only a few cells 
capable of forming a GCT would reach the CNS. This implies that the different 
subtypes can arise from a single cell instead of different progenitors forming 
several different subtypes of GCT. This unifies all GCT subtypes as having a 
common cell of origin regardless of the region that cell originated from. The 
arguments for a PGC or a neural-cell of origin have been examined in Chapter 1, 
and will be tested throughout this thesis.  
 
Why GCTs are sometimes mixed with non-GCTs 
The analyses in this chapter have revealed some unexpected findings. Brain 
tumours that have a known aetiology from endogenous brain cells have been 
found mixed with GCTs in non-CNS locations; for example a meningioma in the 
testis. While this may seem counter-intuitive, it is perhaps evidence of the 
pluripotent nature of these tumours, rather than aetiology linked to a specific 
location in the body. To clarify, it seems unlikely that two rare cancers would 
form independently in the same locations  W it seems more intuitive that a single 
dysregulated mechanism has initiated both.  
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Many brain tumours require stem-cell features and mutations in order to 
cause oncogenesis; for example, mutations in the Wnt or sonic-hedgehog 
pathways. Both the brain-cell and germ-cell hypotheses have predicted that the 
cell of origin for all GCTs is pluripotent or has pluripotent features. Therefore, 
given the correct mutations, any type of tumour/cancer could form from the 
pluripotent progenitors that form GCTs. In fact, a study by Swartling showed that 
a mutation in MYCN gave rise to different tumours when engineered in different 
locations [184]. This suggests that the environment plays an important role in 
the type of tumour that forms from a progenitor. This may explain the strange 
combinations of GCTs with a different type of cancer, such as a GCT mixed with a 
meningioma. 
Examples of CNS GCTs mixed with non-GCTs such as glioblastomas were very 
limited. Makidono et al. 2009 presented an interesting case of a child with a 
metachronous yolk-sac tumour and choriocarcinoma in the suprasellar and 
pineal regions [163]. These tumours are rare when they occur on their own, and 
metachronous GCTs are even more infrequent. This occurrence of two rare 
tumours suggests an underlying mechanism for their formation; perhaps 
disruption to methylation in the ventral midline. More strikingly, these two 
tumours recurred as two different types of brain tumour: astrocytoma and 
glioblastoma. Again, this observation suggests that there is an underlying 
mechanism for cancer formation in the ventral midline. 
Mixed tumours in this study could not be used to definitively answer 
whether the cell of origin of CNS GCTs was a germ-cell or brain-cell. However, I 
propose that these mixed GCTs and non-GCTs have arisen from similar molecular 
defects.  
Molecular characterisation of GCTs mixed with somatic-type malignancy 
showed that teratomas and non-GCTs often shared gain in i(12p) or 12p 
chromosomes [185]. The gain of 12p or i(12p) may therefore be an oncogenic 
mechanism that is capable of causing a range of tumour types to form, including 
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GCTs. Alternatively, disruption to a mechanism such as methylation may allow 
initiation of various types of cancer.  
The hypothesis for gain of i(12p)/12p is not tested in this thesis but there are 
several experiments that could be used to test this; for example, manipulation of 
the i(12p)/12p copy number in embryonic stem cells and in vivo transplantation 
studies. Briefly, since ES cells appear to gain i(12p) after long term passage, it 
should be possible to select a cell line of ES cells that contains this chromosomal 
gain. This i(12p) cell line could then be used to differentiate any lineage since it is 
pluripotent. Additional aberrations such as a mutated form of Kit would allow 
this cell line to be used to test the ability of these cells to form a germinoma. 
So why have GCTs been frequently reported as midline tumours? One 
possibility is that teratomas that have occurred in lateral regions are more likely 
to result in termination of the pregnancy. These tumours would therefore have 
been less likely to appear in the literature. Testing this hypothesis would be very 
difficult since these tumours are incredibly rare, and relies on assaying the 
tumours at a very early stage of development. This topic will be discussed further 
in Chapter 3. 
 
3.4 Conclusion: 
This chapter has outlined the argument for teratomas as representative of 
all GCT subtypes when analysing the cell of origin. Each GCT subtype seems to 
have the same cell of origin despite their distinct expression profiles and 
morphological differences. There appeared to be no restriction in teratoma 
growth regardless of location in the brain. This suggests that there was an event 
in the cells of the midline that preferentially allowed them to form, rather than 
an environment in the lateral regions that protects against GCT formation. 
However, it was difficult to determine the exact location for the cell of origin of 
these teratomas. Therefore, the ability of pluripotent cells to develop into GCTs 
in different regions of the brain is examined in the next chapter.  
80 
 
This meta-analysis set out to test whether non-midline regions can support 
growth of teratomas. Several non-midline regions of the brain allowed teratoma 
growth, so the next chapter tests whether teratomas can be initiated from a low 
number of progenitor cells.  
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Chapter 4: An in vivo study of teratoma formation in 
the brain 
4.1 Introduction 
Our hypothesis that GCTs in the brain have a neural cell of origin raises a 
number of questions. In particular, if the progenitors of CNS GCTs are neural, 
then the higher prevalence of GCTs in the midline regions must be explained. If 
neural stem cells are the cell of origin for CNS GCTs, it seems surprising that GCTs 
are rarely associated with the lateral ventricles where NSCs are most abundant. I 
propose two models to explain this bias in location.  
It may be that there are specific features of the cells of the ventral midline 
that makes them intrinsically more susceptible to GCT formation. In the ventral 
midline, where GCTs are most often found, several genes are differentially 
expressed compared with the lateral hemispheres, of which NR-CAM and VEMA 
are two examples [186, 187]. More importantly, the imprinted genes H19 and 
IGF2 are differentially expressed in the ventral midline. Unlike other brain 
regions, where they are robustly imprinted and so expressed from only one 
allele, these genes are biallelically expressed in cells of the ventral midline [188]. 
Not only does this mean that levels of IGF2 transcript are higher, but it also 
reveals a difference in the methylation of the genome in these cells, a feature 
also seen in the analysis of the imprinted gene, Snrpn [57]. Given our hypothesis 
that activation of Oct4 by demethylation could be a key event in the aetiology of 
these tumours, this lower level of genomic methylation in the ventral midline 
provides both support for this model and a possible reason why the tumours 
occur more often in this location.  
An alternative explanation for the midline locations of GCTs is that the 
unique microenvironment of the ventral midline allows or promotes GCT 
formation. In particular, the ventral midline of the brain is a region of high 
hormonal activity such that the local concentration of factors such as IGFs and 
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GnRH could play a significant role in both the transformation of cells in this 
region and/or the type of tumour that a transformed cell becomes. A mutational 
event in a neural stem cell (NSC) that initiates the formation of a more typical 
type of brain tumour, such as glioma or ependymoma, might result in a GCT in 
the ventral midline because of local cues that promote pluripotency in those 
same cells. Indeed, a recent study showed that over-expression of oncogenic N-
MYC protein in neural stem cells resulted in dramatically different tumour types 
depending on the brain region from which those cells were isolated [184]. 
Embryonic stem (ES) cells consistently develop into teratomas, a type of 
GCT, when transplanted into mice. Therefore, ES cell transplantation can be 
utilised as an assay for how susceptible an area in the brain is to forming a 
teratoma. This tests the hypothesis that the different regions of the brain permit 
or restrict teratoma formation due to their different microenvironments. In 
Chapter 3, teratomas were shown to be able to grow anywhere in the human 
brain, but most often occur in the midline. However, these observations cannot 
determine whether the different locations of the brain vary in their 
permissiveness for teratoma formation, and this is addressed in this chapter. 
In this chapter I set out to assess our hypothesis by testing whether 
teratoma formation or growth is influenced by different regions of the brain. 
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4.2 Aims 
The main objective of the experiments detailed in this chapter was to test 
for the differences in the ability of pluripotent cells to form teratomas in two 
regions of the brain: the ventral midline and the lateral hemispheres. The 
pluripotent cells used were mouse embryonic stem (ES) cells. 
The first aim was to establish a heterogeneous ES cell population that 
stably expressed a protein that could be detected when these cells were grown 
as teratomas in vivo. In this case, luciferase was used. Furthermore, validation 
was required to show that the selection of a luciferase-expressing sub-clone of 
these ES cells had not diminished their ability to form teratomas or change vital 
pluripotent gene expression.  
Luciferase activity was chosen because it was integral to imaging the 
location of cells when transplanted into mice. There were both ethical and 
practical reasons for this. Ethically, the tumour growth needed to be monitored 
in order to terminate the mice if the tumour grew beyond a certain size. 
Tumours in the brain require scans to visualise them because they cannot be 
palpated. Therefore, we did not know how fast the cells would grow into a 
tumour, and luciferase was an effective way of tracking growth. From a practical 
point of view, luminescence shows the location of the tumour, which was 
important in confirming that the tumour formed at the predicted injection site. 
The second aim involved optimising the stereotaxic injection of these ES 
cells into discrete locations of the brain (a technique also utilised in later 
chapters).  
The third and final aim was to control the cell number implanted in order 
to directly compare the tumour volume over time using luminescence as a 
measure in vivo. 
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4.3. Results: 
Establishing an embryonic stem cell population that stably expresses luciferase 
The luciferase plasmid, pORF-LucSh, (Invivogen) (Figure 4.1 A) confers 
resistance to the antibiotic Zeocin. At high concentrations, antibiotics can also kill 
cells that have some resistance; therefore, the first experiment was to test the 
toxicity of Zeocin to untransfected cells. Various concentrations of Zeocin were 
used on untransfected ES cells over several days (Figure 4.1 B) to establish the 
concentration required to eliminate all cells that did not express Zeocin stably by 
4 days. 
Cells cultured in concentrations higher than 10µg/ml proliferated very slowly 
over two or four days. Therefore, the data informed the decision to use 10µg/ml 
of Zeocin for subsequent experiments. 
ES cells were transfected and selected for stable expression of the luciferase 
plasmid using 10µg/ml of Zeocin determined from the toxicity data (Figure 4.1 
B). Figure 4.1 C details a schematic for this process of transfection, selection, and 
repopulation. Embryonic stem (E^ )ĐĞůůƐĞǆƉƌĞƐƐŝŶŐůƵĐŝĨĞƌĂƐĞĂƌĞĚĞƐŝŐŶĂƚĞĚ ‘^-
>ƵĐĐĞůůƐ ? ?
The final population termed ES-Luc cells were only selected using Zeocin i.e. 
we did not derive a clonal line. A heterogeneous population of ES-Luc cells 
ensured that the majority of the cells would express luciferase and the 
luminescence could be used directly to estimate tumour size. In a cloned cell-line 
the luciferase gene could have been inserted into a locus that was silenced upon 
tumour formation or putative cell differentiation.  
The heterogeneous population of ES-Luc cells was stably selected i.e. ES-Luc 
cells could proliferate in medium containing Zeocin at a rate similar to ES cells 
that were untransfected and growing in normal medium.  
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Figure 4.1. Optimisation and stable transfection of a heterogeneous ES cell population 
with a luciferase plasmid (A) The pORF LucSh delta CpG plasmid used to transfect 
embryonic stem cells. This plasmid contains no CpG sites in order to prevent 
methylation. EM7 confers resistance to the antibiotic Zeocin. (B) Ability of embryonic 
stem cells to survive in different concentrations of Zeocin. Each colour represents a 
different concentration over a 4-day period. (C) A schematic of the stable-transfection 
process, which took approximately 10 days. The protocol included transfection of the 
luciferase plasmid, selection of  ES cells that had integrated the plasmid into their 
genome under Zeocin selection, and culturing of a heterogeneous population. (D) Ratios 
between firefly and renilla luminescence. This ratio internally controls the number of 
cells with the amount of luminescence for ES-Luc cells or untransfected ES cells. (E) Bar 
chart representing the relative light units for transfected embryonic stem cells 
compared to controls. (F-G) Immunofluorescence on untransfected ES cells (as a positive 
control), ES-Luc cells, and fibroblasts for a negative control. Green fluorescence is OCT4 
in (F) and NANOG in (G). DAPI is blue staining in both. 
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Detection of luminescence in ES-Luc cells 
The luminescence from ES-Luc cells was detected using a Glomax 96 
microplate illuminator. The cells were cultured in wells of a 96-well plate, Dual-
Glo Luciferase Substrate was added, and the Glomax machine assayed each well 
for luminescence. The addition of Dual-Glo Stop & Glo allowed for the detection 
of Renilla in order to form a normalised ratio of luminescence. One of the 
limitations of the Glomax was the detection of low-level luminescence in an 
empty well when adjacent to a well that contained luminescent cells. Therefore, 
when control- or ES-Luc-cells were placed into a given well in the 96-well plate, 
adjacent wells surrounding the tested well were left empty.  
Five wells of the same heterogeneous ES-Luc population and 4 wells of 
untransfected ES cells were plated into the 96-well plate. Each well was plated to 
contain approximately the same number of cells. The emission readings (data 
not shown) were converted to a ratio using a Renilla control; during detection, 
Firefly luciferase is quenched and any Renilla luminescence is detected. The 
Renilla luminescence can be used to normalise the Firefly luminescence to find a 
ratio, and this ratio is shown in Figure 4.1 D. Figure 4.1 E summarises the results 
of this luminescence assay and clearly shows that each of the ES-Luc wells 
luminesced, confirming that the cells in the ES-Luc population stably expressed 
luciferase. 
 
In vitro validation of pluripotency of the ES-Luc cell population: pluripotency 
markers 
Completing the overall experiment depended on the ES-Luc population 
being undifferentiated, and capable of forming teratomas. The ES-Luc cells had 
been confirmed to stably express luciferase and the next experiment tested 
whether the ES-Luc population retained its pluripotent properties. Complete ES 
medium had been used to culture the ES-Luc cells, which should have prevented 
non-ES cells from proliferating. However, transfection can be a disruptive 
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process and the ES-Luc cells needed to be validated for pluripotency. Therefore, 
the first step was to assay markers of pluripotency using immunohistochemistry.  
ES-Luc cells were tested for the expression of OCT4 and NANOG proteins 
using immunohistochemistry. Untransfected ES cells were used as a positive 
control, and mouse fibroblasts were used as a negative control. ES-Luc cells and 
untransfected ES cells were both positive for OCT4 and NANOG proteins, and 
mouse fibroblasts were negative for both proteins (Figure 4.1 F and G). Overlap 
between OCT4 and NANOG proteins with DAPI staining confirmed that 100% of 
the cells were positive for OCT4 and NANOG. This suggests that no differentiated 
cells were present. 
 
In vivo validation of ES-Luc cells for teratoma formation and luminescence 
Next, the potential of these ES-Luc cells to form teratomas and luminesce in 
vivo needed to be tested. For this, ES-Luc cells were injected into mice kidney 
capsules. 
The kidney capsule is a highly vascularised organ in a mouse, which has been 
shown to support growth of pluripotent cells towards teratoma formation. Since 
there are two kidneys, even if an injected kidney loses function the mouse will 
normally continue to thrive. Both of these reasons informed the decision to use 
the kidney capsule for a preliminary experiment. This first experiment was 
designed to evaluate the potential of ES-Luc cells to luminesce in vivo and form a 
teratoma, which also tested whether the ES-Luc cells retained their pluripotent 
properties. 
ES and ES-Luc cells were transplanted into the kidney capsule of 3 mice each. 
After 6 weeks, each one of these kidneys contained a large tumour. Each tumour 
was sectioned and ƐƚĂŝŶĞĚǁŝƚŚDĂƐƐŽŶ ?ƐƚƌŝĐŚƌŽŵĞ ?the standard approved stain 
to highlight complex regions of the tumour. Figure 4.2 A-D presents four 
different fields of a tumour formed by ES-Luc cells. These four panels are 
representative of findings in the other tumours and show tissue from each of the 
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three germ layers; mesoderm, endoderm, and ectoderm. This confirmed that the 
ES-Luc cell population had the capability of forming teratomas. 
The final preparatory step was to test our ability to detect luminescence of 
these ES-Luc cells in vivo. ES-Luc cells were injected into both the testis (Figure 
4.2 E and F) and kidney (Figure 4.2 G), and all produced teratomas. Figures 4.2 E-
G show both the position and approximate size of the tumour. The tumour 
images were captured by a machine that detected the intensity of light that was 
emitted from the cells in the tumour (Xenogen biophotonic Spectrum and 
IVIS100 Imaging Systems). The light intensity was detected in several different 
planes of view, which allowed for the construction of a three-dimensional image 
seen in Figure 4.2 G. This experiment confirmed that the ES-Luc population 
luminesced in vivo at a level that allowed detection.  
There was some variability in the size of teratomas when comparing kidney 
with testis, and this has been documented previously [189]. Testicular teratomas 
had a fairly large mass of approximately 0.5cm
3
, but the kidney allowed for much 
greater growth. The two testicular tumours varied in the amount of light 
emitted, and this was reflected in the size of the tumours since one was much 
smaller than the other. This analysis confirmed that the luminescence from the 
ES-Luc cells was approximately proportional to the size of teratomas formed. 
This was important because it meant that detection of luminescence in vivo 
could be used as a marker for size for the ethical and practical reasons already 
discussed.  
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Figure 4.2. A teratoma assay using ES-Luc cells in mice testis or kidney. (A- )DĂƐƐŽŶ ?Ɛ
trichrome staining on a teratoma formed from ES-Luc cells. (A) Endoderm. (B) Red 
rosettes representing immature nervous system i.e. ectoderm. (C) Circular light blue 
region indicates cartilage i.e. mesoderm. (D) Uniform lines of cells suggests smooth 
muscle i.e. mesoderm. (E)  IVIS imaging showed hotspots of light produced by 
luminescent ES-Luc cells. Red indicates high levels of light and therefore a high 
concentration of cells, and blue is lower levels of light. (F) Spectral unmixing used to 
remove reflected light. The mouse on the right (ii) has an amplified signal in order to 
determine the location of the tumour, so the intensity of the signal is not comparable to 
(i).(G) (i-iii) Two dimensional or (iv) three-dimensional views of a kidney and tumour 
formed by ES-Luc cells. Light brown areas represent the kidney(s), and orange 
represents the tumour. 
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Optimisation of stereotaxic cell-transplantation into the brain 
The ultimate goal of this chapter involved injecting ES-Luc cells into different 
regions of the brain to test where pluripotent cells had the ability to form a 
teratoma. The two different regions chosen were the ventral midline, where 
GCTs are known to occur; and a lateral region, where GCTs occur much less 
frequently. These two different regions are illustrated by Figure 4.3 A from a 
ventral view.  
Figure 4.3 B (modified from Paxinos [190]) shows the locations of each of the 
injections - highlighted by green circles. Adult mouse brains are very small  W 
approximately 10mm across  W so stereotaxic equipment was required to achieve 
these precise injections. Stereotaxic equipment immobilised an anesthetised 
mouse into a specific position. The equipment used reference points on the 
mouse skull to inject into a specific, replicable, three-dimensional position in the 
mouse brain. Injecting cells through the jaw would have been technically 
challenging and the literature showed that it was best to approach the regions of 
interest by drilling dorsally, i.e. through the top of the skull.  
Once the skin had been removed from the dorsal skull it was possible to use 
the bregma (the convergence of the bone sutures) as a reference point for 
coordinates in three-dimensions. Figure 4.3 C shows the first attempt with 
coordinates: AP -1.6m (anterior-posterior), ML 0.3mm (medial-lateral), DV 5mm 
(dorsal-ventral) relative to the bregma. First, a small hole that a fine needle could 
pass into was drilled. For the preliminary experiments, dead mice and red dye 
were used in order to track the location of injection and the accuracy of the 
needle.  
This initial attempt highlighted two issues: even using a dead mouse, there 
was significant bleeding as the drill entered; and the dye was not all localised 
specifically to the intended area. Figure 4.3 C (iv) highlights the inaccuracy of the 
injection: the actual position was rather lateral compared to the intended 
coordinates. Using Figure 4.3 B it was possible to estimate the coordinates of 
where the dye was placed: AP -1.6mm, ML 1.5mm, DV 4mm.  
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Figure 4.3. Optimisation of stereotaxic mouse brain injection. (A) Illustration of two 
locations where cells should be injected from a ventral view. (B) Schematic of an adult 
mouse brain from a coronal view. Green circles indicate the approximate coordinates of 
the lateral and midline locations targeted in injections. The red square represents the 
ventral midline and the hypothalamic region [190] (C) Validation of the coordinates 
following injection of a red dye. Three sections were taken to show the approximate 
position of the majority of the dye. (i) the track where the needle went in (ii), and 
leakage of dye (iii). (iv) shows that although the needle was placed in straight, the dye 
location is lateral to the target coordinates (highlighted by a green circle). 
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The first issue was to correct the bleeding caused by the drill because a live 
mouse would probably not survive such trauma to a large blood vessel. Figure 
4.4 A shows the vascular network in an adult mouse, and the blood vessel which 
caused the bleeding was most likely the superior sagittal sinus [191]. Ideally the 
stereotaxic injection equipment would have allowed for rotation through the 
coronal plane in order to circumvent the vessel; however, the equipment used 
did not have this capability. Therefore, the original coordinates were altered to 
AP -1.6mm, ML 1mm, DV 5mm for the midline injections, and AP -1.6mm, ML 
2.75mm, DV 3.5mm for lateral. These coordinates did not cause severe bleeding 
when a terminated mouse had a hole drilled and dye injected, and the dye 
appeared to be closer to the midline (Figure 4.4 B). The depth of injection was 
increased slightly for the main experiment in order to target the hypothalamic 
region instead of the thalamus.  
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Figure 4.4. Optimisation of injection site based on the adult mouse brain vasculature. 
(A) Adult mouse brain viewed from the dorsal side highlighting the main vasculature . 
The darkened line in the centre of the brain is the superior sagittal sinus, and this 
branches laterally into the transverse sinus. The two small red circles indicate the 
approximate positions during the first attempts of injecting dye (Image taken from Dorr 
et al. (2007) [191]). (B) A coronal view of an adult mouse brain injected with red dye 
(indicated by a blue arrow) that did not cause bleeding during drilling.  
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Injection of ES-Luc cells into the ventral midline and lateral 
hemispheres 
Drilling into the optimised coordinates caused only minor bleeding, and the 
injection of 100,000 ES-Luc cells into each of seven mice gave rise to no 
complications. Luminescence was not clearly detectable within the first few days 
of injection so the first visualisation was recorded 6 days after injection (Figure 
4.5 A and B).  
The intensity of light emitted from each of the seven mice varied widely. The 
location of injection of ES-Luc cells did not seem to correlate with the differences 
seen in luminescence. Midline mice were labelled M1-M4 and mice injected in 
the lateral region were labelled L1-L3. The two mice that showed the least 
luminescence were from separate groups (Figure 4.5 A mouse M2, and Figure 4.5 
B mouse L3). In contrast, the two strongest signals (M4 from group 1 and L2 from 
group 2) were also from different groups (Figure 4.5 A and B). The same tube of 
ES-Luc cells was used for all injections so the concentration of cells should have 
been equal.  
The preliminary experiment showed that luminescence correlated with the 
size of a teratoma. By day 12, one of the mice (M4) showed luminescent signal 
indicative of a very large teratoma. Therefore, this mouse was terminated and 
the brain was dissected and kept in fixative.  
Luminescence was detected in all the remaining mice by 12 days 
summarised by Figure 4.6, although the signal was very weak in one of the 
midline-group mice (M2). There was no clear correlation between the region that 
ES-Luc cells were transplanted and the rate of growth; in fact, the mouse with 
the most, and the mouse with the least luminescence were both in the midline 
group (Figure 4.6 B).  
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Figure 4.5. Visualisation of luminescence in adult mice 6 days after being injected with 
ES-Luc cells. (A) IVIS imaging of luminescence in the midline group, or (B) in the lateral 
group. (C) A bar chart of each mouse on the X-axis, with bioluminescent intensity (BLI) 
on the y-axis; note the y-axis log scale. 
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Figure 4.6. The light intensity recorded for six separate mice over 12 days following 
injection of ES-Luc cells. (A) Line graph of light intensity recorded over 12 days. Each 
colour represents a different mouse in either the midline- or lateral injected group. Note 
the light intensity on the y-axis log scale (Bioluminescent intensity). (B) IVIS imaging of 
luminescence in the midline group, or (C) in the lateral group from a dorsal view.  
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At 12 days the images showed that each of these mice had probably 
developed a teratoma so all remaining mice were terminated and their brains 
were dissected. Each brain showed substantial morphological differences when 
compared with a control brain that was only injected with dye. From the dorsal 
side, the effects were more subtle (Figure 4.7), with damage probably caused by 
necrosis (Figure 4.7 E) and swelling in the hemispheres of several of the brains 
(Figure 4.7 B, C, D, F and G). In contrast, the ventral view of these brains revealed 
considerable discolouring and damage. Although some of the brains were 
damaged in the process of removing them (Figure 4.8 A and E), it appeared that 
each brain had a large tumour when compared with the control brain (Figure 3.8 
H). Using the relatively normal cerebellum and olfactory bulb as reference 
structures, the ventral midline appeared misshapen (Figure 4.8 A), or necrotic 
(Figure 4.8 B-D). None of the injected brains appeared symmetrical when 
compared to the control, especially those shown in Figure 4.8 B and G. 
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Figure 4.7. Dorsal view of adult mice brains 12 days after injection of ES-Luc cells. 
Injection of ES-Luc cells was into either (A-D) the midline, (E-G) lateral region, or (H) a 
dead mouse injected with dye used as a control. The injection site for each brain can be 
seen to the left of where the two hemispheres join. The anterior of the brain (olfactory 
bulb) is at the top of the images and posterior (cerebellum) is at the bottom. 
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Figure 4.8. Ventral view of adult mice brains 12 days after injection of ES-Luc cells. 
Injection of ES-Luc cells was into either (A-D) the midline, (E-G) lateral region, or (H) a 
dead mouse injected with dye used as a control. The anterior of the brain (olfactory 
bulb) is at the top of the images and posterior (cerebellum) is at the bottom. (H) The 
control has the region in the centre highlighted as the ventral midline, the cerebellum at 
the bottom of the image, and the olfactory bulb at the top of the image to indicate 
where these structures would normally be found as a comparison to the injected brains. 
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Each of the dissected mouse brains was sectioned and one section from 
each brain was stained with haematoxylin and eosin (H&E). The sections were 
examined for regions of tissue that were representative of each of the three 
germ layers  W mesoderm, endoderm, and ectoderm. Using this germ-layer 
criterion, all of the mouse brains injected with ES-Luc cells were histologically 
confirmed as being teratomas. Figures 4.9 and 4.10 represent a brain from the 
midline or lateral region respectively. Each figure shows the gross morphology of 
the brain containing the tumour, two sections of the brain stained with H&E, and 
detailed regions of the section to illustrate the three germ layers.  
The three regions of teratoma that represented the germ layers included: 
high density endodermal cells similar to those in the gastrointestinal lining 
(Figure 4.9 C (i) and 4.10 C (i)); immature cartilage derived from the mesoderm 
(Figure 4.9 C (ii) and 4.10 C (ii) ) ? ĂŶĚ ĐŚĂƌĂĐƚĞƌŝƐƚŝĐ  ‘ŶĞƵƌĂů ƌŽƐĞƚƚĞƐ ? ǁŚich 
represent ectoderm (Figure 4.9 C (iii) and 4.10 C (iii)). An example of these three 
regions and their locations in a tumour can be found in Figure 4.11, and 
highlights the heterogeneous nature of a teratoma. With some brain tumours it 
can be difficult to distinguish normal brain from tumour; however, this was not 
the case with teratomas in the brain, which were well circumscribed and had a 
defined edge where the brain stopped and the tumour began (illustrated in 
Figure 4.12).  
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Figure 4.9. Histology of the midline mouse, M3.  (A) An example of an adult mouse 
brain injected with ES-Luc cells into the midline  W M3. (B) Two sections of (A) with 
haematoxylin and eosin stain. (C) 40x magnification of regions of (B) that represent the 
three germ layers; endoderm (i), cartilage/smooth muscle (ii), and rosettes characteristic 
of neural tissue (iii).  
 
 
 
 
 
 
 
 
 
Figure 4.10. Histology of the lateral mouse, L3 (A) An example of an adult mouse brain 
injected with ES-Luc cells into a lateral region  W L3. (B) Two sections of (A) with 
haematoxylin and eosin stain. (C) 40x magnification of regions of (B) that represent the 
three germ layers; endoderm (i), cartilage (ii), and rosettes characteristic of neural tissue 
(iii).  
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Figure 4.11. Histology of a teratoma in an adult mouse brain injected with ES-Luc cells. 
(A) A section of an adult mouse brain injected with ES-Luc cells that has formed a 
tumour. Stained with haematoxylin and eosin. (B) 10x magnification of only the tumour 
from (A). (C) Three sections of tumour magnified to 40x which represent the three germ 
layers: (i) endoderm; (ii) mesoderm such as cartilage; and (iii) neural rosettes for 
ectoderm. 
 
 
 
 
 
 
 
 
 
Figure 4.12. Histology of normal and tumour tissue in an adult mouse brain injected 
with ES-Luc cells. (A) A section of an adult mouse brain injected with ES-Luc cells that 
have developed into a tumour. Stained with haematoxylin and eosin. (B) An example of 
what normal brain looks like when magnified 10x (i) or 40x (ii). (C) The boundary of brain 
and tumour magnified at 10x (i) or 40x (ii). The normal brain is pink and aligned in a 
uniformed fashion, and the tumour is blue with non-uniform structures. 
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Injection of approximately 5,000 ES-Luc cells into the 
ventral midline and lateral hemispheres 
 The previous experiments show no clear difference between teratoma 
formations in the midline compared to the lateral hemisphere. However, it may 
be possible that a high concentration of ES cells may have the capacity to form a 
microenvironment capable of supporting other ES cells. Considering the 
successful growth of histologically-confirmed teratomas from a large number of 
ES-Luc cells, we repeated the experiment with a lower number of cells.  
Our primary objective was to test whether a biologically relevant number 
of cells had the capability of forming a teratoma in the lateral hemispheres. 
Therefore, we injected approximately 5,000 ES-Luc cells suspended in 5µl of PBS 
into either the midline or lateral region of SCID mice, and three mice per region 
were injected. 
After only 2-3 days, all of the midline mice had to be terminated due to 
weight loss and irregular behaviour. After 6 weeks, one of the mice injected with 
ES-Luc cells into the lateral hemisphere was also terminated due to irregular 
behaviour. The final two mice in the lateral group were imaged for luminescence 
in either three-dimensions (Figure 4.13 A), or two-dimensions (Figure 4.13 B). 
Both scans showed signs of teratoma growth in the lateral regions so the 
remaining mice were terminated. 
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Figure 4.13. Detection of luminescence emitted from ES-Luc/teratoma cells. Two out of 
six mice were imaged for luminescence 7 weeks after injection of ~5,000 ES-Luc cells. ES-
Luc cells were injected into the lateral hemispheres in both mice. Imaging was either 
three-dimensional (A) or two-dimensional (B). (A) Three planes of two-dimensional 
scanning (i-iii) are combined to form a three-dimensional image (iv). The rounded 
tumour can be clearly  seen in the lateral region of the brain (iv). 
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The brains of all six mice were dissected, fixed, sectioned, and stained 
with haematoxylin and eosin. Since the mice of the midline group all died within 
a short time, there were no signs of  tumour growth (Figure 4.14 A-C). Therefore, 
it was not possible to determine whether the cells in these locations would have 
grown. 
All three mice injected with ES-Luc cells in the lateral region showed 
teratoma growth. One out of the three brains in this group only showed signs of 
a small teratoma, but appeared to have disseminated into a wider region (Figure 
4.14 D i-iv). Comparatively, the other two brains in this group contained large 
teratomas (Figure 4.14 E-F). In summary, a small number of ES-Luc cells are 
capable of developing into large teratomas when transplanted into the lateral 
hemispheres of mice brains. 
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Figure 4.14. Teratoma formation in mice brains using low concentrations of ES-Luc 
cells. Approximately 5,000 ES-Luc cells were injected into either the midline of mice 
brains (A-C), or the lateral regions of the brain (D-F). (A-F) After termination of each of 
the mice injected with ES-Luc cells, the brains were removed, fixed, sectioned and 
stained for tumour growth. The midline brains were dissected after only 2-3 days due to 
poor health (A-C) but the lateral brains were left for 6-8 weeks (D-F). Each brain was 
section at the site of injection and one slide from either side of the injection point is 
presented. 
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4.4 Discussion 
The experiments described in this chapter tested whether teratomas could 
form in different regions of the brain. There were two questions to be answered 
by these experiments: firstly, was it possible for teratomas to form in the two 
different regions; and secondly, was there a difference in their growth rate of 
teratomas in these two regions.  
I found that ES-Luc cells had the capacity to form teratomas in both regions 
of the brain that they were injected into. The tumours all increased in size very 
rapidly after injection into the brain, which was similar to the growth rates seen 
in other locations of the mouse body such as the kidney capsule. Therefore, 
there did not appear to be a significant protective environment in the lateral 
hemisphere to explain why teratomas are most frequently found in this region.  
Approximately 100,000 cells were injected into the respective regions; 
however, there may be far fewer progenitors than 100,000 when these tumours 
arise in humans. ES-Luc cells have the potential to form their own collagen 
matrix, which may circumvent any differences in environment in the two 
different regions i.e. the ability of progenitor cells to result in tumours in these 
regions. Therefore, we tested both regions with a relatively low number of cells, 
and teratomas could still form in lateral locations.  
One caveat was that the mice used were adult. Teratomas mainly form in 
the pre- or peri-natal age range, and the brain microenvironment is different 
between a developing embryo and an adult. From a practical perspective the 
issue of using adult mice is very difficult to resolve. The ideal solution would 
involve transplanting cells into embryos younger than E11.5. However, injecting 
cells accurately into an adult brain is challenging. Therefore, injecting cells into 
brains of embryos in utero that are much smaller than adults, as well as the 
embryos surviving to term and developing, is beyond our capability at present. 
Overall, this caveat may be a minor issue. Teratomas have been found to 
arise in adults and are therefore not exclusive to the pre- or peri-natal age range. 
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While the aetiology of these tumours has been disputed, this experiment tested 
the microenvironment, and the non-midline environment did not appear to be 
protective against teratoma initiation and formation. 
The second part of these experiments tested if there was a difference in the 
growth rate between teratoma formation in the midline compared to the lateral 
region. Unfortunately, the tumours proliferated rapidly so there was not enough 
time to track the growth rate over an extended period of time. Ideally the 
luminescence from each tumour would have been detected every two days until 
morbidity, or until the intensity of luminescence indicated that the tumour had 
grown beyond a certain size. This would have perhaps addressed whether there 
was a difference in the growth rate of progenitor cells. Technology at present is 
not sensitive enough to track the rate of growth accurately; however, there did 
not seem to be any substantial differences in the teratomas formed in the lateral 
regions.  
If there was no growth advantage to the ventral midline, why have GCTs 
been more frequently reported to occur in the midline? In the pre- and peri-natal 
period, some parts of the brain may be more important for survival than others. 
Teratomas occurring in the lateral regions of the brain may be detrimental to 
development and are therefore not documented - since the pregnancy is 
terminated naturally or through clinical procedures. This speculation would be 
possible to test with a large cohort of autopsy reports for abortions but is 
beyond the scope of this project. 
Is it likely that GCTs in lateral regions terminate pregnancy at an early stage? 
Perhaps it is more intuitive to think that the midline of the developing brain 
contains cells with a higher propensity, or a mechanism that increases the 
likelihood of developing a GCT. The next chapters will address these issues. 
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4.5 Conclusion 
Overall, the strategy of injecting luminescent pluripotent cells (ES-Luc cells) 
into different regions of mouse brain has been informative. Mice that had been 
injected with ES-Luc cells developed into teratomas with no striking differences 
in growth, regardless of location. Taken together with other literature, it appears 
that non-germ-cell progenitors can form GCTs in either midline or lateral regions 
of the brain.  
So why are certain CNS GCTs found only in particular locations? Why do 
germinomas appear to be confined to the midline? Why are teratomas 
diagnosed in the midline at a higher prevalence than those in the lateral regions? 
The next chapter will investigate the properties of the potential cell of origin for 
GCTs in the brain and suggest a hypothesis for tumour-growth bias.  
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Chapter 5 Neural stem cells and activation of OCT4 
5.1 Introduction 
 The cell of origin for CNS GCTs is hypothesised by Teilum to be a 
mismigrating germ cell progenitor. Our hypothesis contradicts this, and we 
suggest that CNS GCTs arise from a brain-cell.  Therefore, the experiments 
summarised in this chapter test the ability of a neural cell to form a GCT.  
It has been known for many years that ES cells can initiate the formation 
of teratomas [192]. More recently, activation of only a single gene, Oct4, was 
shown to induce neural stem cells to become pluripotent, albeit at a low 
efficiency [81]. We hypothesise that neural stem cells either acquire Oct4 
expression, or Oct4 is not silenced properly during embryogenesis (either 
delayed in silencing, or prevented from undergoing a single silencing mechanism 
altogether), and it is this activation of OCT4 that forms a pluripotent progenitor 
capable of forming a GCT. 
 Our hypothesis that neural progenitors form CNS GCTs by Oct4 
expression presents several challenges. The first is the role of OCT4 in vivo; is 
Oct4 aberrantly expressed after it is silenced, or is there a lack of Oct4 silencing 
during the normal process, i.e. is Oct4 reactivated, or is Oct4 continually 
expressed? 
 The subtle difference between reactivation of Oct4, and continuous 
expression of Oct4, may change our hypothesis dramatically. If neural 
progenitors retain low levels of OCT4, this would require a different 
experimental design to a complete loss of Oct4 expression and reactivation. A 
loss of OCT4 is likely to cause progenitors to differentiate; however, if Oct4 
expression was continued but low, it is much more likely that the progenitors 
have retained their pluripotent properties.  
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These two statements are integral in designing experiments to test this 
hypothesis because one of these mechanisms may not be sufficient to form a 
GCT. Therefore, both these possibilities need to be addressed. 
Each subtype of GCT appears to have a different pattern of occurrence in 
the brain. Examining different regions of the brain at various time-points during 
embryogenesis would be too ambitious for the scope of this project. In light of 
this, it must be assumed that the progenitors are active and have a similar 
capability to form GCTs. Teratomas can apparently form anywhere in the brain; 
this would suggest that the progenitors are present in all regions of the brain, 
although there may be differences in the number of these cells. The differences 
between each class of tumour, especially germinomas compared with teratomas, 
will be discussed later. 
 
5.2 Aims 
The experiments in this chapter were designed to examine the role of OCT4 
in GCT formation, and test the ability of OCT4 activation to induce a multipotent 
stem cell to form a teratoma in vivo. We had hoped to address this using three 
different approaches: induction of OCT4 in vivo, induction of OCT4 in brain tissue 
before transplanting into another mouse, and induction of OCT4 in a neural stem 
cell population before injecting into a mouse brain. 
The original aim was to develop a transgenic mouse model in which OCT4 
only becomes activated in specific cell types. The strategy behind these crosses 
was to use the Nestin promoter  W a marker for neural lineage cells  W to localise 
OCT4 activation to NSCs in the brain (Figure 5.1). With this strategy, it would 
have been possible to target other tissue locations in mice, but it would have 
reduced the major side-effects seen in mouse models that ubiquitously express 
Oct4. The first section of the results briefly describes an initial pilot trial of this 
strategy; however, this system proved unreliable, so the rest of this chapter 
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focusses on a mouse model that ubiquitously expressed Oct4 upon addition of 
doxycycline (Figure 5.2 A).  
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Figure 5.1. A breeding scheme showing the production of mice that express Oct4 in 
NESTIN-expressing cells upon doxycycline treatment. (A) Homozygous NESTIN-Tet mice 
were crossed with (B) homozygous rtTA-OCT4 mice to produce (C) mice capable of 
expressing Oct4 in cells that express NESTIN upon addition of doxycycline. 
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Figure 5.2. OCT4-inducible transgenic mice. (A) M2-rtTA (reverse transcription 
transactivator) is expressed by  the Rosa26 promoter. The addition of doxycycline allows 
rtTA to bind to the TetOP (Tet-operon) in order to allow expression of Oct4 cDNA at the 
Col1A1 locus. The Rosa26 promoter is activated in all cells, so addition of doxycycline 
expresses rtTA, and therefore OCT4, throughout the body. (B and C) Each mouse was 
genotyped for the Rosa26-Tet, and Col1A1-Oct4 loci. This figure shows examples of 
tissue that is positive for Rosa26-Tet (A), and either homozygous, wild-type, or 
heterozygous for Col1A1-Oct4 (C  W left to right).  
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The following experiments aimed to evaluate whether neural stem cells from 
the brain can form a teratoma, but there are limitations on how relevant these 
are in vivo. There is already an established OCT4-inducible mouse so I used this 
model to understand whether OCT4-induction can lead to the formation of a GCT 
(Figure 5.2).  
In this particular experimental mouse model, doxycycline administration 
triggered ubiquitous Oct4 expression. However, Oct4 expression had not been 
clearly evaluated in the embryo. A robust evaluation of the OCT4-inducible 
system was therefore the first aim. This was followed by induction of OCT4 to 
determine the effect on development and survival to birth of embryos. Finally, 
the effect of OCT4 during embryogenesis on the long term survival and tumour 
formation on these mice was tested.  
Since we were unsure of the exact cell type of origin, and it may be possible 
that the progenitors of GCTs are only present during a short window of 
development, we used two strategies as a preliminary step in order to focus on 
when and where these progenitors may be present. The first experiments tested 
whether a neural progenitor has the potential to form a GCT. The strategy uses 
either dissociated brain tissue or an isolated stem cell population.  
The initial experiments required the isolation and characterisation of a 
potential progenitor population; neural stem cells (NSCs). We were unsure 
whether there was an abundance of cells with the potential to form a GCT in the 
brain; therefore, isolating and culturing a subpopulation allowed the number of 
progenitors to be increased.  
Our plan was to activate OCT4 in NSCs and brain tissue, and test whether 
they had the potential to form a GCT. Injection of cells into the kidney capsule is 
an established method of testing pluripotency and whether a cell population has 
a tumour-forming capacity.  
The first experiment evaluated the ability of brain tissue and NSCs to form 
tumours/teratomas when OCT4 was activated using our transgenic system. In 
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these experiments the cells were transplanted into in the kidney capsule of 
severe combined immune-deficient (SCID) mice, and were left to develop for 6 
weeks. The potential of these cells to form teratomas in the brain was used to 
test the hypothesis that a brain cell can form a GCT. 
 
5.3 Results 
Three strategies test the ability of cells in the brain to form a type of germ 
cell tumour: testing whether a multipotent cell population found in the brain 
with OCT4 activation can form a GCT; transplanting portions of brain tissue 
induced with OCT4 into mice kidneys to examine teratoma formation; and 
inducing OCT4 in vivo during embryogenesis. All these experiments were carried 
out in parallel.  
  
OCT4 activation localised to Nestin-expressing cells in a transgenic mouse 
model 
 Neural progenitors express Nestin, and according to our model, these are 
likely progenitors of CNS GCTs. We therefore set out to test this hypothesis by 
crossing two strains of mice: upon administration of doxycycline, the first strain 
expressed a transactivating protein (TA) in cells that already expressed Nestin; 
and the second strain responded to TA by activating OCT4. Therefore, OCT4 
should have been activated in Nestin-expressing cells when doxycycline was 
added. This work was carried out in collaboration with Valerie Wilson at The 
University of Edinburgh.  
 Many rounds of breeding between Nestin-Tet promoter mice and mice 
carrying the Tet-responsive OCT4 gene (Figure 5.1) resulted in a strain that 
contained both the transgenes, confirmed by genotyping. Therefore, the ability 
of doxycycline to activate OCT4 needed to be tested. NSCs were cultured, along 
with controls from non-neural origin. Each of these samples was tested for OCT4 
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and NANOG activation using RT-PCR. The expected result was activation of OCT4 
only in NSCs that had been in contact with doxycycline; however, in several cases 
even those NSCs that should not have been activated by doxycycline expressed 
Oct4 (data not shown).  
 In vivo activation of OCT4 by oral gavage also revealed an inconsistent 
result. OCT4 was being activated without the addition of doxycycline (data not 
shown).  
 These data showed that the system did not work as intended, so a 
different strategy was formulated. Instead of trying to isolate a restricted cell 
population using Nestin-localised expression, we changed to a mouse strain that 
ubiquitously expressed Oct4 when doxycycline was administered (summarised in 
Figure 5.2 A).  
 
Establishing and maintaining a transgenic-mouse colony 
This strategy examines whether OCT4 has the ability to trigger formation 
of a GCT when it is expressed during embryogenesis. As described in Chapter 1, 
Oct4 expression is silenced by around E11.5. Since GCTs are thought to originate 
from a progenitor cell that is activated in the first or second trimester, the ideal 
time window to test the effects of aberrant Oct4 expression is between E11.5 
and birth.  
 Transgenic Rosa26-rtTA/Tet-OCT4 mice were bought from The Jackson 
Laboratory [193] and maintained by BMSU (QMC, Nottingham). The Rosa26 
locus is expressed ubiquitously; therefore, all cells should express rtTA. The rtTA 
protein binds to the TetOP locus upon administration of doxycycline, which 
allows expression of Oct4 in all cells. 
Homozygous, heterozygous, and wild-type mice from the colony were 
crossed. The genotype of these mice was confirmed by PCR. Figure 5.2 A shows 
the result of a typical genotyping PCR: two bands for a heterozygous genotype, 
and a single band of either 551bp for homozygous, or 331bp for wild-type. In this 
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case, wild-type is defined as the absence of the Tet-OCT4 gene inserted at the 
Col1a1 locus; however, these wild-type mice often possess the Rosa26-rtTA 
gene.  
There were several rounds of mouse crosses and intermediate 
experiments which required genotyping (see Appendix I). 
 
Isolation and characterisation of neural stem cells 
 According to our hypothesis, NSCs are a likely candidate for the 
progenitor cell for CNS GCTs. The first set of experiments tested the activation of 
OCT4 upon doxycycline addition, and validated NSCs. The first step was isolation 
and characterisation of NSCs. 
 E^Ɛ ?Žƌ ‘ŶĞƵƌĂů-ƉƌŽŐĞŶŝƚŽƌ ?ĐĞůůƐ ?ǁĞƌĞŝƐŽůĂƚĞĚĨƌŽŵĚŝĨĨĞƌĞŶƚƌĞŐŝŽŶƐŽĨ
mouse brain of different ages. Briefly, a small piece of mouse brain tissue was 
dissected from mice of various ages (E8.5 through to adult), and neural 
progenitors were cultured as neurospheres.  
Neural progenitors could differentiate into both neuronal cells and glia, 
as tested by a differentiation assay followed by immunofluorescence of MAP2 
and GFAP (Figure 5.3 B). Neural progenitors should have the capability to self-
renew, and all regions/ages could serially form neurospheres from a single 
neural stem cell (Figure 5.3 C).  
OCT4 should have been expressed upon treatment with doxycycline. 
Crucially, it was silent in all regions/ages when no doxycycline was added, but 
expressed when doxycycline was added (Figure 5.3 A). When NSCs were treated 
with doxycycline they continued to display NSC characteristics such as 
differentiation, and self-renewal (summarised in Figure 5.3 D). 
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Figure 5.3. Validation of neural stem cell derived from Oct4 mice. (A) Polymerase chain 
reaction on cDNA synthesised from neural stem cells isolated from the ventral midline 
(VML) or lateral ventricular region (LV). Oct4 was only expressed in the presence of 
doxycycline. (B) After differentiation using retinoic acid,  there was increased expression 
of MAP2 (a marker for neuronal cells) and GFAP (a marker for glial cells) in NSC 
populations that were either untreated, or treated with doxycycline. (C) A self-renewal 
assay; neurospheres were dissociated into single cells on Day 1; cell numbers were 
calculated to plate 0 or 1 cell into a well, and these were cultured for 2-5 days; a single 
well containing one neurosphere was dissociated and plated into wells at a 
concentration of 0 or 1 cell  W this constituted one passage. This process was repeated 
until the neuropheres had been passaged three times, which confirmed NSC ability of 
self-renewal. (D) A summary of the properties of neurospheres cultured from the VML 
or LV of Oct4-inducible mice. Both regions are capable of being induced by Oct4, and 
self-renewal. 
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Time delay between doxycycline addition and OCT4 and 
NANOG activation 
 The induction of OCT4 in NSCs to a pluripotent state has already been 
tested using viral vectors. However, these methods took several weeks to form 
pluripotent cells and it was unclear whether the transduction process or the 
expression of Oct4 caused this delay. Therefore, the next set of experiments 
aimed to test the transgenic mouse system for the time between doxycycline 
addition and Oct4 expression. Nanog is a marker for pluripotency, or 
pluripotential ability, so this too was assessed. These experiments were carried 
out in parallel with other experiments in this chapter and informed the design of 
other tests.  
The experimental plan to test the speed of Oct4 and Nanog expression 
was to add doxycycline, and assay NSCs by RT-PCR at certain time-points after 
this addition. Figure 5.4 A shows that Oct4 is expressed after only 2 hours, but 
Nanog requires between 24-48 hours to become active. By day 6, Nanog is 
expressed strongly indicating OCT4 activation leads to NANOG activation, as has 
been shown using other systems [194]. 
 
Time delay between removal of doxycycline and silencing 
of Oct4 
 Next, the removal of doxycycline, and the effect on Oct4 and Nanog 
expression was assessed. In this experiment NSCs were treated with doxycycline 
for 7 days (to ensure robust activation of both OCT4 and NANOG), then 
doxycycline was removed at  ‘0 hours ? and cells were analysed at various time-
points. Oct4 is tightly regulated by the transgene and the message has a very 
short half-life because after only 2 hours there is no detectable transcript (Figure 
5.4 B). Nanog is expressed at low levels in NSCs that do not express Oct4; 
therefore, it is difficult to determine when Nanog was no longer enhanced when 
using RT-PCR. However, Figure 5.4 B shows a gradual decline in intensity of signal 
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over 48 hours; hence, in vitro culturing of NSCs after 7 days of OCT4 activation 
does not result in irreversible expression of Nanog.  
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Figure 5.4. The effect of addition and removal of doxycycline on Oct4 and Nanog 
expression. (A) Doxycycline was added to neural stem cells cultured from postnatal day 
4 Tet-Oct4 mice. The effects of doxycycline addition over time are shown by RTPCR. (A) 
clathrin loading control, (B) Oct4, (C) Nanog. Doxycycline was added and left for 10 days 
before being removed; at several timepoints after removal, RNA was taken for cDNA 
synthesis and RTPCR. (D) Clathrin, (E) Oct4, and (F) Nanog.   
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Activation of OCT4 in E8.5 ex-vivo brain tissue forms 
pluripotent colonies  
 The literature suggests that OCT4 induction in adult neural stem cells can 
activate a small number of cells to become pluripotent [81]. The strategy behind 
the experiments designed here aims at understanding the relationship between 
the cells in the brain and their ability to form a GCT. Our hypothesis is that CNS 
GCTs arise from cells from the brain, but it is not clear to which population the 
progenitor cell belongs. To understand how the stage of brain development of 
the cells might affect the ability to form a teratoma, the following strategy uses 
mixed brain cell types in order to determine if, and when, a brain cell could form 
a teratoma.  
 Transplantation of cells into the kidney capsule of a mouse is a useful 
assay to determine the potential of cells to form a teratoma. This assay shows at 
which ages of brain-cell populations can or cannot form teratomas.  
 However, there are limitations to this experiment. The kidney capsule 
does not have the same microenvironment as the brain. Both the local hormonal 
concentrations and physical interactions will be different, and these may be 
important factors in CNS GCT formation. As a specific example, glial cells often 
support the development of the brain and may be implicated in supporting 
tumour formation. The other major limitation was the age of mice; adult mice 
were used in this experiment but CNS GCTs most frequently occur by puberty.  
 In the first experiment, I examined mouse brain tissue of three different 
ages and their ability to form pluripotent cells when OCT4 was activated. This 
work was in collaboration with Dr. Valerie Wilson at the University of Edinburgh 
and was based on a protocol for culturing pluripotent epiblast stem cells. Figure 
5.5 A shows the regions of brain removed from the mice before being cultured in 
EpiSC medium for 5 days in doxycycline to activate OCT4. These explants were 
assayed for OCT4 and NANOG expression by immunofluorescence. Figure 5.5 B 
shows that OCT4 and NANOG were activated at E11.5. However, at E13.5 
NANOG was not present.  
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Interestingly, Oct4 expression was induced in cells from E13.5 but by 
post-natal day 7 (P7) it remained silent in tested cells. The Jackson Laboratory 
has documented that OCT4 protein is not found in the brain of postnatal mice 
treated with doxycycline so this result for P7 is consistent with these data.  
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Figure 5.5. E8.5 brain tissue with activated OCT4 can form pluripotent cells and 
teratomas, but older tissue loses this ability. (A) A three-dimensional representation of 
the regions of mouse brain taken to test epiblast formation. Pink is forebrain, and blue is 
ventral midline. These regions were cultured in epiblast stem cell medium with 
doxycycline to activate Oct4. (B) Immunofluorescence for E8.5, E11.5 and P7 brain tissue 
using the procedure in (A). DAPI nuclear staining is illustrated in blue, OCT4 in red, and 
NANOG in green. E8.5 epiblasts express both OCT4 and NANOG, but E11.5 only express 
OCT4. By postnatal day 7, OCT4 is no longer expressed; however, this may be due to a 
transgene issue rather than a biological feature. (C) Brain tissue from E8.5 mice was 
cultured for 5 days in epiblast stem cell medium then transplanted into the kidney 
capsule of SCID mice. When Epiblast tissue was induced with OCT4 it formed a large 
teratocarcinoma, but without doxycycline no such tumour was found.  
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Activation of OCT4 triggers cells in E8.5 ex vivo brain tissue 
to form a teratoma in a mouse kidney  
 From the previous experiment, it appeared that Oct4 expression could 
activate NANOG expression at E8.5 and at E11.5, in agreement with published 
literature [195].  
 Our hypothesis predicts that activation of pluripotency may lead to the 
formation of a teratoma. Therefore, E8.5 was chosen as the developmental stage 
at which to test whether Oct4 expression could cause some cells to form a 
teratoma.  
Figure 5.5 C is a schematic of the process to transplant EpiSC-cultured 
brain tissue into the kidney capsule. Whole forebrain tissue was dissected from 
E8.5 mouse embryos and directly transplanted into the kidney capsule of a SCID 
mouse. These SCID mice were treated with doxycycline by oral gavage, which 
activated OCT4 in only the transplanted cells. These tumours were left to 
develop for six weeks. The kidneys of mice treated with doxycycline or control 
mice with no treatment were dissected, wax embedded, and sectioned. Figure 
5.5 C shows the large teratocarcinomas that formed in the kidneys of mice 
treated with doxycycline, but no growth was seen in controls.  
During my time in Edinburgh (in collaboration with Valerie Wilson), 
forebrain tissue was isolated from E8.5 embryos and transplanted into the 
kidney capsule of SCID mice. Some of the host mice were treated with 
doxycycline to induce Oct4 expression and followed for several weeks. There was 
a clear distinction between the OCT4-activated and untreated kidneys; those 
mice treated with doxycycline formed large teratocarcinomas. This shows that 
aberrant expression of Oct4 in E8.5 ex-vivo brain tissue is capable of forming a 
germ cell tumour. 
 However, when this set of experiments was repeated several times in 
Nottingham, there were no signs of teratoma formation. There were several 
differences in the experiment in Nottingham. The main difference was the 
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preparation of tissue; in Nottingham, the tissue had to be dissociated before 
being injected into a kidney capsule, whereas in Edinburgh whole-forebrain was 
transplanted.  
E8.5 is an early stage of development and it is unclear whether brain 
tissue from older mice would be able to form the same kind of tumours. 
However, since the positive result from collaboration in Edinburgh could not be 
repeated, it was not possible to assess which ages could form teratomas.  
 
Induction of OCT4 in mouse embryos from E8.5-E10.5 
causes minimal embryologic disruption 
 Oct4 is the only gene required to initiate neural stem cells to become 
pluripotent. Since the cell of origin for CNS GCTs is believed to be present in the 
first and second trimesters in humans, this equates to approximately E11.5 in 
mice. Therefore, we wanted to test whether activation of OCT4 in vivo before 
E11.5 would form a GCT.  
 The initial experiment tested the doxycycline-responsive system, and the 
effect of OCT4 on early embryogenesis. These were important to minimise the 
effect on animal welfare. Two female mice crossed with heterozygous males 
produced sets of embryos with a range of genotypes. The two females were 
given doxycycline by oral gavage each day from E8.5-E10.5 (Figure 5.6 A). When 
the mice reached E10.5 they were terminated, and the embryos were genotyped 
and assayed for expression of Oct4 by RTPCR (Figure 5.6 B). There appeared to 
be minimal disruption to the morphology of the E10.5 embryos when compared 
to controls (illustrated in Figure 5.2 C and D).  
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Figure 5.6. In vivo activation of OCT4 in mouse embryos.  (A) Stages of embryo and 
length of time induced with doxycycline. Images of the embryonic stages of mice 
including E0.5, E8.5, E10.5/E11.5, E13.5 and a postnatal day 0 mouse. Oct4 was induced 
from varying embryonic ages for different lengths of time, mainly E8.5-E10.5, and E13.5 
to birth. (B) Genotyping and RTPCR on brain tissue from doxycycline treated wild-type or 
homozygous mice. Genotyping was homozygous, wild-type, and heterozygous; and 
OCT4 was positive in the homozygous and heterozygous, but negative in the wild-type. 
(C and D) Induction of Oct4 from E8-10 embryos had minimal effect on embryogenesis. 
A pregnant female was treated by gavage with doxycycline (100µl of 2.4 mg/ml) on 
embryonic day 8 and 9 and the embryos were harvested on E10. (C) is a picture of 4 
homozygous embryos; and (D) is a picture of two wild-type embryos. All embryos were 
severed at the cervical spine and had their tail removed for genotyping. 
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Induction of OCT4 in mouse embryos from E13.5 to birth 
causes minimal disruption to development 
 The experiments discussed above were designed to examine the effects 
of only a small time span of OCT4 induction; the next experiment tested the 
morphological effects over a longer period of time. Our overall objective was to 
induce OCT4 during an early age of embryogenesis and follow mice through to 
adulthood to see if they formed GCTs. 
Pregnant mice were dosed with doxycycline from E13.5 until birth (Figure 
5.6 A). The first female gave birth to her litter but did not feed or look after the 
pups. The pups were genotyped to confirm the presence of the Oct4 transgene, 
ĂŶĚƚŚĞƉƵƉ ?ƐďƌĂŝŶƐǁĞƌĞƌĞŵŽǀĞĚ for analysis. All pups appeared to be normal 
(Figure 5.7 A) and were alive during the time between birth and termination. The 
brains from the pups had no distinct abnormalities, although this is difficult to 
confirm because dissection disrupted the fine detail (Figure 5.7 B and C). Analysis 
of these brains by RT-PCR showed that all of the pups expressed Oct4 compared 
with the wild-type control (Figure 5.7 D).  
The fact that the mother left her pups unattended was an important 
problem because the long term aim of this experiment was to induce OCT4 
during embryogenesis and determine if the pups formed tumours after several 
months of post-natal development. Only one pregnant mouse had been used to 
induce OCT4 in E13.5 embryos, so this experiment was repeated to determine if 
the problem was a result of the treatment. 
 The second pregnant mouse that was induced with OCT4 from E13.5 to 
birth also did not look after her pups. Genotyping confirmed that all of the pups 
carried both the Rosa26 and Col1a1 transgenes. However, this time there were 
some minor developmental defects. Figure 5.3 C is a photo of three pups and a 
very small deformed pup. It is unclear whether the deformity of this pup was 
caused by doxycycline and OCT4. A more consistent feature of Oct4 expression 
between E13.5 and birth was the reduced size of the limbs. In Figure 5.3 A, the 
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ƉƵƉƐ ? ůŝŵďƐ ĂƌĞ ůŽŶŐĞƌ ĂŶĚ ƚŚŝŶŶĞƌ ƚŚĂŶ ƚŚŽƐĞ ŝŶ ƚŚĞ ƌĞƉĞĂƚ ĞǆƉĞƌŝŵĞŶt. This 
suggests that Oct4 expression in other parts of the body is causing a 
morphological effect, and this phenomenon has been documented by The 
Jackson Laboratory. A second female dosed with doxycycline from E13.5-birth 
had a litter of several pups but proceeded to eat them  W therefore, these data 
are not shown. 
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Figure 5.7. Induction of Oct4 from E13.5-birth has minor effects on embryogenesis. 
(A) A pregnant mouse with E13.5 pups was treated by gavage with doxycycline (100µl of 
2.4 mg/ml) every day until birth. At P1 all of the pups looked normal and were moving, 
but were terminated because the mother was not feeding them. (B and C) Two mouse 
brains were dissected and each was imaged from the dorsal and ventral view. Both of 
these brains looked normal, although there may have been subtle morphological 
differences. The dorsal view is pictured on the left, and the ventral image is on the right 
of each of the two brains. (D) Genotyping of the three mice in (A) confirmed the 
presence of the Oct4 transgene, and each mouse brain tested positive for Oct4. (E) A 
repeat of the E13.5-birth Oct4 induction experiment. The experiment in (A) was 
repeated and the pups were terminated at P0. These pups also looked fairly normal 
except for a shortening of the limbs, and deformation of a pup on the far right. (F) 
Genotyping confirmed that all the mice had Oct4 transgenes, and all expressed Oct4. 
The pup on the far right does not look like the others and may have been an anomaly. 
(G) Gavage was suggested to be a potential cause for the pups being left unfed by their 
mothers so doxycycline was changed to administration in the drinking water. The 
concentration was approximately 60mg/kg compared to gavage which was 
approximately 10mg/kg. The mother was terminated while the pups were E17.5 due to 
several morbidities. The uterus was dissected and the embryos revealed are pictured in 
(G). There was evidence of reabsorption in the uterus followed by the pups in this order. 
It is unclear whether this effect was caused by Oct4 or the absorption process. 
(http://www.emouseatlas.org/emap/ema/home.html).  
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 In summary, in these experiments the mother was not looking after the 
pups. Nonetheless, the pups appeared to be able to survive pregnancy with 
minimal developmental disruption. It was suggested that gavage and scruffing 
(pulling the mice into position for gavage) may be causing stress to the pregnant 
mothers especially if they were treated until the day before birth. Therefore, we 
changed the protocol and administered doxycycline in the drinking water instead 
of gavage.  
 Homozygous mice were crossed with heterozygous mice to produce 
embryos that were all carrying the Oct4 transgene. The drinking water was 
supplemented with sucrose to ensure the mice drank it, and the concentration 
was calculated based on mice drinking 5ml of water. Unfortunately the mice 
became dehydrated and the pregnant female needed to be terminated at E17.5. 
The uterus was dissected and when the embryos (Figure 5.7 G) were analysed 
and all embryos were confirmed as either heterozygous or homozygous for the 
Oct4 transgene. There were some significant developmental defects in these 
embryos compared to the relatively normal pups in Figure 5.7 A and E. All the 
embryos had stunted growth and a deformed body. Pregnant females have been 
ĚŽĐƵŵĞŶƚĞĚƚŽ “ƌĞĂďƐŽƌď ?ĞŵďƌǇŽƐŝĨƚŚĞǇĂƌĞŚŝŐŚůǇƐƚƌĞƐƐĞĚƐŽŝƚǁĂƐĚŝĨĨŝĐƵůƚ
to determine whether these results are part of the reabsorption process or a 
direct effect of doxycycline activation of OCT4.  
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Induction of OCT4 from E11.5-E14.5 causes spontaneous embryo reabsorption 
 In our ideal experiment, we would have treated E11.5 embryos with 
doxycycline because Oct4 is expressed but at low levels. Induction of OCT4 would 
therefore mimic a continuation of OCT4, and test whether this would form a GCT 
in the long-term. 
There were four attempts to administer doxycycline by gavage beginning 
at E11.5; however, each time the pregnancy failed to reach term. It is sometimes 
difficult to confirm whether mice with E11.5 embryos are pregnant because the 
mother only shows strong signs of pregnancy between E13.5-E15.5. Therefore, 
all of the mice that had aborted pregnancy were dissected for evidence in the 
uterus, and each of the mice had been pregnant but appeared to have 
reabsorbed their embryos.  
 
Induction of OCT4 from E13.5-E16.5 caused minimal effects 
on later development 
 The ideal situation to test whether OCT4 could cause CNS teratomas 
would have been induction of OCT4 from E11.5 through to birth. However, the 
data above suggested that using oral gavage was too stressful on pregnancy 
around E11.5, and towards birth. Therefore, the period of induction was limited 
to E13.5- ? ? ? ? ? /ŶĨŽƌŵĂƚŝŽŶ ŽŶ ƚŚĞ :ĂĐŬƐŽŶ >ĂďŽƌĂƚŽƌǇ ?Ɛ ǁĞďƐŝƚĞ ƐƵŐŐĞƐƚƐ ƚŚĂƚ
this strain of mice should not be treated for more that 4-5 days because OCT4 
ĂĐƚŝǀĂƚŝŽŶĐĂŶŶĞŐĂƚŝǀĞůǇĂĨĨĞĐƚƚŚĞŵŽƚŚĞƌ ?ƐŚĞĂůƚŚ ?dŚĞƌĞĨŽƌĞ ?ĂĚŵŝŶŝƐƚƌĂƚŝŽŶŽĨ
doxycycline was limited to 4 days.  
 At the end of my project, a total of eight litters were born after being 
treated with doxycycline from E13.5-E16.5. These are now being monitored for 
changes in health, and perhaps brain tumour formation as they age. 
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5.4 Discussion 
 The experiments in this chapter tested the hypothesis that a CNS GCT 
could be formed from a brain cell. The three strategies examined this hypothesis 
in different ways to maximise the chance of forming a teratoma. Several studies 
have examined pluripotentency, and in this section I will discuss how the 
experiments in this chapter have added to the literature. 
 The main aim of this chapter was to test whether a GCT forms when 
OCT4 is activated in brain cells in vivo. Pluripotency studies, such as that by Kim 
et al. (2009), examined induction of NSCs to a pluripotent state using 
overexpression of Oct4 by viral transduction [81]. <ŝŵ ?ƐƵƐĞŽĨǀiral transduction 
as an in vitro technique required cells to be cultured, which may have changed 
their properties. In comparison, our study used in vivo activation of OCT4, which 
had effects on development when activated during embryogenesis.  
 The OCT4 mouse model was validated for rapid activation of OCT4 in 
cultured NSC populations, and in vivo. GCTs often form during childhood, and are 
thought to arise in the first or second trimester. From a technical perspective, 
using a mouse model provides a practical method of rapidly activating OCT4 at a 
stage in development when GCTs are believed to arise.  
 
OCT4 induction in mouse brain tissue and teratoma formation 
 The first important result is the ability of E8.5 forebrain to form 
teratocarcinomas when OCT4 is activated. This shows that when OCT4 is 
dysregulated and aberrantly expressed in a brain cell using our system it has the 
potential to induce the formation of a GCT. However, when the forebrain of an 
E8.5 embryo was dissociated and induced with doxycycline, in a repeat 
experiment, no teratomas formed. While this does not seem consistent, the role 
of the microenvironment may be important in understanding these results. 
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 First, there is inevitable cell death when tissue is dissociated and 
resuspended in PBS. If there are only a few progenitors in an E8.5 forebrain, the 
chances of these surviving are limited by this dissociation.  
Further, dissecting the forebrain and transplanting it directly into a kidney 
capsule maintains both intra- and intercellular structure. There are several 
supportive cell types within the brain, such as glial cells, which may be integral to 
maintaining the progenitors. This would explain why whole forebrain could form 
a teratocarcinoma but dissociated forebrain could not. While matrigel was not 
used during this experiment, it may be a useful addition in further experiments. 
 
OCT4 induction in vivo 
 The in vivo experiments were informative, but had limitations. The 
conditions for doxycycline administration in vivo were optimised to balance 
maximum OCT4 activation with the greatest chance of survival for embryos. This 
period was from E13.5-E16.5, and these pups were looked after by their 
mothers.  
A total of eight litters were born and are currently being kept for several 
months before termination and analysis. The formation of GCTs in the brains of 
these mice would be an indicator of two things: our hypothesis would be 
strengthened, and it would appear that reactivation of Oct4 after normal 
silencing is sufficient to form a GCT.  
 Conversely, would the lack of a CNS GCT disprove our hypothesis? 
Proponents for the hypothesis of a germ-cell or origin would argue that OCT4 is 
not sufficient to induce a GCT. However, since CNS GCTs are rare, it may be 
predictable that the conditions for GCT formation require more than just OCT4 
activation. 
 The mechanism of OCT4 activation in our hypothesis may be intrinsic to 
why GCTs do not efficiently form in the brain. Our hypothesis suggests that 
disruption to the methylation of the Oct4 gene may be responsible for OCT4 
137 
 
activation. Disruption to just one gene seems implausible, and it may be more 
realistic that large sections of the genome lack methylation; for example, due to 
dysregulation of a DNA methyltransferase. A lack of methylation over large 
sections of DNA is likely to activate genes that are normally silenced, such as 
oncogenes, and these oncogenes may be crucial for the initiation of CNS GCTs. In 
summary, we suggest that lack of global methylation may be responsible for 
OCT4 activation, which subsequently activates accessory genes that synergise 
with pluripotency genes to form GCTs. 
Our hypothesis here suggests that OCT4 is activated in a cell that has a 
hypomethylated genome, which may explain the lack of GCT formation in our 
experiments. In support of this hypothesis, the GCT subtypes associated with 
pluripotency, such as germinomas, often display distinctly lower levels of global 
methylation compared with the differentiated subtypes; for example, yolk-sac 
tumours. While we propose disruption to methylation as an initiating event, 
other factors may regulate the pathway the progenitor cells take. This may 
explain the differences between the progenitors proposed, which have low levels 
of methylation, and those that are methylated and differentiated (such as yolk 
sac tumours).  
 There were many factors to consider during the design of these 
experiments. One of the main difficulties was activating OCT4 at an early stage of 
embryogenesis. E8.5-E11.5 is an interesting period of development with regards 
to OCT4. During this E8.5-E11.5 period, endogenous levels of OCT4 are initially 
readily detectable but rapidly decrease. We originally set out to test whether 
GCTs would form after continuation or activation of OCT4. Since induction of 
OCT4 at E11.5 resulted in spontaneous termination of embryos, it was not 
possible to test whether continuation of OCT4 activation could initiate a GCT to 
form. Instead, we had to activate OCT4 at E13.5, which activates OCT4 in cells 
that do not express it. 
It was unclear why doxycycline-treated mothers spontaneously 
reabsorbed their embryos. Stress due to the gavage procedure, or a direct effect 
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of OCT4 on the mother instead of the pups, may have been factors for 
reabsorption. The main argument would be that OCT4 caused abortion by 
ĚŝƐƌƵƉƚŝŶŐĞŵďƌǇŽĚĞǀĞůŽƉŵĞŶƚ ?ŝŶƐƚĞĂĚŽĨƚŚĞŵŽƚŚĞƌ ?ƐĂďŝůŝƚǇƚŽƐƵƉƉŽƌƚƚŚĞŵ. 
If OCT4 causes abortion between the ages of E8.5-E13.5, the equivalent human 
patients would not reach maturity and form a GCT; however, aberrant 
expression of Oct4 probably only happens in one or a few cells in humans. These 
studies were in mice, and mouse development is very different to human 
development. Furthermore, the mothers themselves experienced activation of 
OCT4, which may have been the cause of these abortions. It should be noted that 
this is speculation, and this study could not confirm whether OCT4 can or cannot 
be a mechanism for GCT formation. 
 Our experiments attempted to induce pluripotency using activation of 
OCT4 in vitro and in vivo. We tested the potential for teratomas to form from an 
isolated stem cell population, brain tissue, or in a transgenic mouse model. 
Teratomas were successfully formed by inducing OCT4 in mouse forebrain tissue 
and transplanting the tissue into the kidney capsule. Further work will examine 
the effect OCT4 induction during embryogenesis has on the long-term health of 
our OCT4-transgenic mice. 
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Chapter 6: KIT and ETV1 expression in the CNS as a 
mechanism for germinoma formation  
6.1 Introduction 
Germinomas in the CNS have been documented to mainly occur in the pineal 
and suprasellar regions. They are considered to be a homogeneous tumour and 
have been hypothesised to develop from undifferentiated carcinoma in situ (see 
Chapter 1). In this thesis I have so far examined alternative explanations and 
hypotheses for CNS GCT formation, and in this chapter I examine a specific 
mechanism for germinoma formation; the oncogenic potential of ETV1 and KIT 
interaction. 
Germinomas, seminomas, and dysgerminomas express high levels of KIT, in 
addition to possessing an activating mutation in the KIT coding sequence. The 
activating mutation in the KIT gene causes the KIT protein to be constitutively 
active i.e. it does not require the usual ligand (STEEL) for activation of its tyrosine 
kinase function. These two events may seem counter-intuitive; why would the 
protein need to be highly expressed as well as constitutively active? Several 
further questions follow on from this: is high expression of KIT without an 
activating mutation sufficient to form a germinoma from the cell of origin? 
Alternatively, would low expression of a mutated form of KIT be sufficient to 
signal downstream targets? First, we must understand the relationship between 
KIT and oncogenesis. 
The study of certain gastric cancers has revealed that KIT and ETV1 are 
sufficient to cause a cascade of events that eventually leads to a gastro-intestinal 
stromal tumour (GIST) [196]. KIT activates several proteins by a phosphorylation 
pathway, and one of those paths leads to the stabilisation of the transcription 
factor ETV1 (Figure 6.1 A). KIT only stabilises ETV1 and does not increase its 
expression.  
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Indeed, a key finding by Chi et al. 2010 was that the inhibition of ETV1 in 
cells that expressed a mutated form of KIT failed to induce tumour formations 
[196]. This shows that ETV1 is required for tumour formation in this setting. 
Equally, ETV1 overexpression was shown to have little effect on proliferation 
since it is the stabilisation of the protein that is important, not the amount of 
mRNA.  
The cell of origin for gastro-intestinal stromal tumours (GIST) is a subset of 
interstitial cells of Cajal (ICC). The authors reported high expression of ETV1 in 
these cells, and showed that activation of the KIT pathway triggered the 
formation of cancer. Inhibition of KIT rapidly decreased the amount of ETV1 
protein but did not change the level of ETV1 RNA, which supports the hypothesis 
that KIT stabilises ETV1 protein. Furthermore, overexpression of endogenous KIT 
without mutations did not have a significant effect on the stability of ETV1.  
The increase in activated ETV1 by KIT was the most likely oncogenic 
mechanism because the cells where KIT activation occurred were those that 
already expressed ETV1. Since KIT is both mutated and overexpressed in almost 
all cases of germinoma, we concluded that ETV1 might also be essential to this 
process.  This relationship is important because if ETV1 is required to form a 
germinoma it could be an important therapeutic target.  
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Figure 6.1. In vitro optimisation of Kit and Etv1 probes  (A) A schematic of the 
mechanism by which KIT stabilises ETV1. KIT is bound by its ligand, Steel (SCF), to 
activate its tyrosine kinase function. Phosphorylation of downstream targets RAS, RAF, 
and MEK prevent ETV1 from being degraded and lead to two major effects: decrease in 
apoptosis, and increase in proliferation. KIT signalling stabilises ETV1 leading to 
increased activation of ETV1 targets. Taken from Chi et al. (2010) [196] (B) A schematic 
of the pcDNA3 plasmid used to clone cDNA of Etv1 or Kit. This plasmid was used to 
either clone the cDNA into pBluescript for RNA probe synthesis, or for site directed 
mutagenesis for overexpression.  (C) The sequence data confirming a D816V mutation 
caused by site-directed mutagenesis for overexpression. (D) Kit and Etv1 antisense 
probes on plasmid DNA of the corresponding gene. Concentrations vary from 40ng to 
0ng (E) Kit and Etv1 cross-reactivity dot plots for Etv1 on the left and Kit on the right to 
test probe specificity. Kit and Etv1 plasmid was baked onto membrane and both were 
stained with either Etv1 or Kit probes.  
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6.2 Hypothesis 
Germinomas all express high levels of KIT (often carrying an activating 
mutation), which suggests that KIT is integral to germinoma formation. There are 
at least three potential explanations for this; KIT could initiate an oncogenic 
event in a cell in the brain and eventually trigger the formation of a germinoma; 
KIT is not involved in the initial oncogenic event but is required for a tumour to 
acquire a germinoma phenotype, as opposed to a different type of tumour; or 
germinomas are formed from mismigrating germ cells that already express high 
levels of KIT ŝ ?Ğ ?ĂƐdĞŝůƵŵ ?ƐƚŚĞŽƌǇƉƌĞĚŝĐƚƐ. The latter has been discussed before 
so the first two suggestions will be the main focus of this chapter. 
The majority of GCTs in the CNS, such as teratomas, develop in utero or 
shortly after. Comparatively, the earliest published case of CNS germinoma 
diagnosis was in a 5 year old patient [197], but germinomas more frequently 
occur around puberty [198]. Our hypothesis suggests that all GCTs arise from a 
brain cell that has become pluripotent; so what influences the development of a 
germinoma compared to a teratoma? 
The germ-cell progenitor hypothesis states that these cells are simply 
misplaced germ cells and are encouraged to form germinomas during puberty 
due to high levels of hormonal activity. However, this chapter will examine the 
hypothesis that ETV1 and KIT expression may play a role in the formation of 
germinomas from endogenous brain cells.  
ETV1 has been documented to be required to form GISTs when KIT is 
expressed, so it seems plausible that if the same relationship applies to 
germinomas, ETV1 should be expressed when KIT-positive germinomas occur 
[196]. KIT is known to stabilise ETV1 protein through the RAS/RAF/MEK pathway. 
KIT is both mutated and expressed highly so this hypothesis also predicts that KIT 
might also be normally expressed in regions where germinomas form. Evidence 
that would support this hypothesis would be an overlap of these two genes in 
regions that would then support germinoma formation.  
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6.3 Aims 
The main aim of these experiments was to evaluate the expression patterns 
of Etv1 and Kit in the mouse brain in an unbiased way. Therefore, in situ 
hybridisation was used to detect regional expression of these genes. This 
required an RNA-probe specific and complementary to the RNA of either Kit or 
Etv1. The first aim was to design and test an RNA probe for both. These probes 
were then used to analyse expression in different ages and regions of mice 
brains. 
 
6.4 Results 
RNA-expression plasmid construction 
Full-length Kit and Etv1 cDNA were amplified by RT-PCR and ligated into the 
pcDNA3.1 vector (Figure 6.1 B). Subsequently, each cDNA (Kit and Etv1) was 
ligated into pBluescript for RNA probe synthesis. These plasmids were both 
verified by sequencing (Figure 6.1 C).  
Kit and Etv1 probes were synthesised from the respective pBluescript 
plasmid and tested for the ability to bind to complementary DNA. The plasmids 
that the probes were generated from were used to test this binding. (Figure 6.1 
D). Plasmids were baked onto paper and tested by in situ hybridisation with the 
complementary probe; for example, anti-sense ETV1 probe on ETV1 plasmid. The 
colour solution was either left in development solution for 30 minutes or 
overnight, and an increased concentration of probe produced a more intense 
colour signal. 
Next, the binding specificity was tested by hybridising a control probe onto 
each plasmid. Here, the Kit probe was tested on Etv1 plasmid, and the Etv1 
probe was added to Kit plasmid. Figure 6.1 E shows that the Etv1 probe produces 
a colour when bound to the Etv1 plasmid, but not when attempted on the Kit 
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plasmid. This specificity was similar for the Kit probe, showing that the Kit probe 
was specific to Kit plasmid only. These data show that the probes produced were 
sensitive and specific enough to attempt an in situ hybridisation on mouse tissue.  
 
Etv1 in situ hybridisation on E15.5 and adult mouse brains 
Many attempts were made to optimise the Etv1 and Kit probes (data not 
shown) before the successful attempts in Figure 6.2. The Etv1 probe worked 
much better than the Kit probe so Etv1 was the main focus of the in situ 
hybridisation experiment described. Expression of Etv1 can be clearly seen in the 
E15.5 mouse head using an anti-sense probe (Figure 6.2 A and B). A blue signal is 
absent in the control section (Figure 6.2 C), which is hybridised with a sense 
probe. Although it is difficult to determine the exact regions of expression, it 
appears that there is strong staining in the medial and dorsal pallium which 
develops into the cortex, and widespread expression throughout other areas of 
the E15.5 brain. 
In situ hybridisation using an anti-sense Etv1 probe on adult mouse brain 
sections resulted in more distinct expression patterns (Figure 6.2 D and E) such 
as the cortex. This, compared to the sense-probe in Figure 6.2 G which did not 
show any staining for Etv1, suggests that the positive staining is specific. 
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Figure 6.2. Optimisation of Etv1 probe on sagittal E15.5 embryos and adult mouse 
brain tissue (A-C) Sagittal sections of E15.5 embryo heads hybridised with either anti-
sense (A-B) or sense control (C) probes for Etv1 in situ hybridisation. Etv1 positive 
staining is blue indicating expression, and normal tissue is brown. (D-F) Sagittal sections 
of an adult mouse brain hybridised with either anti-sense (D-E) or sense control (F) 
probes for Etv1 in situ hybridisation. 
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Etv1 in situ hybridisation on a postnatal day 7 mouse brain 
Adult brains have different expression patterns of many genes, including 
Etv1, when compared with embryonic stages. However, sectioning embryonic 
stages is technically difficult and often does not show sufficient detail of where 
genes are expressed. With this in mind, a detailed analysis of a postnatal day 7 
mouse was performed in order to gain a better understanding of developmental 
Etv1 expression. Transverse sections were hybridised with the Etv1 anti-sense 
probe; representative staining of sections are shown in (Figure 6.3 A-F). There 
are several regions of high expression such as the cortex which is consistent with 
the expression in the E15.5 stage and in adults. There is a lack of Etv1 expression 
in the centre of the brain, especially in ventral sections. The only exception to 
this appears to be two small patches of expression in the dorso-medial thalamic 
nucleus. 
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Figure 6.3. Postnatal day 7 mouse transverse sections of a brain hybridised with anti-
sense Etv1 for in situ hybridisation. Etv1 positive staining is blue indicating expression, 
and normal tissue is beige. A-F are sections from ventral through to the dorsal. Several 
regions that have been stained are highlighted in red with the approximate anatomy 
labelled. (C) Two regions of the brain suggest the posterior colliculus. Olfactory staining 
is also present. (D) Staining in outer layers of the cerebral cortex, justified by the 
consistent staining in (E) and (F). (E) both subventricular zones appear to have staining, 
especially a single patch of strong staining anteriorly, which is consistent with (D). (F) 
two distinct patches suggest the dorsomedial thalamic nucleus. These structures are 
within the thalamus which is part of the diencephalon.  
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Allen Brain Atlas expression  
At the end of 2012, the Allen Brain Atlas [199] updated their expression data 
on Kit and Etv1. Previously, the Allen Brain Atlas in situ hybridisation data was of 
poor quality; however the update increased the quality of these images. Figure 
6.4 shows a comparison between the Allen Brain Atlas images and the data 
produced using my Etv1 probes. There was distinct expression of Etv1 in a layer 
of the cortex and cerebellum which was consistent with my results. In addition, 
there is a small patch of expression in the centre of the sagittal section which is 
shown on both the coronal and sagittal sections from the Allen Brain Atlas data. 
Since these figures were such high quality and consistent with my own previous 
attempts, further in situ hybridisations using the anti-sense Etv1 probe on tissue 
of other ages were halted.  
The Allen Brain Atlas update provided an opportunity to analyse the 
expression of Etv1 and Kit in brain tissue of several different ages and from two 
different perspectives; sagittal and coronal. Etv1 expression appeared to be 
localised to the same regions as previously mentioned i.e. a layer of the cortex, 
the granule layer of the cerebellum, and two small patches of expression in the 
thalamic region (Figure 6.4 A-F).  
A brief look at the sections from the Allen Brain Atlas showed an ambiguous 
pattern around E13.5. This pattern needed to be validated so whole mount in 
situ hybridisation was used on E13.5 embryos with sense- and anti-sense probes 
(Figure 6.4 G and H). The sense probe (control) showed no staining, whereas the 
anti-sense probe for Kit showed a distinct staining pattern (Figure 6.4 H).  
The Etv1 anti-sense probe appeared to be reliable because in Figure 6.4 G it 
gave a distinct pattern of forelimb, hindlimb, and somites. This appeared to be 
specific binding because the rest of the forelimb was not stained and repeats 
showed that this pattern was consistent. 
  
149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. A comparison between sections of respective ages from the Allen Brain 
atlas compared to my results. Etv1 positive staining is blue indicating expression, and 
normal tissue is beige. (A-B) Coronal section showing a staining pattern of two regions of 
midline expression similar to (C). (D) Similar staining patterns to (E-F), notably the 
central expression, olfactory, and cortex. (G) Sense-probe whole mount in situ 
hybridisation on an E13.5 embryo compared to anti-sense probe (H). E13.5 embryos 
were cut in half through the sagittal plane. Staining appears to be in the cerebellum, 
forebrain, brainstem, somites, forelimb, hindlimb, and tail in (H). Staining in the 
extremities appears to be in the outer layers only instead of throughout, illustrated by 
staining for the hand. Figure 6.4 A, B, E and F are from Allen Brain Atlas, and all other in 
situ hybridisations used the Etv1 probe developed in previous figures. 
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Etv1 staining was also similar to the Allen Atlas (data not shown). These 
embryos were embedded in wax and sectioned but this was technically 
challenging and was not repeated (See Appendix II). While there was expression 
in the brain, the difficulties with embedding and sectioning meant that detailed 
analysis was not possible.  
Due to the difficulties in sectioning young embryos, the Allen Brain Atlas was 
used to examine specific locations in the brain at several ages. The major 
limitation was a lack of repeats; sometimes there was only one view, for example 
sagittal. 
Allen Brain Atlas sections showed four regions of dual Kit/Etv1 expression: 
the medial habenula, periventricular thalamic nucleus, the medulla oblongata 
region, and the medullary spine. This section examines the first two of the four, 
and the last two are discussed shortly. 
The medial habenula is part of the pineal stalk. Since we are more concerned 
with dual expression of Kit/Etv1 correlating with germinoma formation, this 
region will either be described as the pineal or habenula region. Staining for Etv1 
is strong and discrete from stage E15.5 (Figure 6.6) to adulthood (Figures 6.7-
6.11). Unfortunately there were no coronal sections for Kit, so it was not possible 
to verify expression of Kit in this region. Equally, it was not possible to exclude 
the possibility of Kit expression in this region  W Etv1 staining in the habenula is 
only visible using a coronal section and is not visible on a sagittal section. 
The staining around the periventricular thalamic nucleus changes with age. 
This may be due to the slight differences in depth of section, which can appear 
different if only a thin layer of cells express the gene. For simplicity, this region 
will be termed the thalamic region. Staining in the thalamic region is consistent 
from E15.5 to adulthood for Etv1 (Figure 6.5-6.11). Strong staining only appeared 
visible at P4 for Kit (Figure 6.8); however, upon higher magnification, Kit is 
expressed throughout the mouse brain. Specifically, Kit is strong in single cells, 
but these cells are not densely clustered together like Etv1. An example of this is 
151 
 
E18.5, where there are several denser patches of expression, but diffuse staining 
throughout the brain (Figure 6.7).  
Embryos that were stained with Etv1 and Kit showed expression in several 
regions at E13.5 (Figure 6.5 A-F), and midline regions by E15.5 (Figure 6.6 D-F), 
but the exact regions of expression were unclear. The medial habenula (Figure 
6.6 D), periventricular thalamic nucleus region (Figure 6.6 E), and corpus 
callosum (Figure 6.6 F) were all implicated as regions where Etv1 was expressed 
in these embryonic ages. There were no coronal sections stained for Kit at E15.5.  
In summary, Etv1 and Kit expression overlapped in the pineal stalk, the 
suprasellar region, and cortex over several ages of development and into 
adulthood in mice. Other regions of the mouse brain expressed only Kit, such as 
the cerebellum. 
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Figure 6.5-6.23. In situ hybridisation using a Kit or Etv1 anti-sense probe on various 
ages and views of mouse brain taken from the Allen Brain atlas or EMAGE database. 
Background is pale blue or brown, and positive staining is dark blue. Some areas appear 
dark blue due to the density of cells in that area such as the cerebellum. When 
producing Figures 6.5-6.23, all regions of colour development were labelled according to 
the Allen Brain Atlas. Each colour signal was verified by magnification to confirm that the 
colour signal was within the cells of the tissue, and not solid colour, which can suggest 
non-specific staining. Confirmed regions of expression are indicated by a red line and a 
code. The code refers to a region of the brain found in the abbreviations section. Kit 
staining is weak and found in almost all regions at E18.5 and beyond but only regions of 
intense staining are indicated as positive. Only select regions are highlighted in these 
figures; all regions with positive staining can be found in Appendix II. 
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Figure 6.5-6.11. All regions that show positive staining have been identified except 
those in the medulla or hindbrain regions. Kit is expressed in the cerebellum at E18.5 
(Figure 6.7 A and B), P4 (Figure 6.8 A and B), P14 (Figure 6.9 A and B), P28 (Figure 6.10 A 
and B), and P56 (Figure 6.11 A and B). Sections hybridised with Etv1 probe did not show 
staining in the cerebellum at any age (Figure 6.7-6.11). There are low levels of Kit 
expression throughout the brain when magnified, but Etv1 appears to be distinct to 
specific regions.  
 
There were several midline regions that showed overlap of the expression of both 
genes. The two most striking regions were the thalamic nuclei and habenula. These two 
regions are comparable to the hypothalamic region and the pineal region respectively. 
The thalamic nuclei appeared to express Etv1 and Kit genes at E18.5 (Figure 6.7 C), P4 
(Figure 6.8 A-D), P14 (Figure 6.9 C), P28 (Figure 6.10 C-E), and P56 (Figure 6.11 D). There 
was sparse expression of Kit when examining specific regions as mentioned above.  
 
The habenula or pineal stalk is a very small region but for Etv1 it was clearly seen at 
E15.5 (Figure 6.6 D), E18.5 (Figure 6.7 E), P4 (Figure 6.8 F), P14 (Figure 6.9 E), P28 (Figure 
6.10 F), and P56 (Figure 6.11 G). The habenula was not seen on sagittal section of Etv1 
but were clear when using coronal sections. Unfortunately, since there were only 
sagittal sections for Kit expression, which may have meant that expression was present 
in small areas, such as the habenula, but sagittal sections were not as reliable as coronal 
sections in this instance. 
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Figure 6.12-6.16. In situ hybridisation on whole-mount or whole-embryo sections for 
Kit and Etv1. See Figure 6.5 for further details. The exact locations of expression for ages 
between E9.5-E11.5 are unclear but there is expression of both Kit and Etv1 in the 
hindbrain, forebrain, and spine (Figure 6.12-6.15). A more specific expression pattern for 
Etv1 is evident at E14.5 with clear expression in the hindbrain, forebrain, and spine 
(Figure 6.16). Figure 6.12 and Figure 6.14 A are taken from Bernex et al, 1996 [200]. 
Figure 6.13 and Figure 6.14 B are taken from Wehrle-Haller, 1995 [201]. Figure 6.15 and 
Figure 6.16  are taken from www.emouseatlas.org 
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Kit and Etv1 expression in the medulla oblongata and 
medullary spine region 
While analysing the Allen Brain Atlas sections for expression, both Kit and 
Etv1 were seen in the hindbrain region at several ages (Figure 6.17-6.23).  
The pons region had a consistent expression pattern when using the Kit 
probe (Figure 6.20 A and 6.21 A). This region did not produce a colour signal 
when hybridised with Etv1 probe; however, this specific region may have been 
overlooked due to the sections being thin and only a few were stained. Equally, 
Kit was only expressed around these two ages, and was not found later.  
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Figure 6.17-6.23. All positive staining in the spine, hindbrain or medulla oblongata 
regions are indicated. See Figure 6.5 for further details. All ages from E13.5 to adult 
expressed both Etv1 and Kit near the medulla oblongata (Figure 6.17  W 6.23). Beyond P4, 
expression appears to become weaker but both Kit and Etv1 are expressed in a few cells 
at P56 in the medulla oblongata region (Figure 6.23 C and D).  
 
In addition to the overlap of expression of Etv1 and Kit in the medulla oblongata region, 
both Kit and Etv1 were expressed in the spine at E15.5 (Figure 6.18 A and C). Ages 
beyond E15.5 were either unclear or unavailable.  
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Germinomas can occur in the medulla oblongata and 
medullary spine region 
 Germinomas are commonly found in pineal and suprasellar regions, and 
dual Kit/Etv1 expression was also present in these regions. After discovering 
overlapping expression of Kit and Etv1 in these regions, the next question was 
whether germinomas in human patients are restricted only to regions of dual 
Kit/Etv1 expression or whether germinomas are seen in all regions of dual 
Kit/Etv1 expression.  
 The medulla oblongata and medullary spine regions showed dual Kit/Etv1 
expression and our hypothesis predicts this region should also be the site of 
germinoma formation. Therefore, a thorough literature search of germinomas in 
human patients was carried out. This search subsequently identified the medulla 
oblongata and spinal regions as a third and fourth region for germinoma 
formation. 
All identified clinical cases of germinomas occurring in these two sites 
published between 1990-2013 are included in Table 6.1. Equally, all the images 
that could be accessed are collated in Figure 6.24 and 6.25. The images in Figure 
6.24 show germinomas in almost identical regions: attached to the medulla 
oblongata in the midline of the brain. Germinomas in the medulla oblongata 
region occurred in a wide age-range from 12-40 years old.  
 The images of germinomas occurring in the medullary spine show that 
these tumours do not arise consistently in a specific location (Figure 6.25). 
Germinomas appeared to be able to occur along the entire length of the spine, 
and had a wide age-range from 5-39 years old.  
There was no obvious bias towards male or female cases. The ratios of 
male to female were 3:5 for germinomas in the medulla oblongata region, and 
13:9 for the medullary spine. While the ratios appear to change from a subtle 
female bias to a male bias, this may be due to the small number of cases. 
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Figure 6.24. Images from either a transverse or sagittal view of a germinoma in the 
medulla oblongata region. Red arrows indicate the tumour mass. Each scan is from a 
different patient with a different  age and gender: (A) 28 year old man [202], (B) 27 year 
old woman [203], (C) 30 year old woman [204], (D) 24 year old man [204], (E) 31 year 
old woman [205], (F) 18 year old woman [206], (G) 16 year old girl [207], (H) 30 year old 
woman  [208], and (I) 24 year old woman.  
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Figure 6.25. Sagittal or transverse images of germinomas in the spine. Red arrows 
indicate the tumour mass. The region of the spine, age, and gender are described: (A) 
T6-T7 germinoma in a 35 year old man [209], (B) T7-T9 in a 27 year old man [209], (C) 
C3-C6 in an 18 year old man [210], (D)  T1-T3 in a 33 year old woman [211], (E) C2-T1 in 
a 39 year old woman [212], and (F) T7-T9 in a 33 year old man [213].  
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Table 6.1 Germinomas in the medulla oblongata or medullary spine. Six male and ten 
female cases of germinoma have been recorded as occurring in the medulla oblongata region. 
Thirteen male and nine female cases of germinoma have been recorded as occurring in the 
medullary spine. Each of these categories is organised by male first and female second. All cases 
between 1990-2013 were included.  
  
Germinoma location Age of patient Gender Reference 
 
   
Medulla oblongata 24 Male [204] 
Medulla oblongata 28 Male [202] 
Medulla oblongata 19 Male [204] 
Medulla oblongata 33 Male [204] 
Medulla oblongata 17 Male [203] 
Medulla oblongata 12 Male [203] 
Medulla oblongata 14 Female [214] 
Medulla oblongata 40 Female [204] 
Medulla oblongata 27 Female [203] 
Medulla oblongata 16 Female [207] 
Medulla oblongata 31 Female [205] 
Medulla oblongata 18 Female [206] 
Medulla oblongata 32 Female [214] 
Medulla oblongata 24 Female [215] 
Medulla oblongata 30 Female [204] 
Medulla oblongata 30 Female [208] 
    
Medullary spine 28 Male [216] 
Medullary spine 33 Male [213] 
Medullary spine 35 Male [209] 
Medullary spine 27 Male [209] 
Medullary spine 18 Male [210] 
Medullary spine 5 Male [210] 
Medullary spine 31 Male [210] 
Medullary spine 24 Male [210] 
Medullary spine 24 Male [210] 
Medullary spine 29 Male [210] 
Medullary spine 33 Male [210] 
Medullary spine 7 Male [210] 
Medullary spine 18 Male [210] 
Medullary spine 32 Female [210] 
Medullary spine 34 Female [210] 
Medullary spine 16 Female [210] 
Medullary spine 31 Female [210] 
Medullary spine 34 Female [210] 
Medullary spine 33 Female [211] 
Medullary spine 39 Female [212] 
Medullary spine 16 Female [217] 
Medullary spine 34 Female [217] 
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6.5. Discussion: 
Germinomas in the brain express high levels of KIT and the KIT gene is 
frequently mutated. Research into GISTs has shown that a mutated form of KIT 
interacts with and stabilises ETV1 which results in an oncogenic event. Since 
germinomas are known to have high levels of KIT expression, this set of 
experiments investigated the normal expression levels of Kit and Etv1 in mice of 
several ages. 
 
Overlap of Kit and Etv1 expression correlates with germinoma formation 
The hypothesis at the beginning of this experiment predicted an overlap of 
expression of KIT and ETV1 in the regions where germinomas normally occur in 
the brain: the suprasellar and pineal regions. In fact, the data suggest a much 
more complex pattern of expression. 
As predicted, Kit and Etv1 expression was detected in the thalamic nuclei, 
and in the pineal region at all ages for both genes. There were some regions 
which could have benefited from a more detailed analysis, such as the pineal or 
habenula region for Kit using a coronal section. The pineal or habenula region 
had very strong staining, but the surrounding regions lacked expression. 
Therefore, Kit and Etv1 expression provides evidence in support of the proposed 
mechanism because the pineal region is the most common region for 
germinomas to occur.  
The only other region that showed consistent overlap was the medulla 
oblongata and hindbrain area. This hindbrain region showed strong expression of 
both Etv1 and Kit in samples of all ages. Indeed, the spine also showed some 
overlap of expression but a full description of this was limited by the images 
because only sections up to E15.5 showed the spinal cord. Although germinomas 
are generally discussed as being associated with only two locations, the pineal 
and suprasellar regions, a thorough search of the literature revealed that 
germinomas also occur in both the spine and near the medulla oblongata. 
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Although very rare, the MRI or CT images have shown a consistency in the 
locations of these tumours in the medulla oblongata. Germinomas were found at 
locations throughout the spine which is also consistent with this hypothesis 
because both Kit and Etv1 are expressed along the length of the spine.  
This revelation requires further explanation of the evidence; why do 
germinomas occur much more frequently in the pineal and suprasellar regions if 
the same mechanism may be present in the medulla oblongata and spine? I 
propose that the abundance of growth factors in these respective regions might 
be an integral part of germinoma establishment. We know that seminomas in 
the testis respond to high levels of growth hormones during puberty which 
explains their prevalence around this time. Germinomas diagnosed in regions of 
hormonal centres, such as the pineal and suprasellar regions, presumably have 
much greater growth hormone levels than those in the spine or medulla region. 
The more posterior regions of the CNS may obtain a sufficient amount of 
stimulus over time to form but this is longer than the others in the diencephalon. 
This has been evidenced by medulla oblongata and spinal germinomas occurring 
at a later stage of development, in patients between 5-40 years old (median of 
25.5 and 30 respectively) (Table 6.1). 
 
Expression of only Etv1 or Kit does not correlate with germinoma formation 
Those opposing the above hypothesis would perhaps question why there is 
expression of one or both of these genes in locations where germinomas are not 
known to normally occur - the cerebellum is one such example. Kit was 
expressed in the same layer of the cerebellum in all ages examined. However, 
Etv1 was not strongly expressed in this region. Since ETV1 was required for KIT-
driven oncogenesis in the GIST study [196], it appeared that the lack of 
germinoma formation in the cerebellum strengthens the argument that both KIT 
and ETV1 are required for an oncogenic event.  
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Kit and Etv1 as part of the brain-cell hypothesis 
So far in this chapter, I have proposed that germinomas have arisen from 
cells that already expressed both KIT and ETV1 and acquired a mutation in the 
KIT gene, which caused an oncogenic event. To understand how this integrates 
into the initiation of GCTs as a class of tumours, it is important to discuss when 
germinomas and teratomas develop in humans.  
Germinomas in the pineal or suprasellar regions have a peak incidence 
around puberty between 6-30 years old (Figure 1.2 C). On the other hand, 
teratomas have a peak incidence around birth. This difference in peak incidence 
would suggest a difference in either the cell of origin or the environment the 
cells are in.  
We know that germinomas and teratomas have been diagnosed together in 
tumours, and Chapter 1 and 3 argue that all CNS GCTs have a common cell type 
of origin. Therefore, the environment of CNS GCTs is most likely to be the cause 
of the differences between peak incidences. 
My hypothesis here is that the cells in those regions with an overlap of ETV1 
or KIT have the potential to initiate germinomas. One difficult question regarding 
our hypothesis is in the different regions in which germinomas occur in. 
Germinomas in the spine or medulla oblongata appear to form much later than 
those that arise in the pineal or suprasellar regions. Using our hypothesis that 
hormones influence growth, regions outside of the pineal and suprasellar region 
may receive much lower concentrations than near centres of hormonal activity. 
Comparatively, those progenitor cells in the pineal or suprasellar regions may 
require a lower threshold of growth hormones to drive oncogenesis.  
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GCTs may share KIT activation of ETV1 as a common mechanism regardless of 
location 
ETV1 and KIT are strongly expressed in the testis, ovary, brain, and to some 
extent the spine [218-221]. This observation is evidence that the mechanism for 
germinoma formation could be similar regardless of location. I propose that a 
single activating mutation in the KIT gene is an oncogenic mechanism to 
transform cells in various locations into germinomas.  
Our hypothesis suggests that a KIT mutation in a pluripotent cell leads to 
germinoma formation. I believe that ETV1 is expressed in the progenitors of 
germinomas, and contributes to the formation of germinomas. Germinomas 
appear to be limited to regions where there is dual ETV1/KIT expression. Our 
hypothesis would therefore predict that the brain regions in which germinomas 
do not occur lack ETV1 expression. This is supported by the close correlation of 
dual expression to germinoma formation. 
Most KIT mutations are localised to a D816V point mutation. While several 
other mutations have been found, there are some germinomas/seminomas that 
express KIT but do not appear to have a point mutation in any of the known 
sites. Most germinomas have been assessed for KIT mutations only in specific 
 ‘ŚŽƚƐƉŽƚƐ ? ?^ĂŬƵŵĂet al. 2004 examined five hotspots in KIT, and found gain-of-
function mutations in approximately 25% of germinomas (total of 16 examined) 
[23]. Unfortunately, no studies (to our knowledge) have sequenced the entire KIT 
gene, especially in those germinomas that do not carry mutations in hotspots.  
Another example is the Kuno et al. 2012 paper, which describes a seminoma 
without a KIT mutation [222]. Although only four exons were examined, the 
authors concluded there was a lack of gain-of-function mutations; however, 
according to our hypothesis, other mutations within KIT may have been present 
at locations outside of the amplified regions assessed.   
Research into GCTs with KIT mutations does not at present compare to 
research on other cancers driven by KIT, such as melanoma and leukaemia [223, 
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224]. Carvajal et al. 2011 examined the mutations in KIT for melanomas in many 
more than five exons, and Wang et al. 2005 sequenced the coding regions of the 
KIT gene in over 100 leukaemias. These other studies in non-germinoma cases 
show that mutations outside of the five regions often cited as KIT hotspots can 
also cause gain-of-function. 
One interesting experiment would be to sequence the entire KIT gene in 
tumour samples that do not appear to have mutations, but do express KIT. This 
sequence would be examined for mutations, and these could be tested in vitro 
for an activating function. My hypothesis would be that KIT is particularly prone 
to mutations that change the conformation of the protein, which in turn 
relinquishes the need for an activating ligand.  
I propose that the activation of KIT signals the stabilisation of ETV1, and 
subsequently transforms a cell into a GCT. This theory suggests that ETV1 may be 
activated by other proteins in the KIT-ETV1 pathway; for example RAS and RAF. 
In the case of germinomas that do not possess KIT mutations, other genes within 
the KIT-ETV1 pathway should be examined for activating mutations.  
 
Clinical cases support KIT activation of ETV1 as a mechanism for GCT formation 
A clinical case published by Aker et al. [225] describes the occurrence of a 
pineal germinoma with multiple melanocytic nevi. KIT is associated with 
melanocytic lesions [226], so this rare occurrence of two cancers appears to have 
an oncogenic mechanism of KIT activation. The patient in this case apparently 
had no GCTs in other locations, which suggests that the activation of KIT is not 
linked to progenitor germ-cell mismigration.  If KIT was linked to progenitor 
germ-cell mismigration, we would expect multiple GCTs along the route of 
migration towards the brain.  
This point is controversial but is supported by other data. Proponents of the 
germ-cell progenitor hypothesis may suggest that germinomas in several 
locations of the brain are due to the presence of two germ cells. However, Da 
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Silva et al. 2009 reported a case of three germinomas in a single patient [227]. It 
seems unlikely that three germ cells mismigrated and became lodged in the brain 
without forming a GCT anywhere else in the body  W especially since we know 
germ-cell progenitors transplanted into extra-gonadal locations form GCTs.  
KIT and ETV1 appear to be integral to germinoma formation or maintenance. 
Since radiotherapy can cause long-term damage to patients, clinical research has 
begun to focus on pathway-targeted medicine. Imatinib is a tyrosine-kinase 
inhibitor used to treat GISTs. GISTs have a similar underlying KIT mutation as 
either the initiating or driving oncogenic event. Imatinib has been tested for 
germinoma treatment but the lack of penetration of the drug through tissue is 
an issue. Dasatinib also targets KIT but unlike Imatinib has a greater penetrance 
profile i.e. it can reach tumour cells away from major vasculature. While 
Dasatinib is the most recent drug tested as a pathway-targeted treatment, other 
therapies are likely to target specific pathways of cancer. Therefore, 
understanding the mechanisms and oncogenic events that initiate and drive 
GCTs is integral to both treating the disease and limiting the long-term sequelae.  
 
6.6 Conclusion 
The hypothesis before investigating Kit and Etv1 expression in the brain was 
that a KIT mutation stabilises ETV1 and leads to a germinoma. There is much 
work to be done in order to validate this theory, but there is evidence that Etv1 is 
already expressed in a region where germinomas normally occur. This clearly 
needs to be validated at a functional level, and further in situ hybridisation on 
younger embryos would be useful.  
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Chapter 7: Discussion 
7.1. Introduction 
The findings presented in this thesis challenge the hypothesis that mis-
migrating germ-cell progenitors are the cell of origin for CNS GCTs. Advances in 
our understanding of pluripotency-induction strengthen our opposing hypothesis 
that CNS GCTs arise from brain cells, instead of germ-cells. This final chapter 
discusses the arguments against the germ-cell model; the evidence in support of 
our brain-cell model; how clinical observations can be explained by our model, 
and further work needed to validate our hypothesis. 
 
CNS GCT subtypes have a lineage relationship 
A proposed model for the various histological subtypes of GCT is that they 
represent stages in a progression starting with carcinoma in situ (CIS), also called 
intratubular germ cell neoplasia unclassified (IGCNU).  The germinomatous and 
embryonal carcinoma (EC) forms are believed to arise from CIS. The more 
differentiated teratoma, choriocarcinoma and yolk sac tumour forms are 
proposed to then arise from the EC, by so-ĐĂůůĞĚ  ‘ĂĐƚŝǀĂƚŝŽŶ of 
ƉůƵƌŝƉŽƚĞŶĐǇ ?[228]. Two observations support this model. Firstly, GCTs are often 
found to be of mixed histology, with some containing 4 histological subtypes 
[152, 229]. This is true of all GCT sites, including the brain [153, 158]. 
 Secondly, there are well-documented examples for each subtype of a 
GCT reappearing as a different subtype following resection (Chapter 3). This is 
common for sacrococcygeal tumours, which recur as YSTs [230, 231]. In 
particular, several studies have reported recurrence of a germinoma following 
resection of an intracranial teratoma. This implies that the cells of these tumours 
can give rise to different histological subtypes and therefore share a common 
cellular lineage. Consequently, if activation of Oct4 expression could cause an 
NSC to initiate growth as a teratoma, such a tumour could then convert to any 
one of the other GCT histological subtypes by the time it was diagnosed. 
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In summary, all GCT subtypes appear to have a common cell type of 
origin, regardless of the progenitor hypothesised to form them. Therefore, both 
our and the PGC hypotheses must explain the mechanism behind each subtype 
of GCT developing in the brain. 
 
Challenges for the germ-cell progenitor hypothesis 
This thesis argues that a cell population in the brain has the potential to 
develop into CNS GCTs. The arguments against the hypothesis of a germ-cell 
origin for CNS GCTs have been laid out in Chapter 1 and 3; but will be briefly 
revisited later. 
There are several unanswered questions regarding the mechanism 
suggested for germ-cell progenitors. There are inconsistencies regarding when 
ŐĞŶĞƚŝĐ ĂďĞƌƌĂƚŝŽŶƐ ŽĐĐƵƌ ŝŶ ƚŚĞ  ‘ŵŝƐ-ŵŝŐƌĂƚŝŶŐ ƉƌŽŐĞŶŝƚŽƌƐ ? ? ŚƌŽŵŽƐŽŵĂů
abnormalities such as chromosome 12p duplications or KIT mutations are 
proposed as a mechanism for mis-migration; but why do some CNS GCTs lack 
these mutations? How have CNS GCTs with few mutations by-passed the 
apoptotic pathway designed to eliminate germ-cell progenitors?  
If we are to consider the germ-cell hypothesis, there are a number of 
questions that must be answered. The principal questions revolve around in vivo 
data: when germ-cell progenitors are unshackled from their migratory control 
mechanism in experimental models, why are these progenitors never detected in 
the brain? Indeed, even if there are technical issues with tracking these cells, 
why do the progenitors never form CNS GCTs in these models? 
 
 
7.1.1 Hypothesis 
 GCTs that arise in the gonads have similar chromosomal aberrations, 
histology, and protein markers to CNS GCTs. Proponents of the germ-cell origin 
hypothesis believe the similarity between GCTs in these locations is evidence of a 
common cell of origin, but I propose the parallels are due to a common 
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pathogenesis. Germ-cell progenitors are pluripotent, and the induction of 
pluripotent cells from brain cells would perhaps be equivalent to the germ-cell 
progenitors in the testis; the cell of origin may be different, but the resulting 
tumours the same. Therefore, the similarity in genetic aberrations may indicate 
similar driving mechanisms from a pluripotent cell to a GCT.  
The germ-cell progenitor hypothesis simply describes differentiation of a 
PGC in an extragonadal location. Our hypothesis requires the activation of OCT4, 
which is an extra oncogenic event. Since CNS GCTs have a lower incidence than 
those in gonadal locations, the extra oncogenic event required would explain 
why GCTs are less likely to occur in the brain.  
Our hypothesis proposes aberrant OCT4 activation in a multipotential cell 
to be an initiating event in CNS GCTs pathogenesis. The Oct4 is controlled by 
methylation, so disruption to DNA methylation may explain the expression of 
Oct4. In fact, a lack of methylation is observed in some subtypes of CNS GCTs, 
especially those that express Oct4 [90]. Chromosomal duplications, such as an 
extra X or 12p, may provide an alternative method of activating OCT4 and is 
discussed later.  
The differences between GCT subtypes may be explained by additional 
mutations in genes such as KIT for germinomas. On the other hand, teratomas 
and yolk sac tumours appear to be the consequence of differentiation of 
pluripotent cells; for example when embryonic stem cells are transplanted into 
SCID mice. It is therefore more likely that these tumours are the result of 
differentiation of pluripotent cells in a developing environment (Figure 7.1). We 
propose a testable hypothesis for CNS GCTs initiation and progression that has 
been examined in this thesis. 
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Figure 7.1. A schematic of the potential mechanisms involved in forming different 
subtypes of GCT from a brain cell. The hypothesis begins with a brain cell that can gain 
pluripotent features through one (or a combination) of three mechanisms  W lack of 
methylation to silence Oct4, demethylation (i.e. activation of OCT4), and/or i(12p)/12p 
gain. Once induced to a pluripotent state, each of the different subtypes may be 
influenced by the mechanisms proposed: a KIT mutation in the case of germinomas; 
maintenance of pluripotency for embryonal carcinomas; and methylation and 
differentiation for teratomas and yolk sac tumours. 
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Plasticity and the incidence of CNS GCTs in children 
 Our hypothesis is compatible with the observation that CNS GCTs occur in 
the early years of life. Neural progenitors begin as radial glia and the capacity to 
differentiate into multiple lineages becomes increasingly restricted during 
development. Our hypothesis does not have sufficient evidence to identify a 
specific population of neural progenitors but the ages at which GCTs are 
diagnosed (Chapter 3) suggests that a progenitor for CNS GCTs is present in the 
brain between the first and second trimester.  
 The cells in the CNS undergo various DNA methylation changes during the 
early stages of embryonic or fetal development, and are therefore vulnerable to 
aberrant expression of genes controlled by methylation; for example, 
retinoblastomas (a tumour that occurs in the eye) can be initiated when only a 
single gene  W Rb  W is aberrantly methylated [232]. A lack of methylation of the 
Oct4 prŽŵŽƚĞƌ ŝƐ Ă ƌĞĂƐŽŶĂďůĞ ŵĞĐŚĂŶŝƐŵ ĨŽƌ Kd ?  ‘ĂĐƚŝǀĂƚŝŽŶ ?  W or more 
accurately, lack of silencing.  
  
7.1.2 CNS GCTs are not restricted to the midline 
GCTs are in the midline and PGCs migrate in the midline  
My literature review showed that CNS GCTs are not restricted to the 
ŵŝĚůŝŶĞ ?ǁŚŝĐŚĐŚĂůůĞŶŐĞƐƚŚĞ ‘ŵŝĚůŝŶĞŵŝŐƌĂƚŽƌǇƉĂƚŚ ?ŽĨŐĞƌŵ-cell progenitors. 
If CNS GCTs have a germ-cell progenitor, but are not restricted to the midline, 
how would they migrate to these regions? If they can migrate to any region of 
the body, why are GCTs not seen in a much wider range of sites? These 
observations are more consistent with a small group of local cells of origin that 
are only found in very restricted locations. 
 There are several characterised genetic aberrations and clinical markers 
for GCTs. The germ-cell hypothesis proposes that markers such as KIT and OCT4 
are linked to germ-cell progenitors and mis-migration. However, since both are 
seen in NSCs in the same situations, we propose that these same markers are 
activated or maintained aberrantly in brain tissue and are the driving forces 
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behind local neoplasia, instead of mis-migration.  
CNS GCTs are classified as a single group and can form in any region of 
the brain, but some subtypes have a more defined area of occurrence. 
Teratomas form in almost any region of the brain, but germinomas are restricted 
to the midline. Germinomas are the most common type of CNS GCT so this 
pattern explains the widely-held belief that CNS GCTs occur in the midline.  
 Germinomas, or seminomas, are very similar to undifferentiated 
carcinoma in situ [31]. Pluripotent or undifferentiated cells often require a 
specific combination of factors to maintain pluripotency, which may explain why 
germinomas are restricted to the midline. Based on the restricted pattern of 
germinomas in the midline, I would predict that the midline is rich in 
extracellular signals concerned with maintaining pluripotency rather than 
tumour initiation. The potential for germinomas to form in lateral regions could 
be tested in the same way as teratomas in Chapter 4  W by stereotaxic injection of 
a seminoma/germinoma cell line into the midline and lateral regions. If my 
hypothesis is correct, germinomas would form, and be maintained in the midline, 
but in lateral regions germinomas may struggle to grow or differentiate into one 
of the other CNS GCT subtypes.  
 
GCTs occur in locations other than the CNS and gonads 
 The germ-cell hypothesis provides a logical explanation for GCTs that 
occur in locations such as the peritoneum; however, could a similar alternative 
hypothesis also explain these tumours? Our hypothesis relies on the induction of 
pluripotency through the activation of all four Yamanaka factors. In the case of 
CNS GCTs we propose that OCT4 is activated to induce pluripotency, but there 
may be other cell types that lack a different factor.   
While it is beyond the scope of this thesis, our hypothesis may be 
relevant for other extragonadal GCTs. Briefly, pluripotent progenitors have been 
identified in other non-gonadal locations, such as the sacrococcygeal region. 
Wilson et al. (2002 and 2007) suggest that axial progenitors have the potential to 
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form tumours from pluripotent cells [99, 100]. Aberrant differentiation of these 
axial progenitors would have the potential to form teratomas. Furthermore, 
these progenitors are present during embryogenesis but decrease rapidly post-
natally, which correlates with the peak incidence of sacrococcygeal teratomas 
around birth but few found later in development.  
 
7.1.3 The role of methylation in CNS GCTs 
Do progenitors for CNS GCTs lack imprinting? 
 One of the arguments in favour of a germ-cell progenitor as the cell of 
origin for CNS GCTs is the lack of imprinting. However, in Chapter 1 highlighted 
the presence of neural progenitors that also lack imprinting of genes such as 
SNRPN [57].  
 Many CNS GCTs appear to lack imprinting but it is unclear whether there 
is larger heterogeneity of imprinting patterns in different regions of CNS GCTs. 
Schneider et al. (2001) confirmed that the majority of CNS GCT cells lack 
imprinting [37], which suggests that the progenitor cell for CNS GCTs lacks 
imprinting; however, this does not mean that the cell of origin was a germ-cell 
progenitor. 
 Loss of imprinting (LOI) is an established oncogenic mechanism. LOI for 
/'& ? ?ĨŽƌĞǆĂŵƉůĞ ?ŝƐŝŵƉůŝĐĂƚĞĚŝŶtŝůŵ ?ƐƚƵŵŽƵƌ, kidney, leukaemia, colorectal 
cancer, lung adenocarcinoma, oesophageal cancer, and meningiomas (a type of 
brain tumour) [37]. LOI is also present in hepatoblastoma and laryngeal 
squamous cell carcinoma [37]. More importantly, LOI is observed in 
rhabdomyosarcoma, a tumour very similar to teratomas; gliomas, a type of brain 
tumour; anĚǁŝŶŐ ?ƐƐĂƌĐŽŵĂ ?ĂƚƵŵŽƵƌĚŝƐĐƵƐƐĞĚĨƵƌƚŚĞƌŝŶƚŚŝƐĐŚĂƉƚĞƌ ? 
LOI provides a selective advantage to form cancers and is common 
among both CNS and non-CNS cancers. Therefore, there is potential for this 
mechanism to be an initiating event in CNS GCTs, or even gonadal GCTs. LOI 
affects a wide range of genes including MYCN and RASSF1A, both of which are 
associated with cancer. These two genes will be discussed again later as part of a 
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specific CNS GCT-initiating mechanism. In summary, LOI could be a mechanism to 
initiate CNS GCTs from a brain cell. A lack of imprinting in CNS GCTs does not, 
therefore, imply an origin from PGCs. 
 The methylation status of CNS GCTs ƉŽƐĞƐĂ  ‘ĐŚŝĐŬĞŶĂŶĚĞŐŐ ?ƐŝƚƵĂƚŝŽŶ
with regards to progenitor cells. Did a methylation defect cause activation of 
OCT4, or did pluripotency-activation reduce the levels of methylation? NANOG, 
which can be activated by OCT4 and is generally expressed in germinomas, has 
an important role in regulating TET1 and TET2, and TET proteins control DNA 
methylation [233, 234]. This perhaps explains the lack of methylation in CNS GCT 
subtypes such as germinomas, but it is not possible to confirm whether NANOG 
first demethylates Oct4, or OCT4 first actives Nanog. 
 In summary, there are several key arguments used to support the germ-
cell hypothesis, which we believe can be explained by our brain-cell hypothesis.
 The last part of this thesis describes clinical features, and their 
relationship to our brain-cell hypothesis.  
 
7.2. Chemoresistance and OCT4 
 OCT4 is implicated in cancer formation or progression in several cancers; 
for example, melanoma [235]. Dedifferentiation is cited as the mechanism for 
OCT4 to contribute to oncogenesis. Different subtypes of CNS GCT respond 
differently to chemotherapy and radiotherapy, as reviewed in Chapter 1. 
Chemoresistance is attributed to the loss of OCT4 in some studies [236], but 
Quinn et al. correlated the loss of OCT4 in prostate cancer cell lines with 
decreased chemoresistance [237]. These observations appear contradictory and 
highlight the complex relationship between OCT4 and cancer.  
The role of Oct4 as an oncogene is different from, for example, P53. OCT4 
is controlled by several factors, which may explain the differences in 
chemotherapy resistance when using OCT4 as a marker i.e. some of the factors 
involved in regulating OCT4 may not be present in certain cases. Therefore, a 
more suitable model may be to correlate pluripotency with chemoresistance, 
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instead of using Oct4 expression alone as a marker. But why might loss of 
pluripotency correlate with chemoresistance? 
 Several mechanisms have been examined to explain why pluripotency 
might correlate with chemoresistance. Repair mechanisms and the immune 
system are two of the most studied areas to explain chemoresistance. A reduced 
repair mechanism is a logical hypothesis because a cell that has lowered this 
ability should be more sensitive to chemotherapy; however, there does not 
appear to be a significant correlation in CNS GCTs; specifically, expression of DNA 
repair genes did not correlate to response to cisplatin [48]. 
 Korkola et al. 2006 prefer to correlate chemotherapy resistance with the 
immune system. The presence of an  ‘immune signature ?, mainly in pluripotent 
CNS GCTs, correlates with a good prognosis ? ďƵƚ Ă ůĂĐŬ ŽĨ  ‘ŝŵŵƵŶĞ ƐŝŐŶĂƚƵƌĞ ?
correlates with a bad prognosis. This immune signature is characterised by 
expression of a range of genes associated with IgG, B cell, and T cell genes. 
Increases in differentiation, especially neural differentiation, also correlate with a 
poorer prognosis [48]. The mechanism behind this correlation is unknown but it 
is tempting to suggest an inability for the body to recognise differentiated cells, 
which would explain the lack of immune response and poorer prognosis. 
 In fact, Korkola et al. are not the only group to suggest that immune 
response correlates with prognosis in GCTs. Wang et al. correlated chromosomal 
changes, and lack of immune response with poorer prognosis [16]. Further work 
in this area may reveal genes that can sensitise cancer cells. 
dŚĞ  ‘ŝŵŵƵŶĞ ƐŝŐŶĂƚƵƌĞ ? ŚǇƉŽƚŚĞƐŝƐ ĂƉƉĞĂƌƐ ƚŽ ďĞ ĐŽŵƉĂƚŝďůĞ ǁŝƚh the 
association between pluripotent features and sensitivity to chemotherapy. This 
hypothesis would also be a logical correlation because chemotherapy may 
debulk the tumour and the immune system would target remaining cells. 
Although pluripotent cells appear ƚŽ ŚĂǀĞ ĂŶ  ‘ŝŵŵƵŶĞ ƐŝŐŶĂƚƵƌĞ ?this 
does not necessarily mean that it is the pluripotent state is the reason behind 
resistance. Overexpression of pluripotent genes, or testing chemotherapy on 
186 
 
pluripotent cells compared to differentiated ones would perhaps elucidate the 
true correlation. 
 
7.3. 12p and pluripotency 
 The gain of the 12p or i(12p) chromosome is suggested to be a marker of 
germ-cell origin; but could i(12p) instead be responsible for induction or 
maintenance of pluripotency in a brain cell? Our hypothesis would be 
strengthened if there was evidence that i(12p) influenced a brain cell to become 
a CNS GCT.  
 The first observation is that ES cells undergo the same gain of i(12p) after 
long-term passage. This i(12p) gain in ES cells is suggested to confer a selective 
advantage for proliferation of undifferentiated cells [238].  
 Analysis of the genes on 12p reveals a cluster of stem cell-associated 
genes around 12p13. Importantly, STELLAR, GDF3, and NANOG are all within this 
cluster. NANOG is already known to maintain pluripotency and regulate OCT4. 
Since pluripotency is regulated in a complex manner by several factors, the 
combination of genes on 12p could be the initiating event for a brain cell to 
become pluripotent  W or at least gain pluripotent features. Indeed, 
downregulation of these genes causes differentiation of male GCTs [236]. 
 There is even evidence of 12p gain occurring in CNS tumours such as glial 
tumours [239], myofibroblastic sarcoma [240], and parenchymal tumours of the 
pineal region [51]. The role of 12p gain is unknown in these tumours but shows 
that tumours arising from brain cells can contain 12p gain.  
 There are several reasons it is important to understand 12p gain in CNS 
GCTs. First, 12p gain may be a mechanism to either induce or maintain 
pluripotency, which strengthens our hypothesis. Our hypothesis may not change 
the way CNS GCTs are clinically treated but if the mechanism of forming a CNS 
GCT is different to a gonadal GCT we can compare the role of 12p gain in order to 
understand the effect on pluripotency. 
 
187 
 
7.4. The KIT-ETV1 axis 
 My model suggests that the KIT-ETV1 axis triggers germinoma formation. 
The expression of ETV1 and stabilisation by KIT/RAS/RAF/MEK activation is an 
axis that is found in many cancers and is highly redundant. 
The KIT-ETV1 axis can be split into two parts: the stabilisation of ETV1 by 
KIT; or the aberrant activation of ETV1 target genes. The mechanism for these 
two stages is different in each cancer, but the outcome is the same  W 
transcription of the ETV1 downstream targets. 
 The KIT/RAS/RAF/MEK pathway is commonly activated in a range of 
cancers [241-243]. The mechanism is often point mutation; for example, in the 
case of KIT, a single mutation relieves the KIT receptor from its need for a ligand 
and the tyrosine kinase function of KIT becomes constitutively active. Gain-of-
function point mutations in KIT have been found in several types of cancer 
including gastro-intestinal stromal tumours [196], melanomas [223], and 
leukaemias [224]. The most common mutation site is D816V, but there are 
several other sites of mutation that relinquish the need for a ligand [23]. Indeed, 
KIT is not the only protein to be mutated in this pathway: mutation of RAS, RAF, 
and MEK are all documented to have roles in cancer formation or progression 
[241-243]. 
 I propose that the activation of the KIT/RAS/RAF/MEK pathway is 
necessary, but not sufficient to form a tumour. The end of this pathway activates 
MEK, which stabilises and increases protein levels of ETV1 [196]. In order for 
MEK to do this, ETV1 must already be expressed; therefore, I propose that ETV1 
is already expressed (as in the case of GISTs), or is aberrantly expressed.  
There are a number of methods of activating ETV1, other than 
stabilisation of the protein: fusion proteins [244], chromosomal gains, and 
endogenous expression are all common, with each mechanism seen in a 
different type of cancer. 
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Imprinting and the KIT-ETV1 axis 
 Loss of imprinting is commonly found in CNS GCTs and may activate the 
KIT-ETV1 axis. An analysis of imprinted genes revealed MYCN and RASSF1A as 
imprinted genes  W both of which are strongly associated with cancer. RASSF1A is 
especially relevant because it is a downstream target of KIT in the 
KIT/RAS/RAF/MEK pathway. It would be interesting to test the activation of 
RASSF1A in a brain cell expressing endogenous ETV1 in vitro or in vivo to 
determine whether ETV1 target genes would be activated. If the coding region of 
KIT was sequenced in all germinomas, I would predict that RAS mutations would 
be activated instead of KIT as a redundant mechanism to activate ETV1. 
 
The KIT-ETV1 axis and germinoma incidence 
 An important biological question needs to be addressed in order to 
qualify the KIT-ETV1 hypothesis: why do teratomas occur around birth and 
germinomas occur much later? Both teratomas and germinomas are classified as 
CNS GCTs but they have different age ranges for peak incidence.  
 Between these ages, the biological environment changes dramatically 
from being plastic during development, to being largely differentiated and in a 
low-proliferative state in adulthood. I hypothesise that in the brain, a cell retains 
or acquires pluripotent features, and becomes the cell of origin for all CNS GCTs. 
Figure 7.2 presents teratomas as the result of proliferation and differentiation in 
an environment where there are many proliferative and pluripotent signals. 
These signals decrease over time causing differentiation and the decrease of 
teratoma peak incidence. 
 Germinomas present a different pathogenesis but a similar cell of origin. 
The expression of pluripotent genes may confer several pluripotent features, but 
lack the proliferative drive. I propose these OCT4-expressing cells remain 
quiescent or non-proliferative until puberty, when hormones and growth factors 
that influence the proliferation rate appear. Cells that have acquired a KIT 
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mutation stimulate the KIT/RAS/RAF/MEK pathway, in a cell that already 
expresses ETV1 (in regions such as the pineal and suprasellar regions), which 
responds by proliferating - similar to gonadal GCTs [37]. 
 This hypothesis is still biologically relevant to germinomas that occur in 
non-traditional regions such as in the spine and medulla oblongata regions. I 
propose that the pathogenesis is the same, and the increased age of peak 
incidence is due to the weaker hormonal influence. The pineal and suprasellar 
region have higher concentrations of growth factors and hormones than hind-
brain regions. Therefore, it is plausible that those regions further from hormonal 
centres require more time to grow under conditions with reduced proliferative 
support. 
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Figure 7.2. The proposed differences between teratoma and germinoma formation 
over development. All intracranial GCT are proposed to develop from a brain-cell with 
OCT4 activated. Those without mutations undergo differentiation during embryogenesis 
and form teratomas by birth. Germinomas are proposed to either be cells that had 
pluripotent features but were not recognised by the immune system, or had acquired 
mutations to drive oncogenesis. The mutations in germinoma progenitors, - such as 
those found in KIT  W enable the lesion to respond to factors released during puberty by 
proliferating.  
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7.5. Factors influencing CNS GCT incidence 
 The incidence of CNS GCTs changes significantly depending on 
geographical location, CNS location, age, gender, and with the presence of 
Klinefelter syndrome. In this section I will focus on the role of geographical 
location and Klinefelter syndrome on CNS GCT incidence.  
 
Geographical variation in the incidence of CNS GCTs 
 Chapter 1 highlights the differences in CNS GCT incidence between the 
countries in the East and the West. Studies using exome sequencing have 
highlighted a significant correlation between Eastern populations with a certain 
group of alleles linked to an increased incidence of CNS GCTs. Importantly, a 
higher incidence of CNS GCTs was recorded in people who expressed these genes 
but had moved from the East to the West. This strengthens the hypothesis that 
these genes are responsible for an increased incidence of CNS GCTs. Further, this 
data set was independently corroborated by another group doing a similar study. 
Because this work is unpublished, it is not possible to discuss the group of genes 
specifically (3rd International CNS Germ Cell Tumour Symposium, Cambridge, 
2013 - Koichi Ichimura, Ching Lau, and Keita Terashima). 
 Little is known about the group of genes in question and their mechanism 
of activation, normal expression, or targets. However, they are expressed in 
certain types of cancer, and are implicated in epigenetics. The discovery of these 
genes is an exciting advance in understanding CNS GCT pathogenesis and 
elucidating the mechanism of these genes on cancer formation may help to 
determine the origin of CNS GCTs. 
  
The relationship between Klinefelter syndrome and CNS GCTs 
Klinefelter syndrome is a disease caused by an additional X chromosome 
and correlates with higher CNS GCT formation. While Klinefelter syndrome 
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increases the incidence of CNS GCTs there is no significant correlation for 
gonadal GCTs. This suggests a mechanism that is specific to a CNS GCT progenitor 
in the brain rather than tumours derived from PGCs in general.  
Testing our hypothesis for a brain-cell of origin for CNS GCTs is essential 
to understanding the risk factors involved in initiating these tumours. The extra X 
chromosome in Klinefelter syndrome provides an obvious mechanism for 
forming CNS GCTs according to our hypothesis  W the stabilisation of endogenous 
ETV1. Both A-RAF and E-RAS are located on the X chromosome and our 
hypothesis would be that they could activate MEK, which in turn stabilises ETV1 
protein for transcription of ETV1 target genes.  
 
7.6. Conclusion 
In this thesis I have investigated the hypothesis that CNS GCTs arise from 
a brain cell. Literature searches showed that teratomas could grow in all regions 
of the brain, and an in vivo study confirmed that large teratomas could form in 
the lateral regions of the brain. Neural stem cells were examined as a potential 
cell of origin for CNS GCTs using in vitro and in vivo techniques. Finally, the 
overlap of ETV1 and KIT was proposed as a mechanism for germinoma formation 
in the CNS. I have established a testable mechanism for how a brain cell is 
activated to a pluripotent state and forms one of several subtypes of CNS GCT.  
Several areas of our hypothesis require further work, such as the role of 
12p and the KIT-ETV1 axis. CNS GCTs can be particularly sensitive to radiotherapy 
and chemotherapy, while subtypes such as yolk-sac tumours are difficult to treat. 
Indeed, understanding the pathogenesis of CNS GCTs may reveal the mechanism 
that confers this resistance/sensitivity [245]. 
Acceptance of our brain-cell hypothesis and a strong understanding of 
the pathogenesis of CNS GCTs will help us to develop more appropriate models. 
No transgenic model has yet managed to replicate extragonadal GCTs, making it 
difficult to study these tumours. Further work is required to fully understand the 
193 
 
networks involved in CNS GCT progression in order to develop therapies that 
cause fewer long-term sequelae than at present. 
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Table I.1. Genotyping for transgenic mice. Each mouse was tagged with a 
pedigree number to track the genotype and mating data. The genotypes for each 
mouse are shown next to the corresponding number 
 
Pedigree  
number Genotype 
 
Pedigree 
number Genotype 
 
Pedigree 
number Genotype 
 
Pedigree 
number Genotype 
    
 
    
 
    
 
    
11883 Ht 
 
15502 Ht 
 
25562 Ht 
 
32874 Hm 
11930 Ht 
 
15503 Ht 
 
25563 Hm 
 
32875 Ht 
11931 Hm 
 
19185 Hm 
 
25564 Hm 
 
32876 Hm 
11932 Ht 
 
19186 Wt 
 
25565 Ht 
 
32877 Ht 
11933 Hm 
 
19187 Ht 
 
25566 Ht 
 
32878 Hm 
11934 Hm 
 
19188 Wt 
 
25567 Ht 
 
32879 Hm 
11935 Ht 
 
19189 Hm 
 
26199 Hm 
 
32031 Hm 
11936 Ht 
 
19190 Hm 
 
26200 Hm 
 
32032 Ht 
11937 Ht 
 
19393 Hm 
 
27340 Ht 
 
32033 Ht 
14422 Ht 
 
19394 Hm 
 
27341 Ht 
 
34524 Ht 
14423 Wt 
 
22015 Wt 
 
27342 Ht 
 
32528 Hm 
14424 Wt 
 
22016 Wt 
 
27343 Wt 
 
32529 Ht 
14267 Hm 
 
22017 Ht 
 
27344 Ht 
 
32530 Hm 
14268 Ht 
 
22018 Ht 
 
27345 Wt 
 
32522 Hm 
14269 Hm 
 
22019 Hm 
 
27346 Hm 
 
33500 Ht 
14270 Ht 
 
22020 Wt 
 
30228 Hm 
 
33599 Ht 
14271 Ht 
 
22021 Wt 
 
30229 Ht 
 
33600 Ht 
14420 Wt 
 
22655 Hm 
 
30230 Ht 
 
33601 Hm 
14421 Wt 
 
22656 Hm 
 
30231 Ht 
 
33824 Ht 
14422 Ht 
 
22657 Hm 
 
30232 Ht 
 
33825 Wt 
14423 Wt 
 
22658 Hm 
 
30233 Hm 
 
33826 Ht 
14424 Wt 
 
22659 Hm 
 
28732 Ht 
 
34530 Hm 
15094 Ht 
 
22660 Hm 
 
28959 Wt 
 
36040 Hm 
15095 Ht 
 
23928 Wt 
 
28964 Hm 
 
36050 Ht 
15096 Hm 
 
23929 Ht 
 
28965 Hm 
 
36061 Hm 
15499 Ht 
 
23930 Hm 
 
28966 Hm 
 
36065 Ht 
15500 Hm 
 
23931 Hm 
 
28967 Hm 
 
38408 Hm 
15501 Hm 
 
23932 Ht 
 
28968 Hm 
 
38409 Hm 
   
25561 Ht 
 
32030 Ht 
 
38410 Ht 
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